XIII. MEDICINAL PRODUCTS

The EFTA Surveillance Authority may designate, according to its working procedures, two observers entitled to participate in the tasks of the Committee which are described in Article 2, first indent of the Council Decision 75/320/EEC of 20 May 1975 setting up a pharmaceutical committee.

Notwithstanding Article 101 of the Agreement, the EC Commission shall invite experts from the EFTA States according to Article 99 of the Agreement, to participate in the tasks which are described in Article 2, second indent of the Council Decision 75/320/EEC.

The EC Commission shall, in due time, inform the EFTA Surveillance Authority about the date of the meeting of the Committee and transmit the relevant documentation.

\(^1\) For the purposes of this Chapter and notwithstanding the provisions of Protocol 1 to this Agreement, the terms Member States and competent authorities shall be understood to include, in addition to their meaning in the relevant EU acts, the EFTA States and their competent authorities, respectively.

When decisions on the authorisation of medicinal products are taken according to the Union procedures laid down in Regulation (EC) No 726/2004 of the European Parliament and of the Council, Directive 2001/83/EC of the European Parliament and of the Council, the EFTA States shall simultaneously and within 30 days of the Union Decision take corresponding decisions on the basis of the relevant EU acts referred to in the preceding paragraphs.

relevant acts. The EEA Joint Committee shall be informed and shall periodically publish lists of such decisions in the EEA Supplement to the *Official Journal of the European Union*.

The EFTA Surveillance Authority shall monitor the application of the decisions taken by the EFTA States as provided for in Article 109 of the Agreement.

Where any of the relevant acts provide for Union procedures on the granting, suspension and withdrawal of a marketing authorisation as well as supervision, including pharmacovigilance, and inspections and sanctions, these and similar tasks shall be carried out by the competent authorities in the EFTA States, on the basis of the same obligations as those of the competent authorities of EU Member States.

Should any disagreement between the contracting parties arise as to the administration of these provisions, Part VII of the Agreement shall apply *mutatis mutandis*.


The EFTA States shall therefore participate in the Union contribution referred to in Article 67(3) of Regulation (EC) No 726/2004 of the European Parliament and of the Council.

For this purpose, the procedures laid down in Article 82(1)(a) and Protocol 32 of the Agreement shall apply *mutatis mutandis* with regard to the financial contribution of the EFTA States to the above-mentioned Union contribution.

The EFTA States may send observers to meetings of the Agency’s Management Board.

The EFTA States shall be fully associated with the work of the Committee for Medicinal Products for Human Use (CHMP), the Committee on Orphan Medicinal Products (COMP), the Paediatric Committee, the Pharmacovigilance Risk Assessment Committee (PRAC) and the Committee on Herbal Medicinal Products (HMPC). The provisions of Title IV, Chapter 1, of Regulation (EC) No 726/2004 of the European Parliament and of the Council shall apply to the participation of the EFTA States in the work of the Committees appointed by the EFTA States. Members of the Committees appointed by the EFTA States shall have the same rights and obligations as the members appointed by the EU Member States, except for the right to vote. The positions of the members of the EFTA States shall be recorded separately. The position of Chairman shall be reserved for a member nominated by an EU Member State.

The EFTA States shall be fully associated with the work of the Committee for Veterinary Medicinal Products (CVMP). The provisions of Article 140 of Regulation (EU) 2019/6 of the European Parliament and of the Council shall apply to the participation of the EFTA States in the work of the Committees appointed by the EFTA States. Members of the Committees appointed by the EFTA States shall have the same rights and obligations as the members appointed by the EU Member States, except for the right to vote. The positions of the members of the EFTA States shall be recorded separately. The position of Chairman shall be reserved for a member nominated by an EU Member State.

The EFTA States shall be fully associated with the work of the coordination groups as set up by Article 27 of Directive 2001/83/EC of the European Parliament and of the Council and Article 142 of Regulation (EU) 2019/6 of the European Parliament and of the Council. The members of the EFTA States shall not participate in the voting, however, their positions shall be recorded separately. The position of Chairman shall be reserved for a member nominated by an EU Member State. An objection raised by the competent authority of an EFTA State in accordance with Articles 49(5), 52(6), 53(8) or 66(8) of Regulation (EU) 2019/6 of the European Parliament and of the Council shall initiate the review procedure referred to in Article 54 of that Regulation.

An EFTA State may request the Agency to initiate an arbitration procedure according to Title III, Chapter 4 of Directive 2001/83/EC of the European Parliament and of the Council. Such a request shall, in the first place, be addressed to the Commission which shall, where it considers that the request is of common interest, forward it to the Agency for further processing.

The EFTA States shall participate fully in the Telematic Exchange of Information on Medicinal Products (IMP) programme.

Iceland and Norway shall provide their national competent authorities and the marketing authorisation holders with the linguistic version of the marketing authorisations required to access their own market.

A centralised marketing authorisation granted for a medicinal product shall not be subject to any fees other than those referred to in Article 67(3) of Regulation (EC) No 726/2004 of the European Parliament and of the Council.
The Agency having legal personality shall enjoy in all the States of the Contracting Parties the most extensive legal capacity accorded to legal persons under their laws.

The EFTA States shall grant privileges and immunities to the Agency equivalent to those contained in the Protocol on the Privileges and Immunities of the European Union.


By way of derogation from Article 12(2)(a) of the Conditions of employment of other servants of the European Communities, nationals of the EFTA States enjoying their full rights as citizens may be engaged under contract by the Executive Director of the Agency.

**ACTS REFERRED TO**

1.\[†\] [ ]

2.\[†\] [ ]

3.\[†\] [ ]


5.\[†\] [ ]

6.\[†\] [ ]


10.\[††\] [ ]

---


11.\(^{(11)}\) [ ]


The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptation:

(a) References to other acts in the Regulation shall be considered relevant to the extent and in the form that those acts are incorporated into the Agreement.

(b) An EFTA State may request the Agency to issue an opinion according to Article 9(1), first paragraph of Article 11, Article 15(1) and Article 27(2). Such a request shall, in the first place, be addressed to the Commission which shall, where it considers that the request is of common interest, forward it to the Agency for further processing.


The provisions of the Regulation shall, for the purposes of the EEA Agreement, be read with the following adaptation:


\(^{(18)}\) Indent and words “, as amended by:” added by Decision No 231/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 23.9.2023.
References to other acts in the Regulation shall be considered relevant to the extent and in the form that those acts are incorporated into the Agreement.


- [29] 32012 R 0086: Commission Implementing Regulation (EU) No 86/2012 of 1 February 2012 (OJ L 30, 2.2.2012, p. 6),


\[\text{[Indent added by Decision No 8/2013 (OJ L 144, 30.5.2013, p. 12 and EEA Supplement No 31, 30.5.2013, p. 14), e.i.f. 2.2.2013.}\]

\[\text{[Indent added by Decision No 8/2013 (OJ L 144, 30.5.2013, p. 12 and EEA Supplement No 31, 30.5.2013, p. 14), e.i.f. 2.2.2013.}\]


\[\text{[Indent added by Decision No 157/2013 (OJ L 58, 27.2.2014, p. 9 and EEA Supplement No 13, 27.2.2014, p. 9), e.i.f. 9.10.2013.}\]

\[\text{[Indent added by Decision No 157/2013 (OJ L 58, 27.2.2014, p. 9 and EEA Supplement No 13, 27.2.2014, p. 9), e.i.f. 9.10.2013.}\]

\[\text{[Indent added by Decision No 157/2013 (OJ L 58, 27.2.2014, p. 9 and EEA Supplement No 13, 27.2.2014, p. 9), e.i.f. 9.10.2013.}\]

\[\text{[Indent added by Decision No 189/2013 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 9.11.2013.}\]

\[\text{[Indent added by Decision No 189/2013 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 9.11.2013.}\]

\[\text{[Indent added by Decision No 189/2013 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 9.11.2013.}\]

\[\text{[Indent added by Decision No 189/2013 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 9.11.2013.}\]

\[\text{[Indent added by Decision No 189/2013 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 9.11.2013.}\]

\[\text{[Indent added by Decision No 189/2013 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 9.11.2013.}\]

\[\text{[Indent added by Decision No 189/2013 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 9.11.2013.}\]

\[\text{[Indent added by Decision No 189/2013 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 9.11.2013.}\]

\[\text{[Indent added by Decision No 189/2013 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 9.11.2013.}\]


{[50]} Indent added by Decision No 81/2014 (OJ L 310, 30.10.2014, p. 34 and EEA Supplement No 63, 30.10.2014, p. 25), e.i.f. 17.5.2014.

{[51]} Indent added by Decision No 177/2014 (OJ L 202, 30.7.2015, p. 27 and EEA Supplement No 43, 30.7.2015, p. 27), e.i.f. 26.9.2014.

{[52]} Indent added by Decision No 177/2014 (OJ L 202, 30.7.2015, p. 27 and EEA Supplement No 43, 30.7.2015, p. 27), e.i.f. 26.9.2014.


{[60]} Indent added by Decision No 14/2015 (OJ L 93, 7.4.2016, p. 24 and EEA Supplement No 21, 7.4.2016, p. 21), e.i.f. 26.2.2015.

{[61]} Indent added by Decision No 50/2015 (OJ L 129, 19.5.2016, p. 31 and EEA Supplement No 29, 19.5.2016, p. 32), e.i.f. 21.3.2015.


(66) Indent added by Decision No 177/2015 (OJ L 8, 12.1.2017, p. 5 and EEA Supplement No 3, 12.1.2017, p. 5), e.i.f. 11.7.2015.


[82] Indent added by Decision No 22/2017 (OJ L 297, 22.11.2018, p. 28 and EEA Supplement No 78, 22.11.2018, p. 34), e.i.f. 4.2.2017.
14. [ ]


[95] Indent added by Decision No 62/2019 (OJ L 210, 2.7.2020, p. 29 and EEA Supplement No 44, 2.7.2020, p. 31), e.i.f. 30.3.2019.


[104] Indent added by Decision No 203/2021 (OJ L 2024/308, 8.2.2024 and EEA Supplement No 13, 8.2.2024, p. 33), e.i.f. 10.7.2021.


[106] Indent added by Decision No 261/2023 (OJ L [to be published] and EEA supplement No [to be published]), e.i.f. 28.10.2023.

15.  [ ] [108]


15b.  [ ] [109]

15c.  [ ] [111]

15d.  [ ] [111]

15e.  [ ] [111]

15f.  [ ] [114]

15g.  [ ] [115]


15j. [ ] 134

15k. [ ] 135


The provisions of the Regulation shall, for the purposes of the present Agreement, be read with the following adaptation:

The EFTA States shall be fully associated with the work of the Committee for Orphan Medicinal Products. The detailed arrangements of participation for the representatives of EFTA States shall be in accordance with the provisions of Article 4 of the Regulation. Such representatives will, however, not participate in the voting and their positions shall be recorded separately. The position of Chairman shall be reserved for a member nominated by a Member State of the Community. The internal rules of procedure of this committee shall be amended in order to give full effect to the EFTA States' participation.

The EFTA States shall contribute financially to the work of the Committee in accordance with Article 82(1)(a) of the Agreement.

15n. 32000 R 0847: Commission Regulation (EC) No 847/2000 of 27 April 2000 laying down the provisions for implementation of the criteria for designation of a medical product as an orphan medicinal product and definitions of the concepts 'similar medicinal product' and 'clinical superiority' (OJ L 103, 28.4.2000, p. 5), as amended by:


15o. [ ] 141


The transitional arrangements set out in the Annexes to the Act of Accession of 16 April 2003 for Lithuania (Annex IX, Chapter 1, Point 1) and Poland (Annex XII, Chapter 1, Point 4), shall apply.

The provisions of the Directive shall, for the purposes of this Agreement, be read with the following adaptation:

Liechtenstein shall not be obliged to participate in the decentralised procedure (DCP) and in the mutual recognition procedure (MRP) and shall, therefore, not be obliged to issue the corresponding marketing authorisations. Instead, Austrian marketing authorisations within the DCP and the MRP shall be valid for Liechtenstein upon request of a marketing authorisation applicant.

SECURING THE MARKET ACCESS OF THE PRODUCT


Indent added by Decision No 128/2009 (OJ L 62, 11.3.2010, p. 16 and EEA Supplement No 12, 11.3.2010, p. 15), e.i.f. 23.12.2009. For Liechtenstein, Decision 128/2009 entered into force 1.12.2010 which is the day of entry into force of the Agreement between Liechtenstein and Austria laying down the technical details for Liechtenstein’s recognition of Austrian marketing authorisations within the decentralised procedure (DCP) and the mutual recognition procedure (MRP).

Indent added by Decision No 72/2011 (OJ L 262, 6.10.2011, p. 28 and EEA Supplement No 54, 6.10.2011, p. 38), e.i.f. 2.7.2011.

Indent added by Decision No 72/2011 (OJ L 262, 6.10.2011, p. 28 and EEA Supplement No 54, 6.10.2011, p. 38), e.i.f. 2.7.2011.

Indent added by Decision No 158/2013 (OJ L 58, 27.2.2014, p. 10 and EEA Supplement No 13, 27.2.2014, p. 11), e.i.f. 28.5.2014.


The transitional arrangements set out in the Annexes to the Act of Accession of 16 April 2003 for Cyprus (Annex VII, Chapter 1), Lithuania (Annex IX, Chapter 1, Point 2), Malta (Annex XI, Chapter 1, Point 2), Poland (Annex XII, Chapter 1, Point 5) and Slovenia (Annex XIII, Chapter 1) shall apply.

The transitional arrangements set out in the Annexes to the Act of Accession of 9 December 2011 for Croatia (Annex V, Chapter 1) shall apply.

The provisions of the Directive shall, for the purposes of this Agreement, be read with the following adaptations:

(a) Liechtenstein shall not be obliged to participate in the decentralised procedure (DCP) and in the mutual recognition procedure (MRP) and shall, therefore, not be obliged to issue the corresponding marketing authorisations. Instead, Austrian marketing authorisations within the DCP and the MRP shall be valid for Liechtenstein upon request of a marketing authorisation applicant.

(b) The EFTA States may initiate the urgent Union procedure pursuant to Section 4 of Chapter 3 of Title IX of the Directive.

(c) With respect to Title IX, the obligations of Liechtenstein will be executed by Austria. Liechtenstein will however, as far as applicable to Liechtenstein:

- operate a pharmacovigilance system in accordance with Article 101(1);
- perform a regular audit of its pharmacovigilance system in accordance with Article 101(2);
- designate a competent authority for the performance of its pharmacovigilance tasks in accordance with Article 101(3),


\[162\] Indent added by Decision No 371/2021 (OJ L 107, 24.2021, 11.4.2024, and EEA Supplement No 23, 14.3.2024, p. 76), e.i.f. pending.


- take all appropriate measures to encourage patients, doctors, pharmacists and other healthcare professionals to report suspected adverse reactions to the national competent authority in accordance with Article 102(a);

- facilitate patient reporting through the provision of alternative reporting formats in addition to web-based formats in accordance with Article 102(b);

- impose an obligation on a marketing authorisation holder to operate a risk management system, as referred to in Article 104(3)(c), if there are concerns about the risks affecting the risk-benefit balance of an authorised medicinal product in accordance with Article 104a(2). For the imposition of such obligation Liechtenstein will base itself on a corresponding decision of the Austrian authorities;

- set up and maintain a national medicines web-portal which shall be linked to the European medicines web-portal in accordance with Article 106;

- record all suspected adverse reactions that occur in its territory which are brought to its attention from healthcare professionals and patients and ensure that reports of such reactions may be submitted by means of the national medicines web-portals or by other means in accordance with Article 107a(1), and

- submit reports in accordance with Article 107a(4).

(d) The following subparagraph shall be added to Article 107c(5):

“A Swiss marketing authorisation for a medicinal product taking effect in Liechtenstein by virtue of Liechtenstein law on the basis of the Customs Union between the Principality of Liechtenstein and the Swiss Confederation shall not be considered as a first authorisation to place a product on the market for the purposes of this paragraph.”


15qb.[167] 32012 D 0715: Commission Implementing Decision 2012/715/EU of 22 November 2012 establishing a list of third countries with a regulatory framework applicable to active substances for medicinal products for human use and the respective control and enforcement activities ensuring a level of protection of public health equivalent to that in the Union, in accordance with Directive 2001/83/EC of the European Parliament and of the Council (OJ L 325, 23.11.2012, p. 15), as amended by:

-168) 32013 D 0262: Commission Implementing Decision 2013/262/EU of 4 June 2013 (OJ L 152, 5.6.2013, p. 52),


[168] Indent and words "", as amended by", inserted by Decision No 191/2013 (OJ L [to be published]) and EEA Supplement No [to be published]), e.i.f. 9.11.2013.


15q.{[170]}


15q.4.{[170]}


15q.5.{[170]}


The provisions of the Directive shall, for the purposes of this Agreement, be read with the following adaptation:

The inspections in Liechtenstein shall be performed by the Swiss inspectorate on behalf of Liechtenstein on the basis of the agreement between Swissmedic and Amt für Gesundheit (Verwaltungsvereinbarung betreffend Inspektionen).

15qf.{[170]}


- {[171]}


- {[172]}


- {[173]}


---

For Liechtenstein, Decision 128/2009 entered into force 1.12.2010 which is the day of entry into force of the Agreement between Liechtenstein and Austria laying down the technical details for Liechtenstein’s recognition of Austrian marketing authorisations within the decentralized procedure (DCP) and the mutual recognition procedure (MRP).


The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptations:

(a) The text of Article 11 (2) shall not apply.

(b) In Article 14a a reference is made to the Committee set up by Article 30 of Council Regulation (EC) No 111/2005. When that Committee deals with matters covered by this Regulation the EFTA States shall participate fully in the work of the Committee, but shall not have the right to vote.

The provisions of the Delegated Regulation shall, for the purposes of this Agreement, be read with the following adaptation:

The Regulation shall only apply to the EEA EFTA States with regard to Regulation (EC) No 273/2004.

The provisions of the Implementing Regulation shall, for the purposes of this Agreement, be read with the following adaptation:

The Regulation shall only apply to the EEA EFTA States with regard to Regulation (EC) No 273/2004.


---


[3211] Indent added by Decision No 158/2013 (OJ L 58, 27.2.2014, p. 10 and EEA Supplement No 13, 27.2.2014, p. 11), e.i.f. 28.5.2014.

[3212] Indent added by Decision No 163/2013 (OJ L 58, 27.2.2014, p. 16 and EEA Supplement No 13, 27.2.2014, p. 18), e.i.f. 28.5.2014.


[3215] Indent added by Decision No 371/2021 (OJ L, 2024/711, 14.3.2024 and EEA Supplement No 23, 14.3.2024, p. 76), e.i.f. pending.
The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptation:

The powers vested in the European Commission in relation to the infringement procedure foreseen in Article 84a, including the power to impose financial penalties on the holders of marketing authorisations, shall, in the cases where the marketing authorisation holder is established in an EFTA State, be carried out by the EFTA Surveillance Authority in close cooperation with the Commission. Before the EFTA Surveillance Authority takes a decision regarding financial penalties, the Commission shall provide it with its assessment and a proposal on how to act.


15ze. [ ] (218)

15zf. [ ] (219)


The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptation:

The EFTA States shall be fully associated with the work of the Committee for Advanced Therapy, but without the right to vote.


---


(221) Indent and words “as, as amended by:” added by Decision No 158/2013 (OJ L 58, 27.2.2014, p. 10 and EEA Supplement No 13, 27.2.2014, p. 11), c.i.f. 28.5.2014.


The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptation:
The powers vested in the European Commission in relation to the infringement procedure, including the power to impose financial penalties on the holders of marketing authorisations, shall, in the cases where the marketing authorisation holder is established in an EFTA State, be carried out by the EFTA Surveillance Authority in close cooperation with the Commission. Before the EFTA Surveillance Authority takes a decision regarding financial penalties, the Commission shall provide it with its assessment and a proposal on how to act.

15zk. [ ] (228)


- (228) 32012 D 0067: Commission Implementing Decision 2012/67/EU of 3 February 2012 (OJ L 34, 7.2.2012, p. 5),
- (229) 32012 D 0068: Commission Implementing Decision 2012/68/EU of 3 February 2012 (OJ L 34, 7.2.2012, p. 8),

(228) Indent added by Decision No 335/2021 (OJ L 224/641, 14.3.2024 and EEA Supplement No 33, 14.3.2024, p. 29), e.i.f. 11.12.2021.


The provisions of the Directive shall, for the purposes of this Agreement, be read with the following adaptation:

This Directive shall not apply to Liechtenstein, with the exception of Articles 15 and 16. The definitions in Article 3 and general provisions in Articles 17(2)(h) and 23 shall only apply to Liechtenstein as far as necessary for transposing Articles 15 and 16 of the Directive.


The provisions of the Implementing Directive shall, for the purposes of this Agreement, be read with the following adaptation:

This Implementing Directive shall not apply to Liechtenstein, with the exception of Article 7.

15zo.(38) 32013 R 0198: Commission Implementing Regulation (EU) No 198/2013 of 7 March 2013 on the selection of a symbol for the purpose of identifying medicinal products for human use that are subject to additional monitoring (OJ L 65, 8.3.2013, p. 17).


(38) Point inserted by Decision No 179/2014 (OJ L 202, 30.7.2015, p. 29 and EEA Supplement No 43, 30.7.2015, p. 29), e.i.f. 1.6.2015.


The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptations:

(a) The application of Article 36(3) shall not be made dependent on an authorisation of the medicinal product in Liechtenstein.

(b) The powers vested in the European Commission in relation to the infringement procedure foreseen in Article 49(3), including the power to impose financial penalties on the holders of marketing authorisations, shall, in the cases where the marketing authorisation holder is established in an EFTA State, be carried out by the EFTA Surveillance Authority in close cooperation with the Commission. Before the EFTA Surveillance Authority takes a decision regarding financial penalties, the Commission shall provide it with its assessment and a proposal on how to act.


---


[24c] Indent added by Decision No 371/2021 (OJ L 2024/711, 14.3.2024 and EEA Supplement No 23, 14.3.2024, p. 76), e.i.f. pending.


[24h] Indent added by Decision No 262/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 28.10.2023.

[24i] Indent added by Decision No 313/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 9.12.2023.


The provisions of the Delegated Regulation shall, for the purposes of this Agreement, be read with the following adaptation:

The inspections in Liechtenstein shall be carried out, on behalf of Liechtenstein, by the Swiss inspectorate.


---


\[255\] Point inserted by Decision No 213/2015 (OJ L 85, 30.3.2017, p. 31 and EEA Supplement No 19, 30.3.2017, p. 31), e.i.f. 1.8.2016. Corrigendum to the EU act subsequently taken note of by the EEA Joint Committee on 3.2.2017.


\[259\] Point inserted by Decision No 28/2022 (OJ L 175, 30.6.2022, p. 45 and EEA Supplement No 42, 30.6.2022, p. 42), e.i.f. 5.2.2022.

\[260\] Point inserted by Decision No 63/2022 (OJ L 182, 7.7.2022, p. 41 and EEA Supplement No 45, 7.7.2022, p. 27), e.i.f. 19.3.2022.


\[263\] Point inserted by Decision No 237/2021 (OJ L, 2024/517, 22.2.2024 and EEA Supplement No 17, 22.2.2024, p. 18), e.i.f. 25.9.2021.

\begin{itemize}
\end{itemize}

The provisions of this Regulation shall, for the purposes of the EEA Agreement, be read with the following adaptations:

(a) The following provisions of the Regulation regarding veterinary matters shall not apply to Liechtenstein:

- Article 57
- Articles 103 to 115, included.

(b) Liechtenstein shall not be obliged to participate in the decentralised procedure (DCP) and in the mutual recognition procedure (MRP) and shall, therefore, not be obliged to issue the corresponding marketing authorisations. Instead, Austrian marketing authorisations within the DCP and the MRP shall be valid for Liechtenstein upon request of a marketing authorisation applicant.

(c) In Article 136, the powers vested in the European Commission to impose financial penalties on the holders of marketing authorisations shall, in the cases where the marketing authorisation holder is established in an EFTA State, be carried out by the EFTA Surveillance Authority in close cooperation with the Commission. Before the EFTA Surveillance Authority takes a decision regarding financial penalties, the Commission shall provide it with its assessment and a proposal on how to act.


The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptation:

In Article 6(4), the words “official languages of the Union” shall be replaced by “official languages of the Contracting Parties to the EEA Agreement”.


\textsuperscript{261} Point and adaptations text inserted by Decision No 371/2021 (OJ L, 2024/711, 14.3.2024 and EEA Supplement No 23, 14.3.2024, p. 76), e.i.f. pending.

\textsuperscript{262} Indent and words “as amended by” added by Decision No 5/2022 (OJ L 175, 30.6.2022, p. 9 and EEA Supplement No 42, 30.6.2022, p. 81), e.i.f. pending.

\textsuperscript{263} Indent added by Decision No 179/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. pending.

\textsuperscript{264} Point inserted by Decision No 5/2022 (OJ L 175, 30.6.2022, p. 9 and EEA Supplement No 42, 30.6.2022, p. 8), e.i.f. pending.

\textsuperscript{265} Point inserted by Decision No 5/2022 (OJ L 175, 30.6.2022, p. 9 and EEA Supplement No 42, 30.6.2022, p. 8), e.i.f. pending.

\textsuperscript{266} Point inserted by Decision No 5/2022 (OJ L 175, 30.6.2022, p. 9 and EEA Supplement No 42, 30.6.2022, p. 8), e.i.f. pending.


22h. (292) 32022 R 0209: Commission Implementing Regulation (EU) 2022/209 of 16 February 2022 establishing the format of the data to be collected and reported in order to determine the volume of sales and the use of antimicrobial medicinal products in animals in accordance with Regulation (EU) 2019/6 of the European Parliament and of the Council (OJ L 35, 17.2.2022, p. 7).


**ACTS OF WHICH THE CONTRACTING PARTIES SHALL TAKE NOTE**

The Contracting Parties take note of the content of the following acts:


2. (297) C/115/82/p. 5: Commission Communication on parallel imports of proprietary medicinal products for which marketing authorisation have already been granted (OJ No C 115, 6.5.1982, p. 5).


---

(289) Point inserted by Decision No 119/2022 (OJ L 246, 22.9.2022, p. 60 and EEA Supplement No 61, 22.9.2022, p. 59), e.i.f pending.
(290) Point inserted by Decision No 119/2022 (OJ L 246, 22.9.2022, p. 60 and EEA Supplement No 61, 22.9.2022, p. 59), e.i.f pending.
(293) Point inserted by Decision No 278/2022 (OJ L 117, 4.5.2023, p. 3 and EEA Supplement No 35, 4.5.2023, p. 3), e.i.f. 29.10.2022.
XIV. FERTILIZERS\(^{(279)}\)

ACTS REFERRED TO


The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptations:

(a) The EFTA States shall be free to continue to apply their national limit values for cadmium in phosphate fertilisers existing at the date of entry into force of Decision of the EEA Joint Committee No 77/2023 of 28 April 2023 until such time as harmonised limit values for cadmium content in phosphate fertilisers which are equal to or lower than those limit values become applicable in the European Economic Area.

(b) In Article 1(2), the following points shall be added after point (p):

"(q) the national plant health law of the EFTA States;

(r) the national law on invasive alien species of the EFTA States."
In Article 52, as regards the EFTA States, the words “or the date of entry into force of Decision of the EEA Joint Committee No 77/2023 of 28 April 2023, whichever is the later” are inserted after the words “16 July 2022”.


**ACTS OF WHICH THE CONTRACTING PARTIES SHALL TAKE NOTE**

The Contracting Parties shall take note of the following acts:


---

[2⁷] Point inserted by Decision No 60/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 16.3.2024.
XV. DANGEROUS SUBSTANCES

ACTS REFERRED TO

1. [ ] (286)
2. [ ] (286)
3. [ ] (286)
4. [ ] (286)
5. [ ] (288)
6. [ ] (288)
7. [ ] (288)


12a. [ ] [38]

12b. [ ] [38]

12c. [ ] [38]

12d. [ ] [38]

12e. [ ] [38]

12f. [ ] [38]


12j. [ ] [39]


Indent added by Decision No 159/2014 (OJ L 15, 22.1.2015, p. 87 and EEA Supplement No 5, 22.1.2015, p. 10, e.i.f. pending; it shall apply from 9.7.2014.


Point 12n (Directive 98/8/EC) inserted by Decision No 32/2003 (OJ L 137, 5.6.2003, p. 33 and EEA Supplement No 29, p. 21), e.i.f. 1.3.2004, and subsequently replaced by Decision No 225/2013 (OJ L 154, 22.5.2014, p. 22 and EEA Supplement No 29, 22.5.2014, p. 21), e.i.f. 1.6.2014. For Liechtenstein, this Decision shall enter into force on the same day or on the day of entry into force of the Agreement between Liechtenstein and Switzerland laying down the cooperation in the field of authorisation procedures for biocidal products according to Regulation (EU) No 528/2012, whichever is the later. Corrigendum to the EU act subsequently taken note of by the EEA Joint Committee on 6.7.2018.


Indent added by Decision No 218/2014 (OJ L 230, 3.9.2015, p. 16 and EEA Supplement No 52, 3.9.2015, p. 16), e.i.f. 1.11.2014.


The provisions of the Regulation shall, for the purpose of this Agreement, be read with the following adaptations:


(b) Notwithstanding the provisions of Protocol 1 to the Agreement, the term ‘Member State(s)’ contained in Regulation (EU) No 528/2012 shall be understood to include, in addition to its meaning in that Regulation, the EFTA States.

(c) As regards the EFTA States, the Agency shall, as and when appropriate, assist the EFTA Surveillance Authority or the Standing Committee, as the case may be, in the performance of their respective tasks.

(d) The following paragraph shall be added in Article 35:

“4. The EFTA States shall be entitled to participate fully in the work of the coordination group and shall within it have the same rights and obligations as EU Member States, except the right to vote. The rules of procedures of the coordination Group shall give full effect to the EFTA States’ participation.”

(e) The following subparagraph shall be added in Article 44(5):

“When the Commission grants a Union authorisation or decides that a Union authorisation has not been granted, the EFTA States will simultaneously and within 30 days of the Commission act take corresponding decisions. The EEA Joint Committee shall be informed and shall periodically publish lists of such decisions in the EEA Supplement to the Official Journal.”

(f) The following paragraph shall be added in Article 48:

---

\[\text{(\textsuperscript{[19]}\textsuperscript{i})} \text{Indent added by Decision No 8/2020 (OJ L 49, 16.2.2023, p. 22 and EEA Supplement No 13, 16.2.2023, p. 23), e.i.f. 8.2.2020.}\]  
\[\text{(\textsuperscript{[20]}\textsuperscript{i})} \text{Indent added by Decision No 8/2020 (OJ L 49, 16.2.2023, p. 22 and EEA Supplement No 13, 16.2.2023, p. 23), e.i.f. 8.2.2020.}\]  
\[\text{(\textsuperscript{[21]}\textsuperscript{i})} \text{Indent added by Decision No 8/2020 (OJ L 49, 16.2.2023, p. 22 and EEA Supplement No 13, 16.2.2023, p. 23), e.i.f. 8.2.2020.}\]  
\[\text{(\textsuperscript{[22]}\textsuperscript{i})} \text{Indent added by Decision No 204/2021 (OJ L, 2024/510, 8.2.2024 and EEA Supplement No 13, 8.2.2024, p. 34), e.i.f. 10.7.2021.}\]  
\[\text{(\textsuperscript{[23]}\textsuperscript{i})} \text{Indent added by Decision No 283/2021 (OJ L, 2024/534, 29.2.2024 and EEA Supplement No 19, 29.2.2024, p. 10), e.i.f. 30.10.2021.}\]  
\[\text{(\textsuperscript{[24]}\textsuperscript{i})} \text{Indent added by Decision No 283/2021 (OJ L, 2024/534, 29.2.2024 and EEA Supplement No 19, 29.2.2024, p. 10), e.i.f. 30.10.2021.}\]  
\[\text{(\textsuperscript{[25]}\textsuperscript{i})} \text{Indent added by Decision No 120/2022 (OJ L 246, 22.9.2022, p. 62 and EEA Supplement No 61, 22.9.2022, p. 61), e.i.f. 30.4.2022.}\]  
---
“4. If the Commission cancels or amends a Union authorisation, the EFTA States shall cancel or amend the corresponding decision.”

(g) The following subparagraph shall be added in Article 49:

“If the Commission cancels a Union authorisation, the EFTA States shall cancel the corresponding decision.”

(h) The following paragraph shall be added in Article 50:

“4. If the Commission amends a Union authorisation, the EFTA states shall amend the corresponding decision.”

(i) The following paragraph shall be added in Article 75:

“5. The EFTA States shall be entitled to participate fully in the work of the Biocidal Products Committee and shall within it have the same rights and obligations as EU Member States, except the right to vote.”

(j) The following paragraph shall be added in Article 78:

“3. The EFTA States shall, as from the entry into force of this Decision participate in the financing of the Agency. For this purpose the procedures laid down in Article 82(1)(a) and Protocol 32 of the Agreement shall apply mutatis mutandis.”

(k) Should any disagreement between the Contracting Parties arise as to the administration of these provisions, Part VII of the Agreement shall apply mutatis mutandis.


---


-[(m)] 32022 R 0825: Commission Delegated Regulation (EU) 2022/825 of 17 March 2022 (OJ L 147, 30.5.2022, p. 3).


12nnd.[32015 D 0646]: Commission Implementing Decision (EU) 2015/646 of 23 April 2015 pursuant to Article 3(3) of Regulation (EU) No 528/2012 of the European Parliament and of the Council on bacterial cultures intended to reduce organic solids and to be placed on the market for that purpose (OJ L 106, 24.4.2015, p. 79).


---


12nnn.[(m)]32015 D 1751: Commission Implementing Decision (EU) 2015/1751 of 29 September 2015 on the terms and conditions of the authorisation of a biocidal product containing bromadiolone referred by the United Kingdom in accordance with Article 36 of Regulation (EU) No 528/2012 of the European Parliament and of the Council (OJ L 256, 1.10.2015, p. 15).


---


- [ ] {399}
The provisions of the Regulation shall, for the purposes of the present Agreement, be read with the following adaptations, in addition to the adaptations to the Directive 98/8/EC:

(a) The EFTA States and their producers shall participate in the 10-year programme of work mentioned in Article 16(2) of Directive 98/8/EC. The EFTA States may be designated under Article 7(5) as responsible for the review of active substances under this programme.

(b) The Commission shall take into account information concerning active substances already on the market in the EFTA States on 14 May 2000 submitted under Article 3 paragraph 1 before the entry into force of the Joint Committee Decision integrating this Regulation into the Agreement.

(c) The Commission shall take into account notifications concerning active substances already on the market in the EFTA States on 14 May 2000 submitted under Article 4 paragraph 1 before the entry into force of the Joint Committee Decision integrating this Regulation into the Agreement.


---


\[490\] Indent added by Decision No 181/2014 (OJ L 202, 30.7.2015, p. 31 and EEA Supplement No 43, 30.7.2015, p. 31), e.i.f. 26.9.2014.

\[491\] Indent added by Decision No 181/2014 (OJ L 202, 30.7.2015, p. 31 and EEA Supplement No 43, 30.7.2015, p. 31), e.i.f. 26.9.2014.

\[492\] Indent added by Decision No 181/2014 (OJ L 202, 30.7.2015, p. 31 and EEA Supplement No 43, 30.7.2015, p. 31), e.i.f. 26.9.2014.

\[493\] Indent added by Decision No 181/2014 (OJ L 202, 30.7.2015, p. 31 and EEA Supplement No 43, 30.7.2015, p. 31), e.i.f. 26.9.2014.

\[494\] Indent added by Decision No 181/2014 (OJ L 202, 30.7.2015, p. 31 and EEA Supplement No 43, 30.7.2015, p. 31), e.i.f. 26.9.2014.

\[495\] Indent added by Decision No 181/2014 (OJ L 202, 30.7.2015, p. 31 and EEA Supplement No 43, 30.7.2015, p. 31), e.i.f. 26.9.2014.

\[496\] Indent added by Decision No 181/2014 (OJ L 202, 30.7.2015, p. 31 and EEA Supplement No 43, 30.7.2015, p. 31), e.i.f. 26.9.2014.

\[497\] Indent added by Decision No 181/2014 (OJ L 202, 30.7.2015, p. 31 and EEA Supplement No 43, 30.7.2015, p. 31), e.i.f. 26.9.2014.

\[498\] Indent added by Decision No 181/2014 (OJ L 202, 30.7.2015, p. 31 and EEA Supplement No 43, 30.7.2015, p. 31), e.i.f. 26.9.2014.


---

Footnotes:

{447} Indent added by Decision No 153/2019 (OJ L 291, 10.11.2022, p. 30 and EEA Supplement No 74, 10.11.2022, p. 31), e.i.f. 15.6.2019.

{448} Indent added by Decision No 153/2019 (OJ L 291, 10.11.2022, p. 30 and EEA Supplement No 74, 10.11.2022, p. 31), e.i.f. 15.6.2019.

{449} Indent added by Decision No 153/2019 (OJ L 291, 10.11.2022, p. 30 and EEA Supplement No 74, 10.11.2022, p. 31), e.i.f. 15.6.2019.

{450} Indent added by Decision No 153/2019 (OJ L 291, 10.11.2022, p. 30 and EEA Supplement No 74, 10.11.2022, p. 31), e.i.f. 15.6.2019.

{451} Indent added by Decision No 153/2019 (OJ L 291, 10.11.2022, p. 30 and EEA Supplement No 74, 10.11.2022, p. 31), e.i.f. 15.6.2019.

{452} Indent added by Decision No 153/2019 (OJ L 291, 10.11.2022, p. 30 and EEA Supplement No 74, 10.11.2022, p. 31), e.i.f. 15.6.2019.

{453} Indent added by Decision No 153/2019 (OJ L 291, 10.11.2022, p. 30 and EEA Supplement No 74, 10.11.2022, p. 31), e.i.f. 15.6.2019.

{454} Indent added by Decision No 153/2019 (OJ L 291, 10.11.2022, p. 30 and EEA Supplement No 74, 10.11.2022, p. 31), e.i.f. 15.6.2019.

{455} Indent added by Decision No 153/2019 (OJ L 291, 10.11.2022, p. 30 and EEA Supplement No 74, 10.11.2022, p. 31), e.i.f. 15.6.2019.

{456} Indent added by Decision No 153/2019 (OJ L 291, 10.11.2022, p. 30 and EEA Supplement No 74, 10.11.2022, p. 31), e.i.f. 15.6.2019.


Indent added by Decision No 205/2021 (OJ L, 2024/311, 8.2.2024 and EEA Supplement No 13, 8.2.2024, p. 35), e.i.f. 10.7.2021.


Indent added by Decision No 121/2022 (OJ L 246, 22.9.2022, p. 63 and EEA Supplement No 61, 22.9.2022, p. 62), e.i.f. 30.4.2022.

Indent added by Decision No 122/2022 (OJ L 246, 22.9.2022, p. 64 and EEA Supplement No 61, 22.9.2022, p. 63), e.i.f. 30.4.2022.

Indent added by Decision No 122/2022 (OJ L 246, 22.9.2022, p. 64 and EEA Supplement No 61, 22.9.2022, p. 63), e.i.f. 30.4.2022.


12r. [ ] [480]

12s. [ ] [487]


---

(483) Indent added by Decision No 263/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 28.10.2023.
(484) Indent added by Decision No 265/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 28.10.2023.
(485) Indent added by Decision No 61/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 16.3.2024.


- **32022 R 2291:** Commission Delegated Regulation (EU) 2022/2291 of 8 September 2022 (OJ L 303, 23.11.2022, p. 19),

The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptations:

---


**[483]** Indent added by Decision No 140/2013 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 16.7.2013.


**[488]** Indent added by Decision No 233/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 23.9.2023.

**[489]** Indent added by Decision No 264/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 28.10.2023.

**[490]** Indent added by Decision No 267/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 28.10.2023.
(a) Notwithstanding the provisions of Protocol 1 to the Agreement, and unless otherwise provided for in this Agreement, the terms Member State(s) and competent authorities shall be understood to include, in addition to their meaning in the Regulation, the EFTA States and their competent authorities, respectively.

(b) The following provisions shall not apply to the EFTA States:

(i) The fourth subparagraph of Article 4(2);

(ii) Article 12; and,

(iii) Article 13(3).

(c) In the second subparagraph of Article 13(1), as regards the EFTA States, the words “or at the reporting intervals decided by the Conference of Parties to the Stockholm Convention” shall be inserted after the words “three years”.


The provisions of the Directive shall, for the purposes of this Agreement, be read with the following adaptation:

Article 17 shall not apply to Liechtenstein.


---


biocidal products on the market of certain substances to be examined under the 10-year work programme referred to in Article 16(2) thereof (OJ L 216, 21.8.2007, p. 17).


\[32011 R 0143\] Indent added by Decision No 74/2011 (OJ L 262, 6.10.2011, p. 31 and EEA Supplement No 54, 6.10.2011, p. 42), e.i.f. 2.7.2011.


[ ]


\(^{[645]}\) Indent added by Decision No 28/2021 (OJ L 204/12, 11.1.2024 and EEA Supplement No 3, 11.1.2024, p. 56), e.i.f. 6.2.2021.


\(^{[651]}\) Indent added by Decision No 286/2021 (OJ L 204/538, 29.2.2024 and EEA Supplement No 19, 29.2.2024, p. 14), e.i.f. 30.10.2021.

\(^{[652]}\) Indent added by Decision No 287/2021 (OJ L 204/547, 29.2.2024 and EEA Supplement No 19, 29.2.2024, p. 15), e.i.f. 30.10.2021.


\(^{[654]}\) Indent added by Decision No 122/2022 (OJ L 246, 22.9.2022, p. 64 and EEA Supplement No 61, 22.9.2022, p. 63), e.i.f. 30.4.2022.
The transitional arrangements set out in the Annexes to the Act of Accession of 9 December 2011 for Croatia (Annex V, Chapter 10, Section VI) shall apply.

The Provisions of the Regulation shall, for the purpose of this Agreement, be read with the following adaptations:


(b) Notwithstanding the provisions of Protocol I to the Agreement, the term ‘Member State(s)’ contained in the Regulation shall be understood to include, in addition to its meaning in the Regulation, the EFTA States.

(c) As regards the EFTA States, the Agency shall, as and when appropriate, assist the EFTA Surveillance Authority or the Standing Committee, as the case may be, in the performance of their respective tasks.

(d) For products covered by Council Directive 91/414/EEC, the EFTA States will be free to limit access to their markets according to the requirements of their legislation existing at the date of entry into force of this Agreement. New EC rules will be dealt with according to the procedures laid down in Articles 97 to 104 of the Agreement.

(e) Should any disagreement between the contracting parties arise as to the administration of these provisions, Part VII of the Agreement shall apply mutatis mutandis.

(f) In Article 3, paragraph 10, the following shall be added at the end: “or into the territory of the EFTA States”.

(g) Article 64 (8) shall be read with the following adaptation:

“When the Commission takes authorisation decisions, the EFTA States will simultaneously and within 30 days of the Community Decision, take corresponding decisions. The EEA Joint Committee
shall be informed and shall periodically publish lists of such decisions in the EEA Supplement to the Official Journal.”

(h) The following paragraph shall be added in Article 79:

“4. The EFTA States shall participate fully in the Management Board and shall within it have the same rights and obligations as EC Member States, except for the right to vote. The internal rules of procedure of the Board shall give full effect to the EFTA States’ participation.”

(i) The following paragraph shall be added in Article 85:

“10. The EFTA States shall participate fully in the Member State Committee, in the Committee for Risk Assessment and the Committee for Socio-economic Analysis, and shall have the same rights and obligations as EC Member States, except for the right to vote. The internal rules of procedure of these committees shall give full effect to the EFTA States’ participation.”

(j) The following paragraph shall be added in Article 86:

“5. EFTA States shall participate in the Forum for Exchange of Information on Enforcement. The internal rules of procedure of this Forum shall give full effect to the EFTA States’ participation.’

(k) The following paragraph shall be added in Article 89:

“Nationals of the EFTA States shall be eligible as members, or as alternates, of the Board of Appeal.”

(l) The following paragraph shall be added in Article 96:

“12. The EFTA States shall, as from the entry into force of this Decision, participate in the financing of the Agency. For this purpose the procedures laid down in Article 82(1)(a) and Protocol 32 of the Agreement shall apply mutatis mutandis.”

(m) The following shall be added in Article 102:

“The EFTA States shall grant privileges and immunities to the Agency equivalent to those contained in the Protocol on privileges and immunities of the European Communities.”

(n) The following paragraph shall be added to Article 103:

“By way of derogation from Article 12(2)(a) of the Conditions of employment of other servants of the European Communities, nationals of the EFTA States enjoying their full rights as citizens may be engaged under contract by the Executive Director of the Agency.”

(o) The following paragraph shall be added in Article 118:


(p) The following paragraph shall be added in Article 124:

“Liechtenstein shall not be obliged to establish a national helpdesk. Instead, Liechtenstein will publish a link to the helpdesk of the German Federal Institute for Occupational Safety and Health on the homepage of the competent Liechtenstein authority for chemicals, the Office for Environmental Protection.”


12ze. [ ] [87]


---


12 zm. **32008 R 0465:** Commission Regulation (EC) No 465/2008 of 28 May 2008 imposing, pursuant to Council Regulation (EEC) No 793/93, testing and information requirements on importers and manufacturers of certain substances that may be persistent, bioaccumulating and toxic and are listed in the European Inventory of Existing Commercial Chemical Substances (OJ L 139, 29.5.2008, p. 10).


12 xt. [ ]


---

See notes for detailed information.


[627] Indent added by Decision No 159/2014 (OJ L 15, 22.1.2015, p. 87 and EEA Supplement No 5, 22.1.2015, p. 10), e.i.f. pending; it shall apply from 9.7.2014.


\[\text{(631)} \quad \text{32015 R 0491: Commission Regulation (EU) 2015/491 of 23 March 2015 (OJ L 78, 24.3.2015, p. 12),}\]


\[\text{(641)} \quad \text{32020 R 0011: Commission Delegated Regulation (EU) 2020/11 of 29 October 2019 (OJ L 6, 10.1.2020, p. 8),}\]

\[\text{(642)} \quad \text{32020 R 0217: Commission Delegated Regulation (EU) 2020/217 of 4 October 2019 (OJ L 44,}\]


\[\text{(626)} \quad \text{Indent added by Decision No 159/2014 (OJ L 15, 22.1.2015, p. 87 and EEA Supplement No 5, 22.1.2015, p. 10, e.i.f. pending; it shall apply from 9.7.2014.}\]

\[\text{(629)} \quad \text{Indent added by Decision No 17/2015 (OJ L 93, 7.4.2016, p. 29 and EEA Supplement No 21, 7.4.2016, p. 25), e.i.f. 26.2.2015.}\]

\[\text{(630)} \quad \text{Indent added by Decision No 53/2015 (OJ L 129, 19.5.2016, p. 35 and EEA Supplement No 29, 19.5.2016, p. 36), e.i.f. 21.3.2015.}\]

\[\text{(631)} \quad \text{Indent added by Decision No 152/2015 (OJ L 341, 15.12.2016, p. 45 and EEA Supplement No 69, 15.12.2016, p. 46), e.i.f. 12.6.2015.}\]


\[\text{(633)} \quad \text{Indent added by Decision No 179/2016 (OJ L 80, 22.3.2018, p. 21 and EEA Supplement No 19, 22.3.2018, p. 28), e.i.f. 24.9.2016.}\]

\[\text{(634)} \quad \text{Indent added by Decision No 209/2016 (OJ L 89, 5.4.2018, p. 12 and EEA Supplement No 22, 5.4.2018, p. 4), e.i.f. 29.10.2016.}\]

\[\text{(635)} \quad \text{Indent added by Decision No 131/2017 (OJ L 128, 16.5.2019, p. 23 and EEA Supplement No 40, 16.5.2019, p. 24), e.i.f. 8.7.2017.}\]

\[\text{(636)} \quad \text{Indent added by Decision No 172/2017 (OJ L 174, 27.6.2019, p. 34 and EEA Supplement No 52, 27.6.2019, p. 43), e.i.f. 23.9.2017.}\]

\[\text{(637)} \quad \text{Indent and words “as amended by,” added by Decision No 67/2019 (OJ L 210, 27.7.2020, p. 33 and EEA Supplement No 44, 2.7.2020, p. 37), e.i.f. 30.3.2019.}\]

\[\text{(638)} \quad \text{Indent added by Decision No 180/2018 (OJ L 75, 4.3.2021, p. 13 and EEA Supplement No 15, 4.3.2021, p. 13), e.i.f. 22.9.2018.}\]

\[\text{(639)} \quad \text{Indent added by Decision No 67/2019 (OJ L 210, 2.7.2020, p. 33 and EEA Supplement No 44, 2.7.2020, p. 37), e.i.f. 30.3.2019.}\]

\[\text{(640)} \quad \text{Indent added by Decision No 226/2019 (OJ L 4, 5.1.2023, p. 41 and EEA Supplement No 3, 5.1.2023, p. 41), e.i.f. 28.9.2019.}\]

\[\text{(641)} \quad \text{Indent added by Decision No 103/2020 (OJ L 172, 6.7.2023, p. 18 and EEA Supplement No 51, 6.7.2023, p. 18), e.i.f. 15.7.2020.}\]

\[\text{(642)} \quad \text{Indent added by Decision No 199/2020 (OJ L 240, 28.9.2023, p. 49 and EEA Supplement No 70, 28.9.2023, p. 48), e.i.f. 12.12.2020.}\]

\[\text{(643)} \quad \text{Corrigendum to the EU act subsequently taken note of by the EEA Joint Committee on 10.12.2021.}\]

The Provisions of Regulation (EC) No 1272/2008 shall, for the purpose of this Agreement, be read with the following adaptations:

(a) Liechtenstein shall not be obliged to establish a national helpdesk in the meaning of Article 44 of Regulation (EC) No 1272/2008. Instead, Liechtenstein will publish a link to the helpdesk of the German Federal Institute for Occupational Safety and Health on the homepage of the competent Liechtenstein authority for chemicals, the Office of Environmental Protection.

(b) The following provisions shall not apply to Norway:

(i) Article 51, in conjunction with Articles 4 and 46(1), with respect to the requirements for the classification, labelling and/or specific concentration limits for the substances or groups of substances listed in Part 3 of Annex VI to the Regulation (EC) No 1272/2008 and shown in the following list. Norway may require the use of different classification, labelling and/or specific concentration limits for this substance;

<table>
<thead>
<tr>
<th>Name</th>
<th>CAS No</th>
<th>Index No</th>
<th>EINECS</th>
</tr>
</thead>
<tbody>
<tr>
<td>acrylamide</td>
<td>79-06-1</td>
<td>616-003-00-0</td>
<td>201-173-7</td>
</tr>
</tbody>
</table>

---

[647] Indent added by Decision No 205/2021 (OJ L, 2024/311, 8.2.2024 and EEA Supplement No 13, 8.2.2024, p. 35), e.i.f. 10.7.2021.
[650] Indent added by Decision No 122/2022 (OJ L 246, 22.9.2022, p. 64 and EEA Supplement No 64, 22.9.2022, p. 63), e.i.f. 30.4.2022.
[652] Indent added by Decision No 265/2023 (OJ L No [to be published] and EEA Supplement No [to be published]), e.i.f. 28.10.2023.
[653] Indent added by Decision No 265/2023 (OJ L No [to be published] and EEA Supplement No [to be published]), e.i.f. 28.10.2023.
(ii) Article 51, in conjunction with Articles 4 and 46(1), with respect to the requirements for the classification, labelling and/or specific concentration limits for the substances or group of substances not listed in Part 3 of Annex VI to the Regulation (EC) No 1272/2008 shown in the following list. Norway may require the use of different classification, labelling and/or specific concentration limits for these substances:

<table>
<thead>
<tr>
<th>Name</th>
<th>CAS No</th>
<th>Index No</th>
<th>ELINCS</th>
</tr>
</thead>
<tbody>
<tr>
<td>methyl acrylamidoglycolate</td>
<td>77402-05-2</td>
<td>[NOR-UNN-02-91]</td>
<td>403-230-3</td>
</tr>
<tr>
<td>(containing 0.01% ≤ acrylamide &lt; 0.1%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>methyl acrylamidomethoxacetate</td>
<td>77402-03-0</td>
<td>[NOR-UNN-03-01]</td>
<td>401-890-7</td>
</tr>
<tr>
<td>(containing 0.01% ≤ acrylamide &lt; 0.1%)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(iii) Article 51, in conjunction with Articles 4, 9 and 46(1), with respect to mixtures containing substances as defined in adaptation text (i) and (ii) above.

(iv) These derogations shall elapse as from 1 June 2012 if by that date Norway does not pursue, in accordance with Article 37(1) of Regulation (EC) No 1272/2008, with the proposals for harmonised classification and labelling that were submitted to the European Chemical Agency on 1 June 2009 to support the more stringent classification and labelling.

If the procedure for harmonisation of classification and labelling foreseen in Article 37 of Regulation (EC) No 1272/2008 is pursued, a review of the derogations shall take place before 31 December 2013. If the derogations are supported by the outcome of that procedure, the derogations may be maintained by a Decision of the EEA Joint Committee. In the absence of such a Decision before 1 July 2014, the derogations shall elapse on that date.

(c) The Icelandic and Norwegian versions of the statements referred to in Articles 21 and 22 are set out in Appendices 5 and 6, respectively.


---


\[669\] Point inserted by Decision No 139/2013 (OJ L [to be published] and EEA Supplement No [to be published]), c.f.f. 16.7.2013.

\[670\] Point inserted by Decision No 139/2013 (OJ L [to be published] and EEA Supplement No [to be published]), c.f.f. 16.7.2013.

\[671\] Point inserted by Decision No 194/2013 (OJ L [to be published] and EEA Supplement No [to be published]), c.f.f. 9.11.2013.


\[675\] Point inserted by Decision No 91/2015 (OJ L 211, 4.8.2016, p. 28 and EEA Supplement No 42, 4.8.2016, p. 27), c.f.f. 1.5.2015.


---

[List of numbered points and their corresponding references.]

---


chlorine released from chlorine as an existing active substance for use in biocidal products of product-types 2 

acid generated from tetraacetyl ethylenediamine and sodium percarbonate as an existing active substance 

12zzzu. [(29)] 2017 R 1277: Commission Implementing Regulation (EU) 2017/1277 of 14 July 2017 approving 2-octyl-
isothiazol-3(2H)-one as an active substance for use in biocidal products of product-type 8 (OJ L 184, 
15.7.2017, p. 27).

12zzzuv. [(29)] 2017 R 1278: Commission Implementing Regulation (EU) 2017/1278 of 14 July 2017 approving 2-
methylisothiazol-3(2H)-one as an existing active substance for use in biocidal products of product-type 11 

12zzzw. [(29)] 2017 D 1282: Commission Implementing Decision (EU) 2017/1282 of 14 July 2017 not approving 2-
methyl-1,2-benzisothiazol-3(2H)-one as an active substance for use in biocidal products of product-type 13 

approval of warfarin as an active substance for use in biocidal products of product-type 14 (OJ L 194, 

approval of chlorphacinone as an active substance for use in biocidal products of product-type 14 (OJ L 

12zzzz. [(29)] 2017 R 1378: Commission Implementing Regulation (EU) 2017/1378 of 25 July 2017 renewing the 
approval of coumatetralyl as an active substance for use in biocidal products of product-type 14 (OJ L 194, 

approval of difenacoum as an active substance for use in biocidal products of product-type 14 (OJ L 194, 

12zzzzx.[(29)] 2017 R 1380: Commission Implementing Regulation (EU) 2017/1380 of 25 July 2017 renewing the 
approval of bromadiolone as an active substance for use in biocidal products of product-type 14 (OJ L 194, 

12zzzzz.[(29)] 2017 R 1381: Commission Implementing Regulation (EU) 2017/1381 of 25 July 2017 renewing the 
approval of brodifacoum as an active substance for use in biocidal products of product-type 14 (OJ L 194, 

12zzzzzd.[(29)] 2017 R 1382: Commission Implementing Regulation (EU) 2017/1382 of 25 July 2017 renewing the 
approval of difethialone as an active substance for use in biocidal products of product-type 14 (OJ L 194, 


---


12zzzzzb.[57] 32019 D 1331: Commission Implementing Decision (EU) 2019/1331 of 5 August 2019 on the terms and conditions of the authorisation of a biocidal product containing peppermint oil and citronellol referred by

---

Corrigendum to the EU act subsequently taken note of by the EEA Joint Committee on 13.6.2019.
[52] Point inserted by Decision No 154/2019 (OJ L 291, 10.11.2022, p. 33 and EEA Supplementary No 74, 10.11.2022, p. 34), e.i.f. 15.6.2019.
[56] Point inserted by Decision No 228/2019 (OJ L 4, 5.1.2023, p. 44 and EEA Supplementary No 3, 5.1.2023, p. 44), e.i.f. 28.9.2019.


---

{766} Point inserted by Decision No 11/2020 (OJ L 49, 16.2.2023, p. 27 and EEA Supplement No 13, 16.2.2023, p. 28), e.i.f. 8.2.2020.

{767} Point inserted by Decision No 60/2020 (OJ L 72, 9.3.2023, p. 24 and EEA Supplement No 19, 9.3.2023, p. 25), e.i.f. 1.5.2020.

{768} Point inserted by Decision No 60/2020 (OJ L 72, 9.3.2023, p. 24 and EEA Supplement No 19, 9.3.2023, p. 25), e.i.f. 1.5.2020.

{769} Point inserted by Decision No 60/2020 (OJ L 72, 9.3.2023, p. 24 and EEA Supplement No 19, 9.3.2023, p. 25), e.i.f. 1.5.2020.


{772} Point inserted by Decision No 60/2020 (OJ L 72, 9.3.2023, p. 24 and EEA Supplement No 19, 9.3.2023, p. 25), e.i.f. 1.5.2020.


---


Point inserted by Decision No 206/2021 (OJ L 2024/305, 8.2.2024 and EEA Supplement No 13, 8.2.2024, p. 37), e.i.f. 10.7.2021.

Point inserted by Decision No 206/2021 (OJ L 2024/305, 8.2.2024 and EEA Supplement No 13, 8.2.2024, p. 37), e.i.f. 10.7.2021.


---


\(^{(79)}\) Point inserted by Decision No 290/2021 (OJ L, 2024/540, 29.2.2024 and EEA Supplement No 19, 29.2.2024, p. 19), c.f.f. 30.10.2021

\(^{(80)}\) Point inserted by Decision No 290/2021 (OJ L, 2024/540, 29.2.2024 and EEA Supplement No 19, 29.2.2024, p. 19), c.f.f. 30.10.2021


12zzzzsz.([82]) 2021 D 2149: Commission Implementing Decision (EU) 2021/2149 of 3 December 2021 on unresolved objections regarding the terms and conditions of the provisional authorisation of a biocidal product containing 5-Chloro-2-methyl-2H-isothiazol-3-one (C(M)IT) referred by France in accordance with Article 36(1) of Regulation (EU) No 528/2012 of the European Parliament and of the Council (OJ L 434, 6.12.2021, p. 5).


12zzzzuv.([85]) 2022 D 0146: Commission Implementing Decision (EU) 2022/146 of 1 February 2022 determining whether a product containing Alkyl (C12-16) dimethylbenzyl ammonium chloride is a biocidal product,

---

[76] Point inserted by Decision No 65/2022 (OJ L 182, 7.7.2022, p. 43 and EEA Supplement No 45, 7.7.2022, p. 31), e.i.f. 19.3.2022.
[77] Point inserted by Decision No 65/2022 (OJ L 182, 7.7.2022, p. 43 and EEA Supplement No 45, 7.7.2022, p. 31), e.i.f. 19.3.2022.
[78] Point inserted by Decision No 65/2022 (OJ L 182, 7.7.2022, p. 43 and EEA Supplement No 45, 7.7.2022, p. 31), e.i.f. 19.3.2022.


12zzzzzzzd. [**7**] Commission Implementing Decision (EU) 2022/874 of 1 June 2022 on the terms and conditions of the authorisation of a biocidal product containing N-(trichloromethylthio)phthalimide (Folpet) referred by the Netherlands in accordance with Article 36(1) of Regulation (EU) No 528/2012 of the European Parliament and of the Council (OJ L 152, 3.6.2022, p. 187).


12zzzzzzzf. [**4**]

12zzzzzzzg. [**4**] Commission Implementing Decision (EU) 2022/1487 of 7 September 2022 postponing the expiry date of the approval of etofenprox for use in biocidal products of product-type 8 in accordance

---

**Footnotes:**


12zzzzzzzzb.(83)32023 D 0459: Commission Implementing Decision (EU) 2023/459 of 2 March 2023 not approving 2,2-Dibromo-2-cyanoacetamide (DBNPA) as an existing active substance for use in biocidal products of

---

(81) Point inserted by Decision No 180/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 6.7.2023.
(82) Point inserted by Decision No 234/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 23.9.2023.
(83) Point inserted by Decision No 235/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 23.9.2023.


---


**(33)** Point inserted by Decision No 236/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.l.f. 23.9.2023.

**(34)** Point inserted by Decision No 266/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.l.f. 28.10.2023.

**(35)** Point inserted by Decision No 266/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.l.f. 28.10.2023.

**(36)** Point inserted by Decision No 266/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.l.f. 28.10.2023.

**(37)** Point inserted by Decision No 266/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.l.f. 28.10.2023.

**(38)** Point inserted by Decision No 266/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.l.f. 28.10.2023.

**(39)** Point inserted by Decision No 266/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.l.f. 28.10.2023.

**(40)** Point inserted by Decision No 266/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.l.f. 28.10.2023.

**(41)** Point inserted by Decision No 266/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.l.f. 28.10.2023.

**(42)** Point inserted by Decision No 266/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.l.f. 28.10.2023.

**(43)** Point inserted by Decision No 266/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.l.f. 28.10.2023.


---

\[\text{[4]}\] Point inserted by Decision No 315/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 9.12.2023.

\[\text{[4]}\] Point inserted by Decision No 315/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 9.12.2023.

\[\text{[4]}\] Point inserted by Decision No 15/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

\[\text{[4]}\] Point inserted by Decision No 15/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

\[\text{[4]}\] Point inserted by Decision No 15/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

\[\text{[4]}\] Point inserted by Decision No 15/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

\[\text{[4]}\] Point inserted by Decision No 15/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

\[\text{[4]}\] Point inserted by Decision No 15/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

\[\text{[4]}\] Point inserted by Decision No 62/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 16.3.2024.


\[^{[84]}\] Point inserted by Decision No 62/2024 (OJ L [to be published]) and EEA Supplement No [to be published]), c.i.f. 16.3.2024.

\[^{[85]}\] Point inserted by Decision No 62/2024 (OJ L [to be published]) and EEA Supplement No [to be published]), c.i.f. 16.3.2024.

\[^{[86]}\] Point inserted by Decision No 62/2024 (OJ L [to be published]) and EEA Supplement No [to be published]), c.i.f. 16.3.2024.

\[^{[87]}\] Point inserted by Decision No 62/2024 (OJ L [to be published]) and EEA Supplement No [to be published]), c.i.f. 16.3.2024.

\[^{[88]}\] Point inserted by Decision No 62/2024 (OJ L [to be published]) and EEA Supplement No [to be published]), c.i.f. 16.3.2024.

\[^{[89]}\] Point inserted by Decision No 62/2024 (OJ L [to be published]) and EEA Supplement No [to be published]), c.i.f. 16.3.2024.

\[^{[90]}\] Point inserted by Decision No 62/2024 (OJ L [to be published]) and EEA Supplement No [to be published]), c.i.f. 16.3.2024.

\[^{[91]}\] Point inserted by Decision No 62/2024 (OJ L [to be published]) and EEA Supplement No [to be published]), c.i.f. 16.3.2024.


\[^{[93]}\] Inserted and words “, as amended by:” added by Decision No 18/2015 (OJ L 93, 7.4.2016, p. 30 and EEA Supplement No 21, 7.4.2016, p. 26), c.i.f. pending. It shall apply provisionally pending the entry into force of the 2014 EEA Enlargement Agreement, from the day of entry into force of Decision of the Joint Committee No 203/2014 which c.i.f. 1.6.2015.
The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptations:

(a) The EFTA States shall be free to limit access to their markets of plant protection products containing active substances approved in accordance with Council Directive 91/414/EEC or the Transitional measures in Article 80 of Regulation (EC) No 1107/2009.

(b) The EFTA States, with the exception of Liechtenstein, may be 'rapporteur Member State' and 'co-rapporteur'.

(c) The following shall be added to Article 18:

“The allocation of evaluation of active substances to an EFTA State according to Article 18(f) is subject to consent from that State.”

(d) The following shall be added to Articles 37(4) and 42(2):

“For the EFTA States the time limit of 120 days shall at the earliest run from the date when the Act of approval of the active substances contained in the plant protection product is incorporated into the present Agreement.”

(e) The following shall be added to Article 47(3):

“For the EFTA States the time limit of 120 days shall at the earliest run from the date when the Act of approval of the active substances contained in the low-risk plant protection product is incorporated into the present Agreement.”

(f) The following shall be added to Article 48:
“The EFTA States may limit access to their markets of plant protection products containing genetically modified organisms, when measures to restrict or prohibit those organisms have been taken according to Article 23 of Directive 2001/18/EC, as adapted by this Agreement.”

(g) Article 49 shall not apply to Liechtenstein.

(h) Article 80(6) shall be replaced by the following:

“Plant protection products authorized in accordance with national provisions applicable at the time of authorization may continue to be placed on the market until the plant protection product has been risk assessed according to Regulation (EU) No 1107/2009.”

(i) In Article 80(8), as regards the EFTA States, the words “15 July 2019” shall read “the date of entry into force of Decision of the EEA Joint Committee No 77/2023 of 28 April 2023.”

(j) The following shall be added to “Zone A – North” in Annex I:

“Iceland, Norway”

(k) The following shall be added to “Zone B – Centre” in Annex I:

“Liechtenstein”


Adaptations (i) to (j) are renumbered as adaptations (j) to (k) and adaptation text (i) inserted by Decision 77/2023 (OJ L, 2023/02233, 9.11.2023 and EEA Supplement No 81, 9.11.2023, p. 3), e.i.f. pending


\[\text{Indents added by Decision No 204/2014 (OJ L 202, 30.7.2015, p. 64 and EEA Supplement No 43, 30.7.2015, p. 63), e.i.f. 1.6.2015.}\]

\[\text{Indents added by Decision No 204/2014 (OJ L 202, 30.7.2015, p. 64 and EEA Supplement No 43, 30.7.2015, p. 63), e.i.f. 1.6.2015.}\]

\[\text{Indents added by Decision No 204/2014 (OJ L 202, 30.7.2015, p. 64 and EEA Supplement No 43, 30.7.2015, p. 63), e.i.f. 1.6.2015.}\]

\[\text{Indents added by Decision No 204/2014 (OJ L 202, 30.7.2015, p. 64 and EEA Supplement No 43, 30.7.2015, p. 63), e.i.f. 1.6.2015 and subsequently corrected before publication by Corrigendum of 20.3.2015.}\]

\[\text{Indents added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.}\]

\[\text{Indents added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.}\]

\[\text{Indents added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.}\]

\[\text{Indents added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.}\]

\[\text{Indents added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.}\]

\[\text{Indents added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.}\]

\[\text{Indents added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.}\]


---

\[928]\text{Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.}

\[929]\text{Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015 and subsequently deleted by Decision No 91/2023 (OJ L 202, 24.9.2023, p. 31), e.i.f. 1.6.2023.}

\[930]\text{Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.}

\[931]\text{Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.}

\[932]\text{Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.}

\[933]\text{Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.}

\[934]\text{Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.}

\[935]\text{Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.}

\[936]\text{Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.}

\[937]\text{Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.}

\[938]\text{Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.}

\[939]\text{Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.}

\[940]\text{Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.}

\[941]\text{Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.}

\[942]\text{Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.}

\[943]\text{Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.}

\[944]\text{Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.}

\[945]\text{Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.}


\(^{(225)}\) Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.

\(^{(229)}\) Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.

\(^{(227)}\) Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.

\(^{(228)}\) Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.

\(^{(229)}\) Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.

\(^{(229)}\) Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.

\(^{(223)}\) Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.

\(^{(223)}\) Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.

\(^{(223)}\) Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.

\(^{(223)}\) Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.

\(^{(223)}\) Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.

\(^{(223)}\) Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.

\(^{(223)}\) Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.i.f. 1.6.2015.

\[**48**\] Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.l.f. 1.6.2015.
\[**49**\] Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.l.f. 1.6.2015.
\[**50**\] Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.l.f. 1.6.2015.
\[**51**\] Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.l.f. 1.6.2015.
\[**52**\] Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.l.f. 1.6.2015.
\[**53**\] Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.l.f. 1.6.2015.
\[**54**\] Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.l.f. 1.6.2015.
\[**55**\] Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.l.f. 1.6.2015.
\[**56**\] Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.l.f. 1.6.2015.
\[**57**\] Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.l.f. 1.6.2015.
\[**58**\] Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.l.f. 1.6.2015.
\[**59**\] Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.l.f. 1.6.2015.
\[**60**\] Indent added by Decision No 205/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), e.l.f. 1.6.2015.


**(95)** Indent added by Decision No 207/2014 (OJ L 202, 30.7.2015, p. 92 and EEA Supplement No 43, 30.7.2015, p. 91), e.i.f. 1.6.2015.
**(95)** Indent added by Decision No 207/2014 (OJ L 202, 30.7.2015, p. 92 and EEA Supplement No 43, 30.7.2015, p. 91), e.i.f. 1.6.2015.
**(95)** Indent added by Decision No 207/2014 (OJ L 202, 30.7.2015, p. 92 and EEA Supplement No 43, 30.7.2015, p. 91), e.i.f. 1.6.2015.
**(95)** Indent added by Decision No 207/2014 (OJ L 202, 30.7.2015, p. 92 and EEA Supplement No 43, 30.7.2015, p. 91), e.i.f. 1.6.2015.
**(95)** Indent added by Decision No 207/2014 (OJ L 202, 30.7.2015, p. 92 and EEA Supplement No 43, 30.7.2015, p. 91), e.i.f. 1.6.2015.
**(95)** Indent added by Decision No 207/2014 (OJ L 202, 30.7.2015, p. 92 and EEA Supplement No 43, 30.7.2015, p. 91), e.i.f. 1.6.2015.
**(95)** Indent added by Decision No 207/2014 (OJ L 202, 30.7.2015, p. 92 and EEA Supplement No 43, 30.7.2015, p. 91), e.i.f. 1.6.2015.
**(95)** Indent added by Decision No 207/2014 (OJ L 202, 30.7.2015, p. 92 and EEA Supplement No 43, 30.7.2015, p. 91), e.i.f. 1.6.2015.
**(95)** Indent added by Decision No 207/2014 (OJ L 202, 30.7.2015, p. 92 and EEA Supplement No 43, 30.7.2015, p. 91), e.i.f. 1.6.2015.
**(95)** Indent added by Decision No 207/2014 (OJ L 202, 30.7.2015, p. 92 and EEA Supplement No 43, 30.7.2015, p. 91), e.i.f. 1.6.2015.


\[\text{Indent added by Decision No 221/2014 (OJ L 230, 3.9.2015, p. 22 and EEA Supplement No 52, 3.9.2015, p. 22), e.i.f. 1.6.2015.}\]

\[\text{Indent added by Decision No 221/2014 (OJ L 230, 3.9.2015, p. 22 and EEA Supplement No 52, 3.9.2015, p. 22), e.i.f. 1.6.2015 and subsequently deleted by Decision No 17/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.}\]

\[\text{Indent added by Decision No 221/2014 (OJ L 230, 3.9.2015, p. 22 and EEA Supplement No 52, 3.9.2015, p. 22), e.i.f. 1.6.2015.}\]

\[\text{Indent added by Decision No 221/2014 (OJ L 230, 3.9.2015, p. 22 and EEA Supplement No 52, 3.9.2015, p. 22), e.i.f. 1.6.2015.}\]

\[\text{Indent added by Decision No 221/2014 (OJ L 230, 3.9.2015, p. 22 and EEA Supplement No 52, 3.9.2015, p. 22), e.i.f. 1.6.2015.}\]


\[\text{Indent added by Decision No 270/2014 (OJ L 311, 26.11.2015, p. 21 and EEA Supplement No 71, 26.11.2015, p. 20), e.i.f. 1.6.2015.}\]

\[\text{Indent added by Decision No 271/2014 (OJ L 311, 26.11.2015, p. 22 and EEA Supplement No 71, 26.11.2015, p. 21), e.i.f. 1.6.2015.}\]

\[\text{Indent added by Decision No 271/2014 (OJ L 311, 26.11.2015, p. 22 and EEA Supplement No 71, 26.11.2015, p. 21), e.i.f. 1.6.2015.}\]

\[\text{Indent added by Decision No 271/2014 (OJ L 311, 26.11.2015, p. 22 and EEA Supplement No 71, 26.11.2015, p. 21), e.i.f. 1.6.2015.}\]

\[\text{Indent added by Decision No 271/2014 (OJ L 311, 26.11.2015, p. 22 and EEA Supplement No 71, 26.11.2015, p. 21), e.i.f. 1.6.2015.}\]

\[\text{Indent added by Decision No 271/2014 (OJ L 311, 26.11.2015, p. 22 and EEA Supplement No 71, 26.11.2015, p. 21), e.i.f. 1.6.2015.}\]

\[\text{Indent added by Decision No 271/2014 (OJ L 311, 26.11.2015, p. 22 and EEA Supplement No 71, 26.11.2015, p. 21), e.i.f. 1.6.2015.}\]
ANNEX II – p. 215

15.3.2024

- EEA AGREEMENT -


-{1012} 32015 R 0543: Commission Implementing Regulation (EU) 2015/543 of 1 April 2015 (OJ L 90, 2.4.2015, p. 1),

-{1013} 32015 R 0553: Commission Implementing Regulation (EU) 2015/553 of 7 April 2015 (OJ L 92, 8.4.2015, p. 86),


-{1000} Indent added by Decision No 93/2015 (OJ L 211, 4.8.2016, p. 31 and EEA Supplement No 42, 4.8.2016, p. 30), e.i.f. 1.6.2015.

-{1001} Indent added by Decision No 94/2015 (OJ L 211, 4.8.2016, p. 32 and EEA Supplement No 42, 4.8.2016, p. 31), e.i.f. 1.6.2015.

-{1002} Indent added by Decision No 95/2015 (OJ L 211, 4.8.2016, p. 33 and EEA Supplement No 42, 4.8.2016, p. 32), e.i.f. 1.6.2015.

-{1003} Indent added by Decision No 95/2015 (OJ L 211, 4.8.2016, p. 33 and EEA Supplement No 42, 4.8.2016, p. 32), e.i.f. 1.6.2015. Corrigendum to the EU Act subsequently taken note of by the EEA Joint Committee on 10.6.2022.

-{1004} Indent added by Decision No 95/2015 (OJ L 211, 4.8.2016, p. 33 and EEA Supplement No 42, 4.8.2016, p. 32), e.i.f. 1.6.2015.

-{1005} Indent added by Decision No 95/2015 (OJ L 211, 4.8.2016, p. 33 and EEA Supplement No 42, 4.8.2016, p. 32), e.i.f. 1.6.2015.

-{1006} Indent added by Decision No 95/2015 (OJ L 211, 4.8.2016, p. 33 and EEA Supplement No 42, 4.8.2016, p. 32), e.i.f. 1.6.2015.


-{1012} Indent added by Decision No 183/2015 (OJ L 8, 12.1.2017, p. 12 and EEA Supplement No 3, 12.1.2017, p. 11), e.i.f. 11.7.2015.

-{1013} Indent added by Decision No 183/2015 (OJ L 8, 12.1.2017, p. 12 and EEA Supplement No 3, 12.1.2017, p. 11), e.i.f. 11.7.2015.


\[1104\] Indent added by Decision No 54/2018 (OJ L 26, 30.1.2020, p. 35 and EEA Supplement No 6, 30.1.2020, p. 28), e.i.f. 24.3.2018.

\[1105\] Indent added by Decision No 54/2018 (OJ L 26, 30.1.2020, p. 35 and EEA Supplement No 6, 30.1.2020, p. 28), e.i.f. 24.3.2018.

\[1106\] Indent added by Decision No 54/2018 (OJ L 26, 30.1.2020, p. 35 and EEA Supplement No 6, 30.1.2020, p. 28), e.i.f. 24.3.2018.

\[1107\] Indent added by Decision No 54/2018 (OJ L 26, 30.1.2020, p. 35 and EEA Supplement No 6, 30.1.2020, p. 28), e.i.f. 24.3.2018.

\[1108\] Indent added by Decision No 54/2018 (OJ L 26, 30.1.2020, p. 35 and EEA Supplement No 6, 30.1.2020, p. 28), e.i.f. 24.3.2018.

\[1109\] Indent added by Decision No 54/2018 (OJ L 26, 30.1.2020, p. 35 and EEA Supplement No 6, 30.1.2020, p. 28), e.i.f. 24.3.2018.

\[1110\] Indent added by Decision No 54/2018 (OJ L 26, 30.1.2020, p. 35 and EEA Supplement No 6, 30.1.2020, p. 28), e.i.f. 24.3.2018.


\[1114\] Indent added by Decision No 90/2018 (OJ L 340, 15.10.2020, p. 23 and EEA Supplement No 66, 15.10.2020, p. 28), e.i.f. 28.4.2018.


{[1135]} Indent added by Decision No 69/2019 (OJ L 210, 2.7.2020, p. 36 and EEA Supplement No 44, 2.7.2020, p. 41), e.i.f. 30.3.2019.

{[1136]} Indent added by Decision No 69/2019 (OJ L 210, 2.7.2020, p. 36 and EEA Supplement No 44, 2.7.2020, p. 41), e.i.f. 30.3.2019.

{[1137]} Indent added by Decision No 69/2019 (OJ L 210, 2.7.2020, p. 36 and EEA Supplement No 44, 2.7.2020, p. 41), e.i.f. 30.3.2019.

{[1138]} Indent added by Decision No 69/2019 (OJ L 210, 2.7.2020, p. 36 and EEA Supplement No 44, 2.7.2020, p. 41), e.i.f. 30.3.2019.

{[1139]} Indent added by Decision No 69/2019 (OJ L 210, 2.7.2020, p. 36 and EEA Supplement No 44, 2.7.2020, p. 41), e.i.f. 30.3.2019.

{[1140]} Indent added by Decision No 69/2019 (OJ L 210, 2.7.2020, p. 36 and EEA Supplement No 44, 2.7.2020, p. 41), e.i.f. 30.3.2019.


-\textsuperscript{1172} 2019 R 0706: Commission Implementing Regulation (EU) 2019/706 of 7 May 2019 (OJ L 120, 8.5.2019, p. 11),

\textsuperscript{1165} Indent added by Decision No 229/2019 (OJ L 4, 5.1.2023, p. 46 and EEA Supplement No 3, 5.1.2023, p. 46), e.i.f. 28.9.2019.
\textsuperscript{1175} Indent added by Decision No 31/2020 (OJ L 57, 23.2.2023, p. 3 and EEA Supplement No 16, 23.2.2023, p. 3), e.i.f. 21.3.2020.
\textsuperscript{1176} Indent added by Decision No 32/2020 (OJ L 57, 23.2.2023, p. 5 and EEA Supplement No 16, 23.2.2023, p. 5), e.i.f. 21.3.2020.
\textsuperscript{1177} Indent added by Decision No 33/2020 (OJ L 57, 23.2.2023, p. 7 and EEA Supplement No 16, 23.2.2023, p. 7), e.i.f. 21.3.2020.
\textsuperscript{1178} Indent added by Decision No 33/2020 (OJ L 57, 23.2.2023, p. 7 and EEA Supplement No 16, 23.2.2023, p. 7), e.i.f. 21.3.2020.
\textsuperscript{1179} Indent added by Decision No 33/2020 (OJ L 57, 23.2.2023, p. 7 and EEA Supplement No 16, 23.2.2023, p. 7), e.i.f. 21.3.2020.


\[1181\] Indent added by Decision No 33/2020 (OJ L 57, 23.2.2023, p. 7 and EEA Supplement No 16, 23.2.2023, p. 7), e.i.f. 21.3.2020.
-\(^{(119)}\) **32020 R 0617**: Commission Implementing Regulation (EU) 2020/617 of 5 May 2020 (OJ L 143, 6.5.2020, p. 6).


---


\([1215]\) Indent added by Decision No 239/2021 (OJ L, 2024/502, 22.2.2024 and EEA Supplement No 17, 22.2.2024, p. 21), e.i.f. 25.9.2021.

\([1216]\) Indent added by Decision No 239/2021 (OJ L, 2024/502, 22.2.2024 and EEA Supplement No 17, 22.2.2024, p. 21), e.i.f. 25.9.2021.

\([1217]\) Indent added by Decision No 239/2021 (OJ L, 2024/502, 22.2.2024 and EEA Supplement No 17, 22.2.2024, p. 21), e.i.f. 25.9.2021.

\([1218]\) Indent added by Decision No 239/2021 (OJ L, 2024/502, 22.2.2024 and EEA Supplement No 17, 22.2.2024, p. 21), e.i.f. 25.9.2021.

\([1219]\) Indent added by Decision No 239/2021 (OJ L, 2024/502, 22.2.2024 and EEA Supplement No 17, 22.2.2024, p. 21), e.i.f. 25.9.2021.

\([1220]\) Indent added by Decision No 239/2021 (OJ L, 2024/502, 22.2.2024 and EEA Supplement No 17, 22.2.2024, p. 21), e.i.f. 25.9.2021.

\([1221]\) Indent added by Decision No 239/2021 (OJ L, 2024/502, 22.2.2024 and EEA Supplement No 17, 22.2.2024, p. 21), e.i.f. 25.9.2021.

\([1222]\) Indent added by Decision No 239/2021 (OJ L, 2024/502, 22.2.2024 and EEA Supplement No 17, 22.2.2024, p. 21), e.i.f. 25.9.2021.

\([1223]\) Indent added by Decision No 239/2021 (OJ L, 2024/502, 22.2.2024 and EEA Supplement No 17, 22.2.2024, p. 21), e.i.f. 25.9.2021.

\([1224]\) Indent added by Decision No 239/2021 (OJ L, 2024/502, 22.2.2024 and EEA Supplement No 17, 22.2.2024, p. 21), e.i.f. 25.9.2021.

\[1237\] Indent added by Decision No 67/2022 (OJ L 182, 7.7.2022, p. 46 and EEA Supplement No 45, 7.7.2022, p. 34), e.i.f. 19.3.2022.
\[1238\] Indent added by Decision No 126/2022 (OJ L 246, 22.9.2022, p. 71 and EEA Supplement No 61, 22.9.2022, p. 70), e.i.f. 30.4.2022.
\[1239\] Indent added by Decision No 127/2022 (OJ L 246, 22.9.2022, p. 73 and EEA Supplement No 61, 22.9.2022, p. 72), e.i.f. 30.4.2022.


-1249) 32022 R 0019: Commission Implementing Regulation (EU) 2022/19 of 7 January 2022 (OJ L 5, 10.1.2022, p. 9),


-1254) 32022 R 0698: Commission Implementing Regulation (EU) 2022/698 of 3 May 2022 (OJ L 130, 4.5.2022, p. 3),

\[1246\) Indent added by Decision No 128/2022 (OJ L 246, 22.9.2022, p. 75 and EEA Supplement No 61, 22.9.2022, p. 74), e.i.f. 30.4.2022.

\[1241\) Indent added by Decision No 128/2022 (OJ L 246, 22.9.2022, p. 75 and EEA Supplement No 61, 22.9.2022, p. 74), e.i.f. 30.4.2022.

\[1242\) Indent added by Decision No 128/2022 (OJ L 246, 22.9.2022, p. 75 and EEA Supplement No 61, 22.9.2022, p. 74), e.i.f. 30.4.2022.

\[1245\) Indent added by Decision No 128/2022 (OJ L 246, 22.9.2022, p. 75 and EEA Supplement No 61, 22.9.2022, p. 74), e.i.f. 30.4.2022.

\[1244\) Indent added by Decision No 128/2022 (OJ L 246, 22.9.2022, p. 75 and EEA Supplement No 61, 22.9.2022, p. 74), e.i.f. 30.4.2022.


[(134)] 32022 R 0437: Commission Implementing Regulation (EU) 2022/437 of 16 March 2022 (OJ L 89, 17.3.2022, p. 3).


\[\text{Indent added by Decision No 12/2023 (OJ L, 2023/2319, 19.10.2023 and EEA Supplement No 75, 19.10.2023, p. 17), c.e.f. 4.2.2023.}\]

\[\text{Indent added by Decision No 12/2023 (OJ L, 2023/2319, 19.10.2023 and EEA Supplement No 75, 19.10.2023, p. 17), c.e.f. 4.2.2023.}\]

\[\text{Indent added by Decision No 12/2023 (OJ L, 2023/2319, 19.10.2023 and EEA Supplement No 75, 19.10.2023, p. 17), c.e.f. 4.2.2023.}\]

\[\text{Indent added by Decision No 90/2023 (OJ L, 2023/2245, 9.11.2023 and EEA Supplement No 81, 9.11.2023, p. 28), c.e.f. 29.4.2023.}\]

\[\text{Indent added by Decision No 90/2023 (OJ L, 2023/2245, 9.11.2023 and EEA Supplement No 81, 9.11.2023, p. 28), c.e.f. 29.4.2023.}\]

\[\text{Indent added by Decision No 90/2023 (OJ L, 2023/2245, 9.11.2023 and EEA Supplement No 81, 9.11.2023, p. 28), c.e.f. 29.4.2023.}\]

\[\text{Indent added by Decision No 90/2023 (OJ L, 2023/2245, 9.11.2023 and EEA Supplement No 81, 9.11.2023, p. 28), c.e.f. 29.4.2023.}\]

\[\text{Indent added by Decision No 91/2023 (OJ L, 2023/2246, 9.11.2023 and EEA Supplement No 81, 9.11.2023, p. 31), c.e.f. 29.4.2023.}\]

\[\text{Indent added by Decision No 91/2023 (OJ L, 2023/2246, 9.11.2023 and EEA Supplement No 81, 9.11.2023, p. 31), c.e.f. 29.4.2023.}\]


({1274}) Indent added by Decision No 237/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 23.9.2023.

({1275}) Indent added by Decision No 237/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 23.9.2023.

({1276}) Indent added by Decision No 268/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 28.10.2023.

({1277}) Indent added by Decision No 268/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 28.10.2023.

({1278}) Indent added by Decision No 268/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 28.10.2023.

({1279}) Indent added by Decision No 268/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 28.10.2023.

({1280}) Indent added by Decision No 268/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 28.10.2023.

({1281}) Indent added by Decision No 268/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 28.10.2023.

({1282}) Indent added by Decision No 268/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 28.10.2023.

({1283}) Indent added by Decision No 316/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 9.12.2023.

({1284}) Indent added by Decision No 316/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 9.12.2023.


---

(1285) Indent added by Decision No 16/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

(1286) Indent added by Decision No 17/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

(1287) Indent added by Decision No 17/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

(1288) Indent added by Decision No 18/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

(1289) Indent added by Decision No 18/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

(1290) Indent added by Decision No 18/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

(1291) Indent added by Decision No 18/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

(1292) Indent added by Decision No 18/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

(1293) Indent added by Decision No 18/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

(1294) Indent added by Decision No 18/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

(1295) Indent added by Decision No 18/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

(1296) Indent added by Decision No 18/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

(1297) Indent added by Decision No 18/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

(1298) Indent added by Decision No 18/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

(1299) Indent added by Decision No 18/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.
The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptation:

The EFTA States shall be free to limit access to their markets of plant protection products containing active substances approved in accordance with Council Directive 91/414/EEC or the Transitional measures in Regulation (EC) No 1107/2009 Article 80.

13aa. 32012 R 0823: Commission Regulation (EU) No 823/2012 of 14 September 2012 derogating from Implementing Regulation (EU) No 540/2011 as regards the expiry dates of the approval of the active substances 2,4-DB, benzoic acid, beta-cyfluthrin, carfentrazone ethyl, Coniothyrium minitans Strain CON/M/91-08 (DSM 9660), cyazofamid, cyfluthrin, deltamethrin, dimethenamid-P, ethofumesate, ethoxyfluron, fenamidone, flazasulfuron, flufenacet, flurtamone, foramsulfuron, fosfiazate, imazamox, iodosulfuron, iprodione, isoxaflutole, linuron, mecarbamid, mecoprop, mesosulfuron, mesotrione, oxadiargyl, oxasulfuron, pendimethalin, picoxytrobin, propiconazole, propineb, propoxycarbazone, propyzamide, pyraclostrobin, silthiofam, trifloxystrobin, warfarin and zoxamide (OJ L 250, 15.9.2012, p. 13), as amended by:


---


---

\[^{1300}\] Indent added by Decision No 18/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

\[^{1301}\] Indent added by Decision No 18/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

\[^{1302}\] Indent added by Decision No 64/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 16.3.2024.

\[^{1303}\] Indent added by Decision No 65/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 16.3.2024.

\[^{1304}\] Indent added by Decision No 65/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 16.3.2024.

\[^{1305}\] Indent added by Decision No 65/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 16.3.2024.

\[^{1306}\] Point inserted by Decision No 204/2014 (OJ L 202, 30.7.2015, p. 64 and EEA Supplement No 43, 30.7.2015, p. 63), e.i.f. 1.6.2015.


The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptations:

(a) The following shall be added to the list under the title “RSh 1” in point 1.1. of Annex II:

“IS: Eitrad i snertingi við augu.

NO: Giftig ved øyekontakt.”

(b) The following shall be added to the list under the title “RSh 2” in point 1.1. of Annex II:

“IS: Getur valdið ljósnæmingu.

NO: Kan gi overfølsomhet for sollys/UV-stråling.”

(c) The following shall be added to the list under the title “RSh 3” in point 1.1. of Annex II:


“IS: Efnið kemst í snertingu við húð skal fyrst hreinsa það af með þurrum klut og skola síðan húðina með miklu vatni.

NO: Etter kontakt med huden, fjern først produktet med en tørr klut, og vask deretter med mye vann.”

The following shall be added to the list under the title “SPo 4” under the title “Specific Provisions” in point 2.1 of Annex III:

“The following shall be added to the list under the title “SPo 5” under the title “Specific Provisions” in point 2.1 of Annex III:

“IS: Loftfræsta skal úthúð svæði/gröðurhús (vandlega/eða í tilgreindan tíma/þar til þóinn hefur þornað) áður en farðar er þangad inn aftur.

NO: De behandlede områder/veksthus ventileres (grundig/eller angivelse av tid/inntil produktet har tørket) før man oppholder seg der igjen.”

The following shall be added to the list under the title “SPe 2” in point 2.2 of Annex III:

“The following shall be added to the list under the title “SPe 3” under the title “Specific Provisions” in point 2.1 of Annex III:

“IS: Opna skal ílátið utanhús og við þurr skilyrði.

NO: Beholderen skal åpnes utendørs og under tørre forhold.”

The following shall be added to the list under the title “SPe 1” in point 2.2 of Annex III:

“The following shall be added to the list in point 1 of Annex III:

“IS: Efnið kemst í snertingu við húð og augu í snertingu við gufu og veldur kali í snertingu við vökvu.

NO: Kontakt med damp virker etsende på hud og øyne, og kontakt med væske gir frostskade.”

The following shall be added to the list in point 1 of Annex III:

“IS: Mengið ekki vatn með efninu eða íláti þess. (Hreinsid ekki búnað nálægt yfirborðsvatni/Koma skal í veg fyrir að mengun verði með af retni frá hæjarhliðum og vegum.)

NO: Unngá forurensning av vannmiljøet med produktet eller emballasjen. (Ikke rengjør spredetstyr nær overflatevann/unngá forurensning via avrenning fra gårdsplasser og veier).”

The following shall be added to the list under the title “SPo 1” under the title “Specific Provisions” in point 2.1 of Annex III:

“IS: Loftræsta grunnvæn og jordvægslíverur skal ekki nota þetta eða annað efni sem inniheldur (tilgreinið virkt efni eða flokk virkra efna eftir því sem við á) lengur eða oftar en (tilgreinið hversu lengi eða oft má nota efnið).

NO: For å beskytte (grunnvannet/jordlevende organismer) må dette produktet eller andre produkter som inneholder (angi navnet på virksomt stoff eller gruppe av virksomme stoffer) kun brukes/ikke brukes mer enn (angi tidsperiode eller antall behandlinger).”
“IS: Til að vernda grunnvatn/vatnallífverur skal ekki nota þetta efni (á tilgreinda jörðvegsgerð eða við tilgreindar aðstæður).

NO: For å beskytte (grunnvannet/vannlevende organismer) må dette produktet ikke brukes (på beskrevet jordtype eller under beskrevne forhold).”

(l) The following shall be added to the list under the title “SPe 3” in point 2.2 of Annex III:

“IS: Til að vernda vatnallífverur/plöntur utan markhóps/líðýr utan markhóps/skordýr má ekki nota efnið nær örekutuðu landi/yfirborðsvatni en (tilgreind breidd svæðis sem er ðheimiljú að úða).

NO: For å beskytte (vannlevende organismer/viltlevende planter/insekter/leddyr) må dette produktet ikke brukes nærmere enn (angi avstand) fra (overflatevann/kantvegetasjon).”

(m) The following shall be added to the list under the title “SPe 4” in point 2.2 of Annex III:

“IS: Til að vernda vatnallífverur/plöntur utan markhóps má ekki nota efnið á malbikað, steinsteypt, hellulagð eða malarborð yfirborð eða ðega (jánbrautarspor) eða önnur svæði þar sem hlutt er við afrennsli út í umhverfið.

NO: For å beskytte (vannlevende organismer/viltlevende planter) må dette produktet ikke brukes på harde overflater som asfalterte, betong- brostein- eller graslagte områder og veier/jernbane, eller på andre områder med stor risiko for avrenning.”

(n) The following shall be added to the list under the title “SPe 5” in point 2.2 of Annex III:

“IS: Til að vernda fugla/villt spendýr verður að geta þess vandlega að efnið sé algjörgula hulíð jörðvegi; getið þess sérstaklega að efnið sé hulíð í endum ræða.

NO: For å beskytte (fugler/ville pattedyr) skal produktet innblandes i jorden. Sørg også for at produktet er helt innblanded i enden av radene.”

(o) The following shall be added to the list under the title “SPe 6” in point 2.2 of Annex III:

“IS: Hreinsið upp allt efni, sem hefur farið til spillis, til að vernda fugla/villt spendýr.

NO: For å beskytte (fugler/ville pattedyr) skal alt søl fernes.”

(p) The following shall be added to the list under the title “SPe 7” in point 2.2 of Annex III:

“IS: Þeimiljú er að nota efnið á varþáma fugla.

NO: Må ikke brukes i fuglenes hekketid.”

(q) The following shall be added to the list under the title “SPe 8” in point 2.2 of Annex III:

“IS: Hættulegt frævandi skordýr/Til að vernda hýflugur og önnur frævandi skordyr er ðheimiljú að nota efnið á blómstrandi nytaþlipntur/Æheimiljú er að nota efnið þar sem hýflugur eru í fæðuleið/Fjarlægð hýflkúpur meðan meðhöndlun með efninu fer fram eða hylíð þær á meðan og í (tílega tímþ) að lokinni meðhöndlun/Æheimiljú er að nota efnið ef blómstrandi illgesi er til stadar/Eyða skal illgesi áður en það blómgest/Æheimiljú er að nota efnið fyrir (tílega tímþ).

NO: Farlig for hir. / For å beskytte hier og andre pollinerende insekter må dette produkt ikke brukes mens kulturen blomstrer. / Må ikke brukes der biene søker næring. / Dekk til eller flytt bikuber i behandlingsperioden og i (nevn antall timer/dager) etter behandlingen. / Må ikke brukes i nærheten av blomstrende ugress. / Fjern ugresset før det blomstrer. / Må ikke brukes før (tidspunkt).”

(r) The following shall be added to the list in point 2.3 of Annex III:

“IS: Til að koma í veg fyrir þolmyndun skal ekki nota þetta eða annað vamarefni sem inniheldur (tílegað vîrkt efni eða flogk vîrkt efna efir því sem við á) öftir eða lengur en (tílegað hversu oft eða lengi má nota efnið).”
NO: For å unngå utvikling av resistens må dette produkt eller andre produkter som inneholder (angi virksomt stoff eller gruppe av virksomme stoffer) kun brukes/ikke brukes mer enn (i tidsperioden eller antall ganger)."

The following shall be added to the list under the title “SPt 1” in point 2.4 of Annex III:

"IS: Beitu skal komôð fyrir þannig að ekki sé hætt á að önnur dyr komist í hana. Festa skal beituna tryggilega þannig að nagðyr geti ekki dregið hana í burtu.

NO: Produktet skal plasseres på en slik måte at risikoen for at andre dyr kan innta produktet minimeres. Pass på at produkt i blokkform ikke kan flyttes vekk av de gnagere som skal bekjempes.”

The following shall be added to the list under the title “SPt 2” in point 2.4 of Annex III:

"IS: Auðkennið svæðið, sem meðhöndlja á, meðan á meðhöndlun stendur. Varð skal við hættunni á að verða fyrir eitrun (beinni eða öbeinni) af völdum storkuvarams og tilgreina skal möteirði við honum.

NO: Det behandlede området skal merkes i behandlingsperioden. Faren for forgiftning (primær eller sekunder) ved innatak av antikaguleringsmidler, samt motgift, skal angis på oppslag.”

The following shall be added to the list under the title “SPt 3” in point 2.4 of Annex III:

"IS: Hræ nagðýra skulu fjárlæði daglega af meðhöndlæða svæðinu meðan meðhöndlun stendur yfir. Ekki má setja hræn í opin sorpilat.

NO: Døde gnagere skal fjernes fra behandlingsområdet hver dag. Døde gnagere må ikke plasseres i øpne avfallsbeholdere.”


---

([139]) Point inserted by Decision No 203/2014 (OJ L 202, 30.7.2015, p. 57 and EEA Supplement No 43, 30.7.2015, p. 57), e.i.f. 1.6.2015 and subsequently replaced by Decision No 341/2021 (OJ L 202, 24.7.2021, p. 38), e.i.f. pending.

([132]) Point inserted by Decision No 204/2014 (OJ L 202, 30.7.2015, p. 64 and EEA Supplement No 43, 30.7.2015, p. 63), e.i.f. 1.6.2015.

([131]) Point inserted by Decision No 204/2014 (OJ L 202, 30.7.2015, p. 64 and EEA Supplement No 43, 30.7.2015, p. 63), e.i.f. 1.6.2015.

([132]) Point inserted by Decision No 204/2014 (OJ L 202, 30.7.2015, p. 64 and EEA Supplement No 43, 30.7.2015, p. 63), e.i.f. 1.6.2015.

([133]) Point inserted by Decision No 204/2014 (OJ L 202, 30.7.2015, p. 64 and EEA Supplement No 43, 30.7.2015, p. 63), e.i.f. 1.6.2015.


\[134\] Point inserted by Decision No 204/2014 (OJ L 202, 30.7.2015, p. 64 and EEA Supplement No 43, 30.7.2015, p. 63), c.f.f. 1.6.2015.

\[135\] Point inserted by Decision No 204/2014 (OJ L 202, 30.7.2015, p. 64 and EEA Supplement No 43, 30.7.2015, p. 63), c.f.f. 1.6.2015.

\[135\] Point inserted by Decision No 204/2014 (OJ L 202, 30.7.2015, p. 64 and EEA Supplement No 43, 30.7.2015, p. 63), c.f.f. 1.6.2015.

\[135\] Point inserted by Decision No 204/2014 (OJ L 202, 30.7.2015, p. 64 and EEA Supplement No 43, 30.7.2015, p. 63), c.f.f. 1.6.2015.

\[135\] Point inserted by Decision No 204/2014 (OJ L 202, 30.7.2015, p. 64 and EEA Supplement No 43, 30.7.2015, p. 63), c.f.f. 1.6.2015.

\[135\] Point inserted by Decision No 204/2014 (OJ L 202, 30.7.2015, p. 64 and EEA Supplement No 43, 30.7.2015, p. 63), c.f.f. 1.6.2015.

\[135\] Point inserted by Decision No 204/2014 (OJ L 202, 30.7.2015, p. 64 and EEA Supplement No 43, 30.7.2015, p. 63), c.f.f. 1.6.2015.

\[135\] Point inserted by Decision No 204/2014 (OJ L 202, 30.7.2015, p. 64 and EEA Supplement No 43, 30.7.2015, p. 63), c.f.f. 1.6.2015.

\[135\] Point inserted by Decision No 204/2014 (OJ L 202, 30.7.2015, p. 64 and EEA Supplement No 43, 30.7.2015, p. 63), c.f.f. 1.6.2015.

\[135\] Point inserted by Decision No 204/2014 (OJ L 202, 30.7.2015, p. 73 and EEA Supplement No 43, 30.7.2015, p. 72), c.f.f. 1.6.2015.


13zr.[1588] 2012 D 0677: Commission Implementing Decision 2012/677/EU of 30 October 2012 allowing Member States to extend provisional authorisations granted for the new active substances ametocryn (initially applied for under the development code BAS 650 F) and disodium phosphate (OJ L 305, 1.11.2012, p. 27).


---

15.3.2024 - EEA AGREEMENT - ANNEX II – p. 243

---


---


13zzza.\[140\] 32012 R 0686: Commission Implementing Regulation (EU) No 686/2012 of 26 July 2012 allocating to Member States, for the purposes of the renewal procedure, the evaluation of the active substances whose approval expires by 31 December 2018 at the latest (OJ L 200, 27.7.2012, p. 5), as amended by:


---


\[140\] Indent added by Decision No 144/2017 (OJ L [to be published] and EEA Supplement No [to be published]), c.f.f. 7.7.2018.


Commission Implementing Decision 2013/38/EU of 18 January 2013 allowing Member States to extend provisional authorisations granted for the new active substances enamectin and maltodextrin (OJ L 18, 22.1.2013, p. 17).


Commission Implementing Decision 2013/205/EU of 25 April 2013 allowing Member States to extend provisional authorisations granted for the new active substances acquinocyl, aminopyralid, ascorbic acid, flubendiamide, gamma-cyhalothrin, ipconazole, metaflumizone, orthosulfamuron, Pseudomonas sp. strain DSMZ 13134, pyridalil, pyroxsulam, spiromesifen, thiencarbazone and topramezone (OJ L 117, 27.4.2013, p. 20).

Commission Implementing Regulation (EU) No 485/2013 of 24 May 2013 amending Implementing Regulation (EU) No 540/2011, as regards the conditions of approval of the active substances clothianidin, thiamethoxam and imidacloprid, and prohibiting the use and sale of seeds treated with plant protection products containing those active substances (OJ L 139, 25.5.2013, p. 12), as amended by:


Indent added by Decision No 19/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

Indent added by Decision No 65/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 16.3.2024.

Point inserted by Decision No 206/2014 (OJ L 202, 30.7.2015, p. 87 and EEA Supplement No 43, 30.7.2015, p. 86), e.i.f. 1.6.2015.

Point inserted by Decision No 206/2014 (OJ L 202, 30.7.2015, p. 87 and EEA Supplement No 43, 30.7.2015, p. 86), e.i.f. 1.6.2015.

Point inserted by Decision No 206/2014 (OJ L 202, 30.7.2015, p. 87 and EEA Supplement No 43, 30.7.2015, p. 86), e.i.f. 1.6.2015.

Point inserted by Decision No 206/2014 (OJ L 202, 30.7.2015, p. 87 and EEA Supplement No 43, 30.7.2015, p. 86), e.i.f. 1.6.2015.


Point inserted by Decision No 206/2014 (OJ L 202, 30.7.2015, p. 87 and EEA Supplement No 43, 30.7.2015, p. 86), e.i.f. 1.6.2015.


\[\text{[147]}\] Indent and words “as, as amended by” added by Decision No 128/2022 (OJ L 246, 22.9.2022, p. 75 and EEA Supplement No 61, 22.9.2022, p. 74), e.i.f. 30.4.2022.


---

{1438} Point inserted by Decision No 221/2014 (OJ L 230, 3.9.2015, p. 22 and EEA Supplement No 52, 3.9.2015, p. 22), e.i.f. 1.6.2015 and subsequently deleted by Decision No 17/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.


{1440} Point inserted by Decision No 221/2014 (OJ L 230, 3.9.2015, p. 22 and EEA Supplement No 52, 3.9.2015, p. 22), e.i.f. 1.6.2015.

{1441} Point inserted by Decision No 271/2014 (OJ L 311, 26.11.2015, p. 22 and EEA Supplement No 71, 26.11.2015, p. 21), e.i.f. 1.6.2015.

{1442} Point inserted by Decision No 271/2014 (OJ L 311, 26.11.2015, p. 22 and EEA Supplement No 71, 26.11.2015, p. 21), e.i.f. 1.6.2015.

{1443} Point inserted by Decision No 271/2014 (OJ L 311, 26.11.2015, p. 22 and EEA Supplement No 71, 26.11.2015, p. 21), e.i.f. 1.6.2015.

{1444} Point inserted by Decision No 271/2014 (OJ L 311, 26.11.2015, p. 22 and EEA Supplement No 71, 26.11.2015, p. 21), e.i.f. 1.6.2015.

{1445} Point inserted by Decision No 271/2014 (OJ L 311, 26.11.2015, p. 22 and EEA Supplement No 71, 26.11.2015, p. 21), e.i.f. 1.6.2015.

{1446} Point inserted by Decision No 274/2014 (OJ L 311, 26.11.2015, p. 27 and EEA Supplement No 71, 26.11.2015, p. 26), e.i.f. 1.6.2015.

{1447} Point inserted by Decision No 95/2015 (OJ L 211, 4.8.2016, p. 33 and EEA Supplement No 42, 4.8.2016, p. 32), e.i.f. 1.6.2015.


---


---


---


32016 R 1826: Commission Implementing Regulation (EU) 2016/1826 of 14 October 2016 concerning the non-approval of the active substance tricyclazole, in accordance with Regulation (EC) No


\[1524\] Indent and words “as amended by:” added by Decision No 293/2021 (OJ L 204/556, 29.2.2024 and EEA Supplement No 19, 29.2.2024, p. 24), e.i.f. 30.10.2021.


13zzzzzzz.\footnote{1550}32017 R 1526: Commission Implementing Regulation (EU) 2017/1526 of 6 September 2017 concerning the non-approval of the active substance beta-cypermethrin in accordance with Regulation


\[156\] Point inserted by Decision No 14/2019 (OJ L [to be published] and EEA Supplement No [to be published]), c.f. 9.2.2019.


Notes:


---


---


\(^{(166)}\) Point inserted by Decision No 208/2021 (OJ L, 2024/303, 8.2.2024 and EEA Supplement No 13, 8.2.2024, p. 40), e.i.f. 10.7.2021.
\(^{(167)}\) Point inserted by Decision No 239/2021 (OJ L, 2024/502, 22.2.2024 and EEA Supplement No 17, 22.2.2024, p. 21), e.i.f. 25.9.2021.
\(^{(168)}\) Point inserted by Decision No 239/2021 (OJ L, 2024/502, 22.2.2024 and EEA Supplement No 17, 22.2.2024, p. 21), e.i.f. 25.9.2021.


---


[1465] Indent and words “as amended by: “ added by Decision No 18/2024 (OJ L [to be published] and EEA Supplement No [to be published]), c.f.f. 3.2.2024.


---


---

[1682] Point inserted by Decision No 237/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 23.9.2023.
[1683] Point inserted by Decision No 237/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 23.9.2023.
[1684] Point inserted by Decision No 267/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 28.10.2023.
[1685] Point inserted by Decision No 267/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 28.10.2023.
[1686] Point inserted by Decision No 267/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 28.10.2023.
Point inserted by Decision No 268/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 28.10.2023.

Point inserted by Decision No 268/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 28.10.2023.

Point inserted by Decision No 268/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 28.10.2023.

Point inserted by Decision No 16/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

Point inserted by Decision No 17/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

Point inserted by Decision No 18/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.

Point inserted by Decision No 18/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.


---

[1007] Point inserted by Decision No 18/2024 (OJ I [to be published] and EEA Supplement No [to be published]), c.f. 3.2.2024.
[1008] Point inserted by Decision No 18/2024 (OJ I [to be published] and EEA Supplement No [to be published]), c.f. 3.2.2024.
[1009] Point inserted by Decision No 18/2024 (OJ I [to be published] and EEA Supplement No [to be published]), c.f. 3.2.2024.
[1010] Point inserted by Decision No 18/2024 (OJ I [to be published] and EEA Supplement No [to be published]), c.f. 3.2.2024.
[1011] Point inserted by Decision No 18/2024 (OJ I [to be published] and EEA Supplement No [to be published]), c.f. 3.2.2024.
[1012] Point inserted by Decision No 18/2024 (OJ I [to be published] and EEA Supplement No [to be published]), c.f. 3.2.2024.
[1013] Point inserted by Decision No 18/2024 (OJ I [to be published] and EEA Supplement No [to be published]), c.f. 3.2.2024.
[1014] Point inserted by Decision No 18/2024 (OJ I [to be published] and EEA Supplement No [to be published]), c.f. 3.2.2024.
[1015] Point inserted by Decision No 18/2024 (OJ I [to be published] and EEA Supplement No [to be published]), c.f. 16.3.2024.
[1016] Point inserted by Decision No 65/2024 (OJ I [to be published] and EEA Supplement No [to be published]), c.f. 16.3.2024.


[1757] Point inserted by Decision No 65/2024 (OJ L [to be published]) and EEA Supplement No [to be published]), e.i.f. 16.3.2024.


**ACTS OF WHICH THE CONTRACTING PARTIES SHALL TAKE NOTE**

The Contracting Parties take note of the content of the following acts:

1. \[\] \{1721\}


13. \[^{1733}\] 32004 H 0394: Commission Recommendation 2004/394/EC of 29 April 2004 on the results of the risk evaluation and the risk reduction strategies for the substances: Acetonitrile; Acrylamide; Acrylonitrile; Acrylic acid; Butadiene; Hydrogen fluoride; Hydrogen peroxide; Methacrylic acid; Methyl methacrylate; Toluene; Trichlorobenzene (OJ L 144, 30.4.2004, p. 72), as corrected by OJ L 199, 7.6.2004, p. 41.

14. \[^{1734}\] 32006 H 0283: Commission Recommendation of 11 April 2006 on risk reduction measures for the substances: Dibutylphthalate; 3,4-Dichloroaniline; Di-isodecyl phthalate; 1,2-Benzene dicarboxylic acid, di-C9-11-branched alkyl esters, C10-rich; Di-isoxonyl phthalate; 1,2-Benzene dicarboxylic acid, di-C8-10-branched alkyl esters, C9-rich; Ethylenediaminetetraacetate; Methyl acetate; Monochloroacetic acid; n-Pentane; Tetrasodium ethylenediaminetetraacetate (OJ L 104, 13.4.2006, p. 45).

XVI. COSMETICS

ACTS REFERRED TO

1. [ ] \[^{1735}\]


[1277] Indent and words “, as amended by:,” , added by Decision No 195/2013 (OJ L [to be published] and EEA Supplement No [to be published]), c.f. 9.11.2013.

[1278] Indent added by Decision No 196/2013 (OJ L [to be published] and EEA Supplement No [to be published]), c.f. 9.11.2013.


9. 1111

10. 1111

11. 1111
12.\footnote{1794} [ ]\footnote{1795}

13.\footnote{1796} [ ]\footnote{1797}


\textbf{ACTS OF WHICH THE CONTRACTING PARTIES SHALL TAKE NOTE}\footnote{1799}

The Contracting Parties take note of the content of the following acts:


XVII. ENVIRONMENT PROTECTION

ACTS REFERRED TO

1. [ ]

2. [ ]

3. [ ]

4. [ ]

5. [ ]

6. [ ]


The provisions of the Directive shall, for the purposes for the present Agreement, be read with the following adaptations:

(a) In point 4 (outermost regions) of Article 2, the words “Iceland, with regard to all of its territory,” shall be inserted after the word “departments.”.

(b) In point 1 of Article 6, the words “Article 95(10) of the Treaty” shall be replaced by reference to “Article 75 of the Agreement”.

(c) In Article 2(5), the word “Iceland” shall be added after the word “Finland” and the word “Norway” shall be added after the word “Lithuania”.

(d) In Article 3(4), the following subparagraph shall be added after the first subparagraph:

“Iceland may permit the placing on the market, during the summer period, of petrol containing ethanol or methanol with maximum vapour pressure of 70 kPa, on condition that the ethanol used is a biofuel or that the greenhouse gas emission saving from the use of methanol fulfils the criteria specified in Article 7b(2).”

(e) Articles 7a to 7e shall not apply to Liechtenstein.

(f) Article 7b(6) shall not apply to the EFTA States.


6aa.  

6ab.  

6ac.  

6ad.  

6ae.  

6af.  

6ag.
6ai. [ ]
6aj. [ ]
6ak. [ ]
6al. [ ]


\[190\] Point inserted by Decision No 156/2019 (OJ L 291, 10.11.2022, p. 36 and EEA Supplement No 74, 10.11.2022, p. 37), e.i.f. 15.6.2019.


1) Listed here for information purposes only; for application see Annex IV on Energy.


The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptation:

By way of derogation to paragraph 8 of Protocol 1 to the EEA Agreement, Article 2 shall not apply to grasslands situated within the territories of the EFTA States.


The provisions of the Directive, shall for the purposes of this Agreement be read with the following adaptation:

References to other acts in the Directive shall apply to the extent and in the form that those acts are incorporated into this Agreement.


The transitional arrangements set out in the Annexes to the Act of Accession of 16 April 2003 for the Czech Republic (Annex V, Chapter 7, Section A), Cyprus (Annex VII, Chapter 9, Section B), Latvia (Annex VIII, Chapter 10, Section B, point 2), Lithuania (Annex IX, Chapter 10, Section B), Hungary (Annex X, Chapter 8, Section A, point 2), Malta (Annex XI, Chapter 10, Section B, point 2), Poland (Annex XII, Chapter 13, Section B, point 2), Slovenia (Annex XIII, Chapter 9, Section A) and Slovakia (Annex XIV, Chapter 9, Section B, point 2) shall apply.

The transitional arrangements set out in the Annexes to the Act of Accession of 25 April 2005 for Bulgaria (Annex VI, Chapter 10, Section B, point 2) and Romania (Annex VII, Chapter 9, Section B, point 2), shall apply.

The provisions of the Directive shall, for the purposes of this Agreement, be read with the following adaptations:

In Article 6(7), the words “Iceland” shall be inserted after the word “Ireland” and “the, the presence of rural areas and low population density” shall be inserted after the word “areas”.


7a. 397 D 0129:

7b. [ ]

7c. [ ]


The provisions of the Decision shall, for the purposes of this Agreement, be read with the following adaptation:

For the purposes of Article 6c and Annex II, Liechtenstein shall use an equivalent method to determine the weight of the municipal waste recycled.


The transitional arrangements set out in the Annexes to the Act of Accession of 16 April 2003 for Estonia (Annex VI, Chapter 9, Section A), Latvia (Annex VIII, Chapter 10, Section A), Lithuania (Annex IX, Chapter 10, Section A), Malta (Annex XI, Chapter 10, Section A), Poland (Annex XII, Chapter 13, Section A, point 1) and Slovakia (Annex XIV, Chapter 9, Section A) shall apply.
The transitional arrangements set out in the Annexes to the Act of Accession of 25 April 2005 for Bulgaria (Annex VI, Chapter 10, Section A, point 1) and Romania (Annex VII, Chapter 9, Section A), shall apply.

The provisions of the Directive, for the purposes of the present Agreement, shall be read with the following adaptation:

Paragraph 4 of Annex I shall not apply to existing terminals in Iceland with a throughput of less than 5 000 metric tons per year, which are serviced by ships.


The provisions of the Directive shall, for the purposes for the present Agreement, be read with the following adaptation:

In Article 3(4), the words "", and for Iceland for a period of 36 months following the latter date in Annex II, to finish the Icelandic stocks" shall be inserted after the word "force".

9a. [ ] [^1878]

9aa. [ ] [^1879]


The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptations:

(a) In Article 4(2), as regards the EFTA States, the words “31 December 2016” shall read “one year after the date of entry into force of Decision of the EEA Joint Committee No 160/2019 of 14 June 2019”.

(b) In Article 5(2), as regards the EFTA States, the words “1 January 2017” shall read “one year after the date of entry into force of Decision of the EEA Joint Committee No 160/2019 of 14 June 2019”.


[^1877] Indent added by Decision No 317/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. pending.


(c) In Article 12(3)(c), as regards the EFTA States, the words “1 January 2017” shall read “one year after the date of entry into force of Decision of the EEA Joint Committee No 160/2019 of 14 June 2019”.

(d) Articles 14 to 19 and Article 25(2) shall not apply.


---


The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptations:

(a) The first paragraph of Article 3 shall not apply to the EFTA States.

(b) In the second paragraph of Article 3, with regard to the EFTA States, the words “Annex A, B or C to Regulation (EC) No 338/97” shall read “the relevant parts of the legislation implementing the Convention on International Trade in Endangered Species of Wild Fauna and Flora in that EFTA State”.

(c) In Article 8(3), (5) and (6), if monitoring organisations of an EFTA State are concerned and without prejudice to Protocol 1 to the Agreement, the word “Commission” shall read “the EFTA Surveillance Authority”.


The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptation:

If monitoring organisations of an EFTA State are concerned and without prejudice to Protocol 1 to the Agreement, the word “Commission” shall read “the EFTA Surveillance Authority”.


The provision of the Regulation shall, for the purposes of this Agreement, be read with the following adaptation:

In Article 6(2)(b), if monitoring organisations of an EFTA State are concerned and without prejudice to Protocol 1 to the Agreement, the word “Commission” shall read “the EFTA Surveillance Authority”.

---


\{1889\} Point and adaptation text inserted by Decision No 75/2013 (OJ L 291, 31.10.2013, p. 32 and EEA Supplement No 61, 31.10.2013, p. 36), e.i.f. 1.5.2015.

\{1891\} Point and adaptation text inserted by Decision No 75/2013 (OJ L 291, 31.10.2013, p. 32 and EEA Supplement No 61, 31.10.2013, p. 36), e.i.f. 1.5.2015.

\{1892\} Point and adaptation text inserted by Decision No 75/2013 (OJ L 291, 31.10.2013, p. 32 and EEA Supplement No 61, 31.10.2013, p. 36), e.i.f. 1.5.2015.


9dc. 32022 D 0162: Commission Implementing Decision (EU) 2022/162 of 4 February 2022 laying down rules for the application of Directive (EU) 2019/904 of the European Parliament and of the Council as regards the calculation, verification and reporting on the reduction in the consumption of certain single-use plastic products and the measures taken by Member States to achieve such reduction (OJ L 26, 7.2.2022, p. 19), as amended by:


The provisions of the Decision shall, for the purposes of this Agreement, be read with the following adaptation: Articles 1 and 2(1) shall not apply to Liechtenstein.


The provisions of the Directive shall, for the purposes of this Agreement, be read with the following adaptation: Articles 7, 11 and 16 shall not apply to Liechtenstein.


---

1188) Indent and words “as amended by:” added by Decision No 67/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.l.f. 16.3.2024.
The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptation:
This Regulation shall not apply to Liechtenstein.


ACTS OF WHICH THE CONTRACTING PARTIES SHALL TAKE NOTE {1981}

The Contracting Parties take note of the content of the following acts:


XVIII. INFORMATION TECHNOLOGY, TELECOMMUNICATION AND DATA PROCESSING

ACTS REFERRED TO

1. [ ]{1984}

2. [ ]{1985}


4. [ ]{1986}

4a. {1997} [ ]{1998}

4b. {1999} [ ]{1910}

---


4c. \[1911\] [ ]
4d. \[1912\] [ ]
4e. \[1913\] [ ]
4f. \[1914\] [ ]
4g. \[1915\] [ ]
4h. \[1916\] [ ]
4i. [ ] \[1917\]
4j. [ ] \[1918\]
4k. [ ] \[1919\]
4l. [ ] \[1920\]
4m. \[1921\] [ ] \[1922\]
4n. [ ] \[1923\]


4o. [ ]


4u. [ ]

4v. [ ]


4x. [ ]


---


4ze. \[ ] \[^{[140]}\]

4zf. \[ ] \[^{[141]}\]

4zg. \[ ] \[^{[142]}\]


4zu. 398 D 0482: Council Decision 98/482/EC of 20 July 1998 on a common technical regulation for the attachment requirements for connection to the analogue public switched telephone networks (PSTNs) of terminal equipment (excluding terminal equipment supporting the voice telephony justified case service) in which network addressing, if provided, is by means of dual tone multi-frequency (DTMF) signalling (OJ L 216, 4.8.1998, p. 8).


4zha. 399 D 0303: Commission Decision 1999/303/EC of 12 April 1999 on a common technical regulation for connection to the analogue public switched telephone networks (PSTNs) of terminal equipment supporting the voice telephony justified case service in which network addressing, if provided, is by means of dual tone multi-frequency (DTMF) signalling (OJ L 118, 6.5.1999, p. 55).


---


4zjl.\[1974\] \[ ] \[1975\]

4zzm. \[ ] \[1976\]


(1) Listed here for purposes of information only. For application, see Annex XIV on competition.

4zzq.\[1980\] 32013 D 0638: Commission Decision 2013/638/EU of 12 August 2013 on essential requirements relating to marine radio communication equipment which is intended to be used on non-SOLAS vessels and to participate in the Global Maritime Distress and Safety System (GMDSS) (OJ L 296, 7.11.2013, p. 22).


ACTS OF WHICH THE CONTRACTING PARTIES SHALL TAKE NOTE

The Contracting Parties take note of the content of the following acts:


XIX. GENERAL PROVISIONS IN THE FIELD OF TECHNICAL BARRIERS TO TRADE

ACTS REFERRED TO

The provisions of the Directive shall, for the purposes of this Agreement, be read with the following adaptations:

(a) The second subparagraph of Article 1(1)(c) shall be replaced by the following:

“The term ‘technical specification’ also covers production methods and processes used in respect of products intended for human and animal consumption, and in medicinal products as defined in Article 1 of Directive 2001/83/EC (as incorporated into point 15 q of Chapter XIII of Annex II to the Agreement by Decision of the EEA Joint Committee No 82/2002 of 25 June 2002\[1988\]), as well as production methods and processes relating to other products, where these have an effect on their characteristics.”;

(b) The following shall be added to the first subparagraph of Article 5(1):

“A full text of the draft technical regulation notified shall be made available in the original language as well as in a full translation into one of the official languages of the Union.”;

(c) The following subparagraph shall be added to Article 5(1):

“The Commission on behalf of the Union, on the one side, and the EFTA Surveillance Authority or the EFTA States through the EFTA Surveillance Authority, on the other side, may ask for further information on a draft technical regulation notified.”;

(d) The following subparagraph shall be added to Article 5(2):

“The comments of the EFTA States shall be forwarded by the EFTA Surveillance Authority to the Commission in the form of a single coordinated communication and the comments of the Union shall be forwarded by the Commission to the EFTA Surveillance Authority.”;

(e) The terms “Member State” and “Commission” in Article 6(1), (2) and (7) shall be replaced respectively by the terms “EFTA State” and “EFTA Surveillance Authority”.

(f) Article 6(3), (4), (5) and (6) shall not apply.


The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptation:

In Article 2(7), the words “Article 57 TFEU” shall be replaced by “Article 37 of the EEA Agreement”.

3. \[1990\]

3a. \[1991\]


The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptations:

(a) The following shall be added at the end of Article 4(2):

"Liechtenstein shall also have recourse to the national accreditation body of Switzerland for the product sectors covered by the Agreement between the European Community and the Swiss Confederation on mutual recognition in relation to conformity assessment and in respect of which EU and Swiss requirements are deemed equivalent pursuant to Article 1(2) and (3) of that Agreement."

(b) Products exported from Liechtenstein to the other Contracting Parties may be subjected to border controls according to Articles 27-29.


- [1998] 1 03 T: Act concerning the conditions of accession of the Czech Republic, the Republic of Estonia, the Republic of Cyprus, the Republic of Latvia, the Republic of Lithuania, the Republic of Hungary, the Republic of Malta, the Republic of Poland, the Republic of Slovenia and the Slovak Republic and the adjustments to the Treaties on which the European Union is founded adopted on 16 April 2003 (OJ L 236, 23.9.2003, p. 33),


---


[1993] Indent and words "as, as amended by:" added by Decision No 317/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. pending.

[1994] Adaptation (b) to be deleted by Decision No 317/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. pending.


[2000] Indent added by Decision No 159/2014 (OJ L 15, 22.1.2015, p. 87 and EEA Supplement No 5, 22.1.2015, p. 10), e.i.f. pending; it shall apply from 9.7.2014.
The provisions of the Directive shall, for the purposes of the present Agreement, be read with the following adaptations:

(a) In Annex I, point 1(a) the following shall be added to the list of written indications concerning "upper":

<table>
<thead>
<tr>
<th>IS</th>
<th>Efri hluti</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>Overdel</td>
</tr>
</tbody>
</table>

(b) In Annex I, point 1(b) the following shall be added to the list of written indications concerning "lining and sock":

<table>
<thead>
<tr>
<th>IS</th>
<th>Fóður og bindsóli</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>För og bindsåle</td>
</tr>
</tbody>
</table>

(c) In Annex I, point 1(c) the following shall be added to the list of written indications concerning "outer sole":

<table>
<thead>
<tr>
<th>IS</th>
<th>Slitsóli</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>Yttersåle</td>
</tr>
</tbody>
</table>

(d) In Annex I, point 2(a)(i) the following shall be added to the list of written indications concerning "leather":

<table>
<thead>
<tr>
<th>IS</th>
<th>Leður</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>Lær</td>
</tr>
</tbody>
</table>

(e) In Annex I, point 2(a)(ii) the following shall be added to the list of written indications concerning "coated leather":

<table>
<thead>
<tr>
<th>IS</th>
<th>Húðað leður</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>Belagt lær</td>
</tr>
</tbody>
</table>

(f) In Annex I, point 2(b) the following shall be added to the list of written indications concerning natural textile materials and synthetic or non-woven textile materials:

<table>
<thead>
<tr>
<th>IS</th>
<th>Tekstilefni</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>Tekstilmaterialer</td>
</tr>
</tbody>
</table>

(g) In Annex I, point 2(c) the following shall be added to the list of written indications concerning "all other materials":

| IS | Öll önnur efni |

---

N Andre materialer

3f. [ ]


- [2010] 03 T: Act concerning the conditions of accession of the Czech Republic, the Republic of Estonia, the Republic of Cyprus, the Republic of Latvia, the Republic of Lithuania, the Republic of Hungary, the Republic of Malta, the Republic of Poland, the Republic of Slovenia and the Slovak Republic and the adjustments to the Treaties on which the European Union is founded adopted on 16 April 2003 (OJ L 236, 23.9.2003, p. 33),


3k. [2017] 32006 D 0502: Commission Decision 2006/502/EC of 11 May 2006 requiring Member States to take measures to ensure that only lighters which are child-resistant are placed on the market and to prohibit the placing on the market of novelty lighters (OJ L 198, 20.7.2006, p. 41), as amended by:


3n. (2026) 32009 D 0251: Commission Decision 2009/251/EC of 17 March 2009 requiring Member States to ensure that products containing the biocide dimethylfumarate are not placed or made available on the market (OJ L 74, 20.3.2009, p. 32), as amended by:


(2028) Point and indent inserted by Decision No 118/2010 (OJ L 58, 3.3.2011, p. 75 and EEA Supplement No 12, 3.3.2011, p. 16), e.i.f. 11.11.2010.


This Directive shall not apply to Liechtenstein.

The provisions of the Directive shall, for the purposes of the present Agreement, be read with the following adaptation:

Article 11 shall not apply.

3r.\[2034\] **32011 D 0477**: Commission Decision 2011/477/EU of 27 July 2011 on the safety requirements to be met by European standards to address certain risks posed to children by internal blinds, corded window coverings and...


The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptations:

(a) As regards the EFTA States, this Regulation shall only apply to products covered by Article 8(3) of the EEA Agreement.

(b) The Regulation shall not apply to Liechtenstein in relation to products covered by Annex I, Chapters XII and XXVII of Annex II and Protocol 47 to the EEA Agreement, as long as the application of the Agreement between the European Community and the Swiss Confederation on trade in agricultural products is extended to Liechtenstein.

(c) The words “Article 34 TFEU” shall read “Article 11 of the EEA Agreement”.

(d) The words “Article 36 TFEU” shall read “Article 13 of the EEA Agreement”.

(e) In Article 8, the words “the Commission” shall be replaced by the words “the EFTA Surveillance Authority” when the administrative decision in question has been taken by an authority located in an EFTA State.


The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptations:

(a) Unless otherwise specified, references to Union law shall be understood as referring to the EEA Agreement.

(b) Article 3 shall be amended as follows:

(i) in paragraph 24, the words “or the customs administrations of the EFTA States responsible for applying the customs legislation and any other authorities of the EFTA States empowered under
national law to apply certain customs legislation” shall be added after the reference to Regulation (EU) No 952/2013;

(ii) in paragraph 25, the words “or, as regards the EFTA States, the corresponding procedures in accordance with their respective national customs legislation” shall be added after the reference to Regulation (EU) No 952/2013;

(iii) in paragraph 26, the words “or within the customs territories of the EFTA States” shall be added after the words “customs territory of the Union”.

(c) In paragraph 2 of Article 14, the words “, including the principles of the Charter of Fundamental Rights of the European Union” shall not apply to the EFTA States.

(d) In paragraphs 3 and 4 of Article 25 and in the second subparagraph of Article 28(4), references to Regulation (EU) No 952/2013 of the European Parliament and of the Council shall, as regards the EFTA States, be understood to refer to corresponding provisions of national customs law.

(e) As regards Liechtenstein, obligations on authorities designated under Article 25(1) shall be governed by national law.

(f) Products exported from Liechtenstein to the other Contracting Parties may be subjected to controls in accordance with Articles 25 to 28 when entering the EEA.

(g) Articles 25(2), (4) and (6) and 34(6) shall not apply to Liechtenstein.

(h) Article 26(4) shall not apply to the EFTA States.

(i) In Article 28, as regards the EFTA States, the words “the customs data-processing system” shall read “any notification issued to the affected parties in accordance with national procedures”.

(j) The EFTA States shall participate fully, without the right to vote, in the Union Product Compliance Network in accordance with Articles 29-31. The EFTA Surveillance Authority shall participate as observer.

3va. [2048] 32021 R 1121: Commission Implementing Regulation (EU) 2021/1121 of 8 July 2021 specifying the details of the statistical data to be submitted by the Member States as regards controls on products entering the Union market with regard to product safety and compliance (OJ L 243, 9.7.2021, p. 37).

The provisions of the Implementing Regulation shall, for the purposes of this Agreement, be read with the following adaptations:

(a) In paragraphs 1(c) and 4 of Article 1, references to Commission Delegated Regulation (EU) 2015/2446 shall, as regards the EFTA States, be understood to refer to corresponding provisions of national customs law.

(b) In paragraph 1(c)(ix) of Article 1, the words “Union legislation” shall be replaced by the words “provisions of the EEA Agreement”.


**ACTS OF WHICH THE CONTRACTING PARTIES SHALL TAKE NOTE**

The Contracting Parties take note of the content of the following acts:

---

[2048] Point and adaptation inserted by Decision No 317/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. pending.

[2048] Point inserted by Decision No 317/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. pending.


---


Point inserted by Decision No 64/98 (OJ L 100, 15.4.1999, p. 52 and EEA Supplement No 16, 15.4.1999, p. 113), c.f.f. 15.7.1998 and subsequently corrected by Corrigendum noted in the EEA Joint Committee Meeting on 4.10.2013.

Point inserted by Decision No 64/98 (OJ L 100, 15.4.1999, p. 52 and EEA Supplement No 16, 15.4.1999, p. 113), c.f.f. 15.7.1998 and subsequently corrected by Corrigendum noted in the EEA Joint Committee Meeting on 4.10.2013.


XX. FREE MOVEMENT OF GOODS – GENERAL

ACTS REFERRED TO


ACTS OF WHICH THE CONTRACTING PARTIES SHALL TAKE NOTE

The Contracting Parties take note of the content of the following acts:

2. Communication from the Commission concerning the consequences of the judgment given by the Court of Justice of the European Communities on 20 February 1979 in Case 120/78 ("Cassis de Dijon") (OJ No C 256, 3.10.80, p. 2).

3. Commission Communication on the completion of the Internal Market COM (85) 310 Final ("White Paper").


5. [ ]

References:


**XXI. CONSTRUCTION PRODUCTS**

**ACTS REFERRED TO**


---


1f. [ ]


---


1n. [ ] [2008]


---


1za.


**1zr.**

[ ] **113**


**1zt.**


**1zu.**


**1zv.**


**1zw.**


---

**Note:**


---


---


The provisions of this Decision shall, for the purposes of the present Agreement, be read with the following adaptations:

(a) The second paragraph of chapter 3.2.2. of the Annex shall be replaced by the following:

‘If consensus is achieved in the Technical Board on applications according to Article 8.2a of the CDP, then the appropriate information is sent with the approval of the President of EOTA to the EEA Joint Committee to obtain authority to issue ETAs. If consensus cannot be achieved in the Technical Board it will be passed to the Executive Commission for decision, as to whether it should be submitted to the EEA Joint Committee.’

(b) In the third paragraph of chapter 3.2.2. of the Annex the term ‘Commission of the EC’ shall be replaced by the term ‘EEA Joint Committee’.

---


\[2144\] Indent added by Decision No 69/2022 (OJ L 182, 7.7.2022, p. 49 and EEA Supplement No 45, 7.7.2022, p. 37), e.i.f. 19.3.2022.

\[2145\] Indent added by Decision No 131/2022 (OJ L 246, 22.9.2022, p. 80 and EEA Supplement No 61, 22.9.2022, p. 79), e.i.f. 30.4.2022.


\[2149\] Indent added by Decision No 272/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 28.10.2023.

\[2150\] Indent added by Decision No 273/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 28.10.2023.


(c) In the last sentence of chapter 3.2.5, of the Annex the words ‘shall be referred to the Standing Committee on Construction (the Directive, Article 9.2) via the Commission of the EC.’ shall be replaced by ‘shall be referred to the EEA Joint Committee.’


2h.\footnote{2161} 32010 D 0081: Commission Decision 2010/81/EU of 9 February 2010 establishing the classes of reaction to-fire performance for certain construction products as regards adhesives for ceramic tiles (OJ L 38, 11.2.2010, p. 9).


2i. \[2162\] **32010 D 0082**: Commission Decision 2010/82/EU of 9 February 2010 establishing the classes of reaction-to-fire performance for certain construction products as regards decorative wallcoverings in roll and panel form (OJ L 38, 11.2.2010, p. 11).


2t. \[2173\] **32014 R 1293**: Commission Delegated Regulation (EU) No 1293/2014 of 17 July 2014 on the conditions for classification, without testing, of metal lath and beads for internal plastering covered by the harmonised standard EN 13658-1, metal lath and beads for external rendering covered by the harmonised standard EN 13658-2 and metal beads and feature profiles covered by the harmonised standard EN 14353, with regard to their reaction to fire (OJ L 349, 5.12.2014, p. 29).

---


\[2170\] Point inserted by Decision No 24/2015 (OJ L 93, 7.4.2016, p. 38 and EEA Supplement No 21, 7.4.2016, p. 33), e.i.f. 26.2.2015.


2v. 32017 R 1228: Commission Delegated Regulation (EU) 2017/1228 of 20 March 2017 on the conditions for classification, without testing, of external renders and internal plasters based on organic binders covered by the harmonised standard EN 15824 and rendering and plastering mortars covered by the harmonised standard EN 998-1 with regard to their reaction to fire (OJ L 177, 8.7.2017, p. 4).


**ACTS OF WHICH THE CONTRACTING PARTIES SHALL TAKE NOTE**

The Contracting Parties take note of the content of the following acts:


**XXII. PERSONAL PROTECTIVE EQUIPMENT**

**ACTS REFERRED TO**

1. [ ]


**ACTS OF WHICH THE CONTRACTING PARTIES SHALL TAKE NOTE**

---


\[\text{2176} \] Point inserted by Decision No 59/2018 (OJ L 26, 30.1.2020, p. 44 and EEA Supplementary No 6, 30.1.2020, p. 36), c.i.f. 24.3.2018.


The Contracting Parties take note of the content of the following acts:


**XXIII. TOYS**

**ACTS REFERRED TO**

1. [ ] {1285}


---


ACTS OF WHICH THE CONTRACTING PARTIES SHALL TAKE NOTE{294}

The Contracting Parties take note of the content of the following acts:

2. Commission Communication pursuant to Article 9(2) of Council Directive 88/378/EEC regarding the list of bodies approved by the Member States responsible for carrying out the EC type-examination referred to in Articles 8(2) and 10 of that Directive (OJ No C 87, 27.3.1993, p. 3).


XXIV. MACHINERY

---

[Notes and references related to the text are not transcribed here.]
1. [ ] {2201}

1a. [ ] {2204}

1b. [ ] {2205}


---


{2207} Indent and words “, as amended by:” added by Decision No 279/2014 (OJ L 311, 26.11.2015, p. 32 and EEA Supplement No 71, 26.11.2015, p. 31), e.i.f. 1.6.2015.


{2213} Indent added by Decision No 38/2020 (OJ L 57, 23.2.2023, p. 16 and EEA Supplement No 16, 23.2.2023, p. 16), e.i.f. 1.8.2020.

{2214} Indent added by Decision No 70/2022 (OJ L 182, 7.7.2022, p. 50 and EEA Supplement No 45, 7.7.2022, p. 38), e.i.f. 19.3.2022.


**ACTS OF WHICH THE CONTRACTING PARTIES SHALL TAKE NOTE\{2224\}**

The Contracting Parties take note of the content of the following acts:


---


\{2216\} Indent and words “as amended by:” added by Decision No 70/2019 (OJ L 210, 2.7.2020, p. 39 and EEA Supplement No 44, 2.7.2020, p. 44), c.i.f. 30.3.2019.


**XXV. TOBACCO**

**ACTS REFERRED TO**

1. **[222]** []

2. **[222]** []


The provisions of the Directive shall, for the purposes of this Agreement, be read with the following adaptations:

(a) In the second subparagraph of Article 5(1), as regards the EFTA States, the words “by 20 November 2016” shall read “at the latest six months after the date of entry into force of Decision of the EEA Joint Committee No 6/2022 of 4 February 2022”.

(b) The following subparagraph shall be added to Article 6(4) and Article 7(13):

“In cases concerning manufacturers and importers in the EFTA States, the EFTA Surveillance Authority shall collect any fees charged by the Commission.”.

(c) With regard to Norway, the following subparagraph shall be added to Article 12(1):

“Taking into account the specific national circumstances supported by statistics regarding the health risks related to the use and use patterns of tobacco for oral use, tobacco for oral use placed on the market in Norway may carry the following alternative health warning:

“This tobacco product increases the risk of harm to the foetus and stillbirth”.”

---


[229] Indent added by Decision No 239/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. pending.
In Article 15(13), as regards the EFTA States, the words “20 May 2019” shall read “sixteen months after the date of entry into force of Decision of the EEA Joint Committee No 6/2022 of 4 February 2022”.

In Article 16(3), as regards the EFTA States, the words “20 May 2019” shall read “sixteen months after the date of entry into force of Decision of the EEA Joint Committee No 6/2022 of 4 February 2022”.

The prohibition in Article 17 shall not apply to the placing on the market in Norway of the product defined in Article 2, point (8). Norway shall ban export of the product defined in Article 2, point (8), to all Contracting Parties to this Agreement, with the exception of Sweden.

In Article 30, as regards the EFTA States, the words “20 May 2017” shall read “one year after the date of entry into force of Decision of the EEA Joint Committee No 6/2022 of 4 February 2022”.

In Article 30, points (a) and (c), as regards the EFTA States, the words “20 May 2016” shall read “the date of entry into force Decision of the EEA Joint Committee No 6/2022 of 4 February 2022”.

In Article 30, point (b), as regards the EFTA States, the words “20 November 2016” shall read “six months after the date of entry into force of Decision of the EEA Joint Committee No 6/2022 of 4 February 2022”.


3f. 32016 D 0786: Commission Implementing Decision (EU) 2016/786 of 18 May 2016 laying down the procedure for the establishment and operation of an independent advisory panel assisting Member States and the Commission in determining whether tobacco products have a characterising flavour (OJ L 131, 20.5.2016, p. 79).

3g. 32016 D 0787: Commission Implementing Decision (EU) 2016/787 of 18 May 2016 laying down a priority list of additives contained in cigarettes and roll-your-own tobacco subject to enhanced reporting obligations (OJ L 131, 20.5.2016, p. 88).

The provisions of the Decision shall, for the purposes of this Agreement, be read with the following adaptation:

---


[2233] Point inserted by Decision No 7/2022 (OJ L 175, 30.6.2022, p. 15 and EEA Supplement No 42, 30.6.2022, p. 13), e.i.f. pending.

[2234] Point inserted by Decision No 7/2022 (OJ L 175, 30.6.2022, p. 15 and EEA Supplement No 42, 30.6.2022, p. 13), e.i.f. pending.

[2235] Point inserted by Decision No 7/2022 (OJ L 175, 30.6.2022, p. 15 and EEA Supplement No 42, 30.6.2022, p. 13), e.i.f. pending.

[2236] Point inserted by Decision No 7/2022 (OJ L 175, 30.6.2022, p. 15 and EEA Supplement No 42, 30.6.2022, p. 13), e.i.f. pending.
In Article 2, as regards the EFTA States, the words “1 January 2017” shall read “the date of entry into force of Decision of the EEA Joint Committee No 7/2022 of 4 February 2022”.


The provisions of the Regulation shall, for the purposes of the EEA Agreement, be read with the following adaptations:

(a) In Article 7(6)(a), as regards the EFTA States, the words “20 May 2020” shall read “sixteen months after the entry into force of the EEA Joint Committee No 9/2022 of 4 February 2022”.

(b) In Article 7(6)(b), as regards the EFTA States, the words “20 May 2021” shall read “two years after the entry into force of the EEA Joint Committee No 9/2022 of 4 February 2022”.

(c) In Article 37(1), as regards the EFTA States, the words “20 May 2019” shall read “calendar year in which the Decision of the EEA Joint Committee No 9/2022 of 4 February 2022 enters into force”.

(d) In Article 37(2), as regards the EFTA States, the words “20 May 2020” shall read “two years and four months after the entry into force of Decision of the EEA Joint Committee No 9/2022 of 4 February 2022”.


The provisions of the Decision shall, for the purposes of the EEA Agreement, be read with the following adaptations:

(a) In Article 3(4), as regards the EFTA States, the words “20 September 2018” shall read “eight months after the entry into force of Decision of the EEA Joint Committee No 9/2022 of 4 February 2022”.

(b) In Article 4(3), as regards the EFTA States, the words “20 September 2018” shall read “eight months after the entry into force of Decision of the EEA Joint Committee No 9/2022 of 4 February 2022”.

---

[2237] Point 3h inserted by Decision No 8/2022 (OJ L 175, 30.6.2022, p. 17 and EEA Supplement No 42, 30.6.2022, p. 15), e.i.f. pending.

[2238] Point 3j inserted by Decision No 9/2022 (OJ L 175, 30.6.2022, p. 18 and EEA Supplement No 42, 30.6.2022, p. 16), e.i.f. pending.

[2239] Point 3j and adaptation text inserted by Decision No 9/2022 (OJ L 175, 30.6.2022, p. 18 and EEA Supplement No 42, 30.6.2022, p. 16), e.i.f. pending.

[2240] Indent and words “as amended by:” added by Decision No 21/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. pending, 3.2.2024.

(c) In Article 9(1), the words “20 May 2019” shall, as regards the EFTA States, read “sixteen months after the date of the entry into force of Decision of the EEA Joint Committee No 9/2022 of 4 February 2022”.

In Article 9(1), the words “20 May 2020” shall, as regards the EFTA States, read “two years and four months after the date of the entry into force of Decision of the EEA Joint Committee No 9/2022 of 4 February 2022”.

(d) In Article 9(2), the words “20 May 2024” shall, as regards the EFTA States, read “five years after the date of the entry into force of Decision of the EEA Joint Committee No 9/2022 of 4 February 2022”.

In Article 9(2), the words “20 May 2026” shall, as regards the EFTA States, read “seven years after the date of the entry into force of Decision of the EEA Joint Committee No 9/2022 of 4 February 2022”.


XXVI. ENERGY

ACTS REFERRED TO

1. [ ]

XXVII. SPIRIT DRINKS

Contracting Parties shall authorise imports and marketing of spirit drinks which are in conformity with the Community legislation as listed in this Chapter. For all other purposes, EFTA States may continue to apply their national legislation.

This Chapter shall not apply to Liechtenstein as long as the application of the Agreement between the European Community and the Swiss Confederation on trade in agricultural products is extended to Liechtenstein.

ACTS REFERRED TO:

1. [ ]


2. [ ]

3. [ ]

4.  

5.  

6.  

7.  

8.  

9.  
   32019 R 0787: Regulation (EU) 2019/787 of the European Parliament and of the Council of 17 April 2019 on the definition, description, presentation and labelling of spirit drinks, the use of the names of spirit drinks in the presentation and labelling of other foodstuffs, the protection of geographical indications for spirit drinks, the


The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptations:

(a) The provisions of the Regulation shall not prejudice the right of the EFTA States to prohibit, on a non-discriminatory basis, the placing on their national market of spirit drinks for direct human consumption which exceed an alcoholic strength of 60%.

(b) The EFTA States shall be invited to send observers to the meetings of the Committee for Spirit Drinks, as referred to in Article 47, dealing with matters which fall within acts referred to in the Agreement. The representatives of the EFTA States shall participate fully in the work of the Committee, but shall not have the right to vote.

(c) Paragraph 4(d) of Protocol 1 to the Agreement shall not apply to Chapter III of the Regulation.

9a. [ ] [229]


---


9af (227) 32020 R 0179: Commission Implementing Regulation (EU) 2020/179 of 3 February 2020 approving amendments to the specification for a spirit drink whose name is registered as a geographical indication (Berliner Kümmele) (OJ L 37, 10.2.2020, p. 4).

9ag (228) 32020 R 0623: Commission Implementing Regulation (EU) 2020/623 of 30 April 2020 approving amendments to the specification for a spirit drink whose name is registered as a geographical indication (Ratafia de Champagne) (OJ L 144, 7.5.2020, p. 10).


9an (235) 32021 R 0724: Commission Implementing Regulation (EU) 2021/724 of 3 March 2021 laying down rules for the application of Regulation (EU) 2019/787 of the European Parliament and of the Council as regards the communications to be made by Member States to the Commission with regard to the bodies appointed to supervise ageing processes for spirit drinks and the competent authorities responsible for ensuring compliance with that Regulation (OJ L 155, 5.5.2021, p. 3).

The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptation:

In Article 3(1), as regards the EFTA States, the words “25 August 2021” shall read “three months after the date of entry into force of the Decision of the EEA Joint Committee No 241/2022 of 23 September 2022”.

---


The provisions of the Regulation shall, for the purpose of this Agreement, be read with the following adaptation:

The following shall be added in Article 13:

“Notwithstanding the provisions of Protocol 1 to the Agreement, the communications made by the competent authorities of the EFTA States to the Commission pursuant to Article 13(1) shall follow the procedure set out in point (b). Point 4 of Protocol 1 shall not apply to Article 13.”


9aw. (284) 32022 R 0888: Commission Implementing Regulation (EU) 2022/888 of 31 May 2022 registering a geographical indication of a spirit drink under Article 30(2) of Regulation (EU) 2019/787 of the European

---


The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptations:

The EFTA States concerned shall be invited to send observers to the meetings of the Committee on aromatised wine products, as referred to in Article 34, dealing with matters which fall within the acts referred to in the Agreement. The representatives of the EFTA States shall participate fully in the work of the Committee, but shall not have the right to vote.


10. [ ]


---

1287 Point inserted by Decision No 274/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 28.10.2023.
1288 Point inserted by Decision No 22/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 3.2.2024.
1289 Point inserted by Decision No 68/2024 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 16.3.2024.
XXVIII. CULTURAL GOODS \[2295\]

ACTS REFERRED TO

1. \[ \] \[2296\]


The provisions of the Directive shall, for the purposes of this Agreement, be read with the following adaptations:

In Article 14, the reference to “on or after 1 January 1993” shall with regard to Iceland and Norway read “on or after 1 January 1995” and with regard to Liechtenstein read “on or after 1 May 1995”.

XXIX. EXPLOSIVES FOR CIVIL USE \[2298\]

ACTS REFERRED TO


3. \[2302\] [ ]

---


\[2301\] Indent and words “, as amended by:” added by Decision No 216/2012 (OJ L 81, 21.3.2013, p. 16 and EEA Supplement No 18, 21.3.2013, p. 18), e.i.f. 8.12.2012.


**ACTS OF WHICH THE CONTRACTING PARTIES SHALL TAKE NOTE**

The Contracting Parties take note of the content of the following acts:


**XXX. MEDICAL DEVICES**

**ACTS REFERRED TO**

1. [ ]


The transitional arrangements set out in the Annexes to the Act of Accession of 16 April 2003 for Poland (Annex XII, Chapter I, Point 3), shall apply.


5. \[ ] \[221]\[1]\[221]


7. \[ ] \[223]\[1]\[223]


\[222]\[1]\[222] Point inserted by Decision No 141/2013 (OJ L [to be published] and EEA Supplement No [to be published], e.l.f. 16.7.2013.
9. \[ \text{[ ]} \] \{238\}


The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptations:

(a) The EFTA States shall participate fully in the Medical Device Coordination Group (‘MDCG’) established under Article 103, but shall not have the right to vote.

(b) The EFTA States shall participate in the European database on medical devices (Eudamed) set up by the Commission as referred to in Article 33.


The provisions of the Regulation shall, for the purposes of this Agreement, be read with the following adaptation:

Notwithstanding the provisions of Protocol 1 to this Agreement, and unless otherwise provided for in this Agreement, the terms Member State(s) and competent authorities shall be understood to include, in addition to their meaning in the Regulation, the EFTA States and their competent authorities, respectively.


---


\(^{2388}\) Indent and words “, as amended by:” added by Decision No 276/2023 (OJ L [to be published] and EEA Supplement No [to be published]), e.i.f. 28.10.2023.


\(^{2391}\) Indent and words “, as amended by:” added by Decision No 177/2022 (OJ L 267, 13.10.2022, p. 21 and EEA Supplement No 66, 13.10.2022, p. 19), e.i.f. 11.6.2022.

\(^{2392}\) Indent added by Decision No 153/2023 (OJ L, 2023/2550, 30.11.2023 and EEA Supplement No 87, 30.11.2023, p. 16), e.i.f. pending.

\(^{2393}\) Indent added by Decision No 275/2023 (OJ L, 2023/2570, 19.10.2023 and EEA Supplement No 75, 19.10.2023, p. 23), e.i.f. pending.


**ACTS OF WHICH THE CONTRACTING PARTIES SHALL TAKE NOTE**[2350]

The Contracting Parties take note of the content of the following acts:


---

[2349] Point inserted by Decision No 211/2021 (OJ L, 2024/284, 8.2.2024 and EEA Supplement No 13, 8.2.2024, p. 46), e.i.f. 10.7.2021.
XXXI. RECREATIONAL CRAFT\(^\text{[2352]}\)

ACTS REFERRED TO

1. \(^{[2353]}\)


XXXII. MARINE EQUIPMENT\(^{[2356]}\)

ACTS REFERRED TO

1. \(^{[2357]}\)


---


\(^{[2354]}\) Point inserted by Decision No 224/2014 (OJ L 230, 3.9.2015, p. 27 and EEA Supplement No 52, 3.9.2015, p. 27), c.f. 1.11.2014. Corrigendum to the EU act subsequently taken note of by the EEA Joint Committee on 11.12.2015.


\textsuperscript{23M1} \textsuperscript{23M2} Point inserted by Decision No 147/2018 (OJ L 67, 25.2.2021, p. 40 and EEA Supplement No 13, 25.2.2021, p. 42), e.i.f. 7.7.2018

\textsuperscript{23M2} Point inserted by Decision No 244/2018 (OJ L 337, 23.9.2021, p. 38 and EEA Supplement No 62, 23.9.2021, p. 35), e.i.f. 6.12.2018
APPENDIX 1[{2363}]

ENERGY LABELS

SECTION I[{2364}]

---


SECTION 2[\textsuperscript{2}\textsuperscript{3}M] [ ]

\textsuperscript{2}\textsuperscript{3}M Section 2 (Commission Directive 95/12/EC) and heading added by Decision No 22/98 (OJ L 342, 17.12.1998, p. 32 and EEA Supplement No 52, 17.12.1998, p. 1), e.i.f. 1.4.1998. The following labels correspond to the labels previously contained in former adaptation a) to the second indent of point 4 of Chapter IV, subsequently reinserted as point 4b by Decision No 22/98 subsequently deleted by Decision No 218/2012 (OJ L 81, 21.3.2013, p. 18 and EEA Supplement No18, 21.3.2013, p. 21), e.i.f. 1.6.2013.
SECTION 3[\textsuperscript{2366}] [ ]

SECTION 4\(^{(2367)}\)

Commission Directive 96/60/EC

(household combined washer-driers)

# Energi

## Kombinert vaske- og tørmaskin

<table>
<thead>
<tr>
<th>Merke</th>
<th>Modell</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOGO</td>
<td>A B C 1 2 3</td>
</tr>
</tbody>
</table>

### Lavt forbruk

- **Energiforbruk** kWh
- **Vask & sentrifugering** kWh

Don faktiske energiavheng av hvordan vaske- og tørmaskinen brukes.

<table>
<thead>
<tr>
<th>Vaskeevne</th>
<th>A: høy</th>
<th>G: lav</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sentrifugeringshastighet (omr/min.)</td>
<td>1100</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Kapasitet</th>
<th>Vasking</th>
<th>Tørkning</th>
</tr>
</thead>
<tbody>
<tr>
<td>(bomull) kg</td>
<td>y.z</td>
<td>y.z</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Vannforbruk</th>
<th>(totalt)</th>
<th>yx</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Lydnivå</th>
<th>Vasking</th>
<th>Sentrifugering</th>
<th>Tørkning</th>
</tr>
</thead>
<tbody>
<tr>
<td>dB(A) (Støy)</td>
<td>xyz</td>
<td>xyz</td>
<td>xyz</td>
</tr>
</tbody>
</table>

Produktbeskyttede innhold: yttligere opplysninger

Europeisk standard EN 50569

Unike hensikt for energibekjennelse av kombinert vaske- og tørmaskiner.
SECTION 5[{2368}] [ ]

Orka

Valnsnotkun: Hávædi

Slababöðubærur

Orkukun

Slæm nýni

ABC D E F G

ABC D E F G

Staðabærufélag

G. minni

A. meiri

Purrkunnehafni

Framleiðandi

G. minni

A. meiri

Orkukun

G. Ġerð

ABC

Framleiðandi

G. Ġerð

123
# Energimærke

<table>
<thead>
<tr>
<th>Merke</th>
<th>Modell</th>
</tr>
</thead>
<tbody>
<tr>
<td>Logo</td>
<td>ABC 123</td>
</tr>
</tbody>
</table>

## Lave forbruksenergier

<table>
<thead>
<tr>
<th>Energiforbruk kWh/oppvask (på grunnlag av testresultater for nøyaktighet ved feil i matriktstilling)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Den faktiske energibruk avhenger av hvordan maskinen brukes.</td>
</tr>
</tbody>
</table>

## Høye forbruksenergier

<table>
<thead>
<tr>
<th>Rengjøringsfunksjon</th>
<th>A: høy</th>
<th>G: lav</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tørkefunksjon</td>
<td>A: høy</td>
<td>G: lav</td>
</tr>
</tbody>
</table>

## Standardkurerer

<table>
<thead>
<tr>
<th>Vannforbruk l/oppvask</th>
</tr>
</thead>
<tbody>
<tr>
<td>YZ</td>
</tr>
</tbody>
</table>

## Lydnyttig

<table>
<thead>
<tr>
<th>DB(A) (Støy)</th>
</tr>
</thead>
<tbody>
<tr>
<td>XY</td>
</tr>
</tbody>
</table>

Produktbrosjyren inneholder ytterligere opplysninger.
SECTION 6\(^{(2309)}\)

*Commission Directive 2002/40/EC*

*(household electric ovens)*

## Orka

### Framleiðandi

<table>
<thead>
<tr>
<th>Gerð</th>
<th>Log o</th>
</tr>
</thead>
<tbody>
<tr>
<td>Góð nýtni</td>
<td>ABC 1 2 3</td>
</tr>
<tr>
<td>Slæm nýtni</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Orkunotkun (kWh)</th>
<th>Hitun:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hefðbundinn</td>
</tr>
<tr>
<td></td>
<td>Blástursofn</td>
</tr>
</tbody>
</table>

(mðað við staðalálag)

<table>
<thead>
<tr>
<th>Notkunarrými (lítrar)</th>
<th>X.YZ</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Stærð:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lítill</td>
</tr>
<tr>
<td>Meðal</td>
</tr>
<tr>
<td>Stór</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hávaði (dB(A) re 1 pW)</th>
</tr>
</thead>
</table>

Nánari upplýsingar er að finna í bæklingum sem fylgja vörunum

Norm EN 50304
Rafmagnsböknarofn

Tilskipun 2002/40/EB um orkuneringar
### Energierådighet

<table>
<thead>
<tr>
<th>Merke</th>
<th>Modell</th>
<th>Logotyp</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>ABC 123</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Høyt energiforbruk</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D</td>
<td></td>
<td></td>
</tr>
<tr>
<td>E</td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td></td>
<td></td>
</tr>
<tr>
<td>G</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lavt energiforbruk</th>
<th>Energiforbruk (kWh)</th>
<th>Oppvarmingsfunksjon:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Tradisjonell oppvarming</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Varmluft</td>
</tr>
</tbody>
</table>

(basert på standardbelastning)

<table>
<thead>
<tr>
<th>Nettovolum (liter)</th>
<th>XYZ</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Type:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Liten</td>
<td></td>
</tr>
<tr>
<td>Middels stor</td>
<td></td>
</tr>
<tr>
<td>Stor</td>
<td>X.YZ</td>
</tr>
</tbody>
</table>

| Lydnivå (støy) (dB(A) re 1 pW) |     |

Produktbrosjyrene inneholder ytterligere opplysninger.

Standard EN 50304
Elektriske stekeovner
Direktiv 2002/40/EF om energimerking
**Energi**

**Merke**

**Modell**

**Høyt energiforbruk**

A
B
C
D
E
F
G

**Lavt energiforbruk**

Energiforbruk (kWh)

Oppvarmingsfunksjon:
- Tradisjonell oppvarming
- Varmluft

(basert på standardbelastning)

Nettovolum (liter)

**Type:**
- Liten
- Middels stor
- Stor

**Lydnivå (støy)**

(dB(A) re 1 pW)

Produktbrosjyrene inneholder ytterligere opplysninger

Standard EN 50304
Elektriske stekeovner
Direktiv 2002/40/EF om energimerking
SECTION 7\(^{(2370)}\) [ ]
APPENDIX 2\(^{[2371]}\)

ENERGY TABLES

SECTION I\(^{[2372]}\) [ ]
SECTION 2[2(277)] [ ]

SECTION 3[{2374}]

**SECTION 4{2375}**

Commission Directive 96/60/EC

*(household combined washer-driers)*

<table>
<thead>
<tr>
<th>Note</th>
<th>Fiche</th>
<th>Mail order</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annex I</td>
<td>Annex II</td>
<td>Annex III</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>□</td>
<td>Energy</td>
<td>Energi</td>
</tr>
<tr>
<td>□</td>
<td>Washer-drier</td>
<td>Kombinert vaske- og tørkemaskin</td>
</tr>
<tr>
<td>I</td>
<td>Manufacturer</td>
<td>Merke</td>
</tr>
<tr>
<td>II</td>
<td>Model</td>
<td>Modell</td>
</tr>
<tr>
<td>□</td>
<td>More efficient</td>
<td>Lavt forbruk</td>
</tr>
<tr>
<td>□</td>
<td>Less efficient</td>
<td>Høyt forbruk</td>
</tr>
<tr>
<td>3</td>
<td>Energy efficiency class ...... on a scale of A (more efficient) to G (less efficient)</td>
<td>Relativ energibruk ...... på skalaen A (lavt forbruk) til G (høyt forbruk)</td>
</tr>
<tr>
<td>V</td>
<td>Energy consumption</td>
<td>Energiforbruk</td>
</tr>
</tbody>
</table>

| V | kWh | kWh | kWh |
| 5 | Energy consumption for washing, spinning and drying | Energibruk til vasking, sentrifugering og tørking | Orkunotkun við þvott, þeytvindingu og þurrkun |
| | (To wash and dry a full capacity washer load at 60 °C) | (ved 60 °C vasking og tørking med full kapasitetsutnyttelse) | (Til að þvo og þurrka þvott á 60 °C- þvottalotu miðað við leyfilegt ámarksmagn tauts) |
| VI | Washing (only) kWh | Vask og sentrifugering kWh | Þvottur og þeytvinding kWh |
| 6 | Energy consumption for washing and spinning only | Energibruk pr vask og sentrifugering alene | Orkunotkun við þvott og þeytvindingu eingöngu |
| □ | Actual consumption will depend on how the appliance is used | Den faktiske energibrukken avhenger av hvordan vaske- og tørkemaskinen brukes | Raunnotkun fer eftir því hvernig tækið er notað |

| VII | Washing performance A (higher) G (lower) | Vaskeevne A (høyt) G (lav) | Þvottafætun A (meiri) til G (minni) |
| 7 | Washing performance class ...... on a scale of A (higher) to G (lower) | Vaskeevne ...... på skalaen fra A (høyt) til G (lav) | Þvottafætunflokkur...... á kvarðanum A (meiri) til G (minni) |

---

<table>
<thead>
<tr>
<th>Note</th>
<th>EN</th>
<th>NO</th>
<th>IS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Label Fiche Mail order</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annex I</td>
<td>Annex II</td>
<td>Annex II</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>5</td>
<td>Water remaining after spin ...% (as a proportion of dry weight of wash)</td>
<td>Restvanninnhold etter sentrifugering ....% (i forhold til vekten av tørt tøy)</td>
</tr>
<tr>
<td>VIII</td>
<td>9</td>
<td>6</td>
<td>Spin speed (rpm)</td>
</tr>
<tr>
<td>IX/X</td>
<td>10/11</td>
<td>7/8</td>
<td>Capacity (cotton) kg</td>
</tr>
<tr>
<td>X</td>
<td>10</td>
<td>7</td>
<td>Washing</td>
</tr>
<tr>
<td>IX</td>
<td>11</td>
<td>8</td>
<td>Drying</td>
</tr>
<tr>
<td>XI</td>
<td></td>
<td></td>
<td>Water consumption (total)</td>
</tr>
<tr>
<td>12</td>
<td>9</td>
<td>Water consumption washing, spinning and drying</td>
<td>Vannforbruk vasking, sentrifuger og tørking</td>
</tr>
<tr>
<td>13</td>
<td>10</td>
<td>Water consumption for washing and spinning only</td>
<td>Vannforbruk til vask- og sentrifuger alene</td>
</tr>
<tr>
<td>14</td>
<td></td>
<td>Washing and drying time</td>
<td>Vaske- og tørketid</td>
</tr>
<tr>
<td>16</td>
<td>11</td>
<td>Estimated annual consumption for a 4-person household, always using the drier (200 cycles)</td>
<td>Anslått árlig forbruk for en husstand på fire personer som altid tørker tøyet i maskinen (200 ganger)</td>
</tr>
<tr>
<td>17</td>
<td>12</td>
<td>Estimated annual consumption for a 4-person household, never using the drier (200 cycles)</td>
<td>Anslått árlig forbruk for en husstand på fire personer som aldri tørker tøyet i maskinen (200 ganger)</td>
</tr>
<tr>
<td>XII</td>
<td>18</td>
<td>13</td>
<td>Noise (dB(A) re 1 pW)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Washing</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Spinning</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Drying</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Further information is contained in product brochures</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Norm EN 50229</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Washer-drier Label Directive 96/60/EC</td>
</tr>
</tbody>
</table>
SECTION 5[2376] [ ]

### SECTION 6(277)

Commission Directive 2002/40/EC

*(household electric ovens)*

<table>
<thead>
<tr>
<th>Note Label</th>
<th>Fiche Annex II</th>
<th>Mail order Annex III</th>
<th>EN</th>
<th>IS</th>
<th>NO</th>
</tr>
</thead>
<tbody>
<tr>
<td>‡</td>
<td></td>
<td></td>
<td>Energy</td>
<td>Orka</td>
<td>Energi</td>
</tr>
<tr>
<td>‡</td>
<td></td>
<td></td>
<td>Electric oven</td>
<td>Rafmagnsbökunaröfn</td>
<td>Elektrisk stekeovn</td>
</tr>
<tr>
<td>I</td>
<td>1</td>
<td>1</td>
<td>Manufacturer</td>
<td>Framleiðandi</td>
<td>Merke</td>
</tr>
<tr>
<td>II</td>
<td>2</td>
<td>1</td>
<td>Model</td>
<td>Gerð</td>
<td>Modell</td>
</tr>
<tr>
<td>‡</td>
<td></td>
<td></td>
<td>More efficient</td>
<td>Góð nýtni</td>
<td>Lavt energiforbruk</td>
</tr>
<tr>
<td>‡</td>
<td></td>
<td></td>
<td>Less efficient</td>
<td>Slæm nýtni</td>
<td>Høyt energiforbruk</td>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td></td>
<td>Energy efficiency class … on a scale of A (more efficient) to G (less efficient)</td>
<td>Orkunýtniflokkur …á kvarðanum A (góð nýtni) til G (slæm nýtni)</td>
<td>Klassifisering av energieeffektivitet etter en skala fra A (lavt energiforbruk) til G (høyt nergiforbruk)</td>
</tr>
<tr>
<td>V</td>
<td>5</td>
<td>3</td>
<td>Baking area</td>
<td>Bökunarrými</td>
<td>Stekeoverflate</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Energy consumption</td>
<td>Orkunotkun</td>
<td>Energiforbruk</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Note Label</th>
<th>Fiche Annex II</th>
<th>Mail order Annex III</th>
<th>EN</th>
<th>IS</th>
<th>NO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annex I</td>
<td>5 3 kWh</td>
<td>kWh</td>
<td>kWh</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annex I</td>
<td>5 3 Heating function</td>
<td>Hitun</td>
<td>Oppvarmingsfunksjon</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annex I</td>
<td>5 3 Conventional</td>
<td>Hefðbundinn</td>
<td>Tradisjonell oppvarming</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annex I</td>
<td>5 3 Forced air convection</td>
<td>Blástursoður</td>
<td>Varmluft</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AnnexII</td>
<td>5 3 Based on standard load</td>
<td>Miðað við staðalálag</td>
<td>Basert på standardbelastning</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annex III</td>
<td>6 4 Usable volume(litres)</td>
<td>Notkunarrými (lítrar)</td>
<td>Nettovolum (liter)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annex III</td>
<td>7 5 Size</td>
<td>Stærð</td>
<td>Type</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annex III</td>
<td>7 5 Small</td>
<td>Líttill</td>
<td>Liten</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annex III</td>
<td>7 5 Medium</td>
<td>Meðal</td>
<td>Middels stor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Annex III</td>
<td>7 5 Large</td>
<td>Stór</td>
<td>Stor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VIII</td>
<td>9 6 Time to cook standard load</td>
<td>Bökunartími við staðalálag</td>
<td>Koketid ved standardbelastning</td>
<td></td>
<td></td>
</tr>
<tr>
<td>⊗</td>
<td>Further information is contained in product brochures</td>
<td>Nánari upplýsingar er að finna í bæklingum sem fylgja vörunum</td>
<td>Produktbrosjyrenes inneholder ytterligere opplysninger</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>The area of the largest baking sheet</td>
<td>Stærð stærstu bökunarplötu</td>
<td>Arealet til den største stekeplaten</td>
<td></td>
<td></td>
</tr>
<tr>
<td>⊗</td>
<td>Norm EN 50304</td>
<td>Norm EN 50304</td>
<td>Standard EN 50304</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SECTION 7[2378] [ ]
HAZARD AND PRECAUTIONARY STATEMENTS IN ICELANDIC

The following shall be added to Annex III to Regulation (EC) No 1272/2008:

<table>
<thead>
<tr>
<th>No.</th>
<th>Icelandic</th>
</tr>
</thead>
<tbody>
<tr>
<td>H200</td>
<td>Óstöðugt, sprengifimt efni.</td>
</tr>
<tr>
<td>H201</td>
<td>Sprengifimt efni, hætta á alsprengingu.</td>
</tr>
<tr>
<td>H202</td>
<td>Sprengifimt efni, mikil hætta á sprengibroti.</td>
</tr>
<tr>
<td>H203</td>
<td>Sprengifimt efni, hætta á bruna, höggbylgju eða sprengibrotum.</td>
</tr>
<tr>
<td>H204</td>
<td>Hætta á bruna eða sprengibrotum.</td>
</tr>
<tr>
<td>H205</td>
<td>Hætta á alsprengingu í bruna.</td>
</tr>
<tr>
<td>H220</td>
<td>Afar elfim lofttegund.</td>
</tr>
<tr>
<td>H221</td>
<td>Eldfim lofttegund.</td>
</tr>
<tr>
<td>H222</td>
<td>Úðabrúsi með afar elfimum efnum.</td>
</tr>
<tr>
<td>H223</td>
<td>Úðabrúsi með elfimum efnum.</td>
</tr>
<tr>
<td>H224</td>
<td>Afar elfimur vöðvi og gufa.</td>
</tr>
<tr>
<td>H225</td>
<td>Mjög elfimur vöðvi og gufa.</td>
</tr>
<tr>
<td>H226</td>
<td>Eldfimur vöðvi og gufa.</td>
</tr>
<tr>
<td>H228</td>
<td>Eldfim, fast efni.</td>
</tr>
<tr>
<td>H240</td>
<td>Sprengifimt við hitun.</td>
</tr>
<tr>
<td>H241</td>
<td>Eldfim eða sprengifimt við hitun.</td>
</tr>
<tr>
<td>H242</td>
<td>Eldfim við hitun.</td>
</tr>
<tr>
<td>H250</td>
<td>Kviknar í sjálfkrafa við snertingu við loft.</td>
</tr>
<tr>
<td>H251</td>
<td>Sjálfhitandi, hætta á sjálfsvíkvinun.</td>
</tr>
<tr>
<td>H252</td>
<td>Sjálfhitandi í miklu efnismagni, hætta á sjálfsvíkvinun.</td>
</tr>
<tr>
<td>H260</td>
<td>Í snertingu við vatn myndast elfimar lofttegundir sem er hætt við sjálfsvíkvinun.</td>
</tr>
<tr>
<td>H261</td>
<td>Elfimar lofttegundir myndast við snertingu við vatn</td>
</tr>
<tr>
<td>H270</td>
<td>Getur valdið eða aukið bruna, eldmyndandi (oxandi).</td>
</tr>
<tr>
<td>H271</td>
<td>Getur valdið bruna eða sprengingu, mjög eldmyndandi (oxandi).</td>
</tr>
<tr>
<td>H272</td>
<td>Getur aukið bruna, eldmyndandi (oxandi).</td>
</tr>
<tr>
<td>H280</td>
<td>Inniheldur lofttegund undir þrýstingi, getur sprungið við hitun.</td>
</tr>
</tbody>
</table>

---


<table>
<thead>
<tr>
<th>No.</th>
<th>Icelandic</th>
</tr>
</thead>
<tbody>
<tr>
<td>H281</td>
<td>Inniheldur kælda lofttegund, getur valdið kalsárum.</td>
</tr>
<tr>
<td>H290</td>
<td>Getur verið ætandi fyrir málma.</td>
</tr>
<tr>
<td>H300</td>
<td>Banvænt við inntóku.</td>
</tr>
<tr>
<td>H301</td>
<td>Eitrað við inntóku.</td>
</tr>
<tr>
<td>H302</td>
<td>Hættulegt við inntóku.</td>
</tr>
<tr>
<td>H304</td>
<td>Getur verið banvænt við inntóku ef það kemst í öndunarveg.</td>
</tr>
<tr>
<td>H310</td>
<td>Banvænt í snertingu við húð.</td>
</tr>
<tr>
<td>H311</td>
<td>Eitrað í snertingu við húð.</td>
</tr>
<tr>
<td>H312</td>
<td>Hættulegt í snertingu við húð.</td>
</tr>
<tr>
<td>H313</td>
<td>Veldur alvarlegum bruna á húð og augnskaða.</td>
</tr>
<tr>
<td>H315</td>
<td>Veldur húdertingu.</td>
</tr>
<tr>
<td>H317</td>
<td>Getur valdið ofnæmisviðbrögðum í húð.</td>
</tr>
<tr>
<td>H318</td>
<td>Veldur alvarlegum augnskaða.</td>
</tr>
<tr>
<td>H319</td>
<td>Veldur alvarlegri augnertingu.</td>
</tr>
<tr>
<td>H330</td>
<td>Banvænt við innöndun.</td>
</tr>
<tr>
<td>H331</td>
<td>Eitrað við innöndun.</td>
</tr>
<tr>
<td>H332</td>
<td>Hættulegt við innöndun.</td>
</tr>
<tr>
<td>H334</td>
<td>Getur valdið ofnæmis- eða asmaeinknum eða öndunarerfjöleikum við innöndun.</td>
</tr>
<tr>
<td>H335</td>
<td>Getur valdið ertingu í öndunarfærnum.</td>
</tr>
<tr>
<td>H336</td>
<td>Getur valdið sljóleika eða svíma.</td>
</tr>
<tr>
<td>H340</td>
<td>Getur valdið erfðagöllum (tilgreinið váhrifaleið ef sannað hefur verið svo öyggjandi sé að engin önnur váhrifaleið hefur þessa hættu í för með sér).</td>
</tr>
<tr>
<td>H341</td>
<td>Grunað um að valda erfðagöllum (tilgreinið váhrifaleið ef sannað hefur verið svo öyggjandi sé að engin önnur váhrifaleið hefur þessa hættu í för með sér).</td>
</tr>
<tr>
<td>H350</td>
<td>Getur valdið krabbameini (tilgreinið váhrifaleið ef sannað hefur verið svo öyggjandi sé að engin önnur váhrifaleið hefur þessa hættu í för með sér).</td>
</tr>
<tr>
<td>H351</td>
<td>Grunað um að valda krabbameini (tilgreinið váhrifaleið ef sannað hefur verið svo öyggjandi sé að engin önnur váhrifaleið hefur þessa hættu í för með sér).</td>
</tr>
<tr>
<td>H360</td>
<td>Getur haft skaðleg áhrif á frjósemi eða börn í móðurkviði (tilgreinið sérstök áhrif ef þau eru kunn) (tilgreinið váhrifaleið ef sannað hefur verið svo öyggjandi sé að engin önnur váhrifaleið hefur þessa hættu í för með sér).</td>
</tr>
<tr>
<td>H361</td>
<td>Grunað um að hafa skaðleg áhrif á frjósemi eða börn í móðurkviði (tilgreinið sérstök áhrif ef þau eru kunn) (tilgreinið váhrifaleið ef sannað hefur verið svo öyggjandi sé að engin önnur váhrifaleið hefur þessa hættu í för með sér).</td>
</tr>
<tr>
<td>H362</td>
<td>Getur skaðað börn á brjósti.</td>
</tr>
<tr>
<td>No.</td>
<td>Icelandic</td>
</tr>
<tr>
<td>-----</td>
<td>-----------</td>
</tr>
<tr>
<td>H370</td>
<td>Skaðar líffæri (eða tilgreinið öll líffæri sem verða fyrir áhrifum, ef þau eru kunn) (tilgreinið váhrifaleið ef sannað hefur verið svo öyggjandi sé að engin önnur váhrifaleið hefur þessa hættu í för með sér).</td>
</tr>
<tr>
<td>H371</td>
<td>Getur skaðað líffæri (eða tilgreinið öll líffæri sem verða fyrir áhrifum, ef þau eru kunn) (tilgreinið váhrifaleið ef sannað hefur verið svo öyggjandi sé að engin önnur váhrifaleið hefur þessa hættu í för með sér).</td>
</tr>
<tr>
<td>H372</td>
<td>Skaðar líffæri (tilgreinið öll líffæri sem verða fyrir áhrifum, ef þau eru kunn) við langvinn eða endurtekin váhrif (tilgreinið váhrifaleið ef sannað hefur verið svo öyggjandi sé að engin önnur váhrifaleið hefur þessa hættu í för með sér).</td>
</tr>
<tr>
<td>H373</td>
<td>Getur skaðað líffæri (tilgreinið öll líffæri sem verða fyrir áhrifum, ef þau eru kunn) við langvinn eða endurtekin váhrif (tilgreinið váhrifaleið ef sannað hefur verið svo öyggjandi sé að engin önnur váhrifaleið hefur þessa hættu í för með sér).</td>
</tr>
<tr>
<td>H400</td>
<td>Mjög eitrað lífi í vatni.</td>
</tr>
<tr>
<td>H410</td>
<td>Mjög eitrað lífi í vatni, hefur langvinn áhrif.</td>
</tr>
<tr>
<td>H411</td>
<td>Eitrað lífi í vatni, hefur langvinn áhrif.</td>
</tr>
<tr>
<td>H412</td>
<td>Skaðlegt lífi í vatni, hefur langvinn áhrif.</td>
</tr>
<tr>
<td>H413</td>
<td>Getur valdið langvinnum, skaðlegum áhrifum á lífi í vatni.</td>
</tr>
<tr>
<td>H350i</td>
<td>Getur valdið krabbameini við innöndun.</td>
</tr>
<tr>
<td>H360F</td>
<td>Getur haft skaðleg áhrif á frjósemi.</td>
</tr>
<tr>
<td>H360D</td>
<td>Getur haft skaðleg áhrif á börn í móðurkviði.</td>
</tr>
<tr>
<td>H361f</td>
<td>Grunað um að hafa skaðleg áhrif á frjósemi.</td>
</tr>
<tr>
<td>H361d</td>
<td>Grunað um að hafa skaðleg áhrif á börn í móðurkviði.</td>
</tr>
<tr>
<td>H360FD</td>
<td>Getur haft skaðleg áhrif á frjósemi. Getur haft skaðleg áhrif á börn í móðurkviði.</td>
</tr>
<tr>
<td>H361fd</td>
<td>Grunað um að hafa skaðleg áhrif á frjósemi. Grunað um að hafa skaðleg áhrif á börn í móðurkviði.</td>
</tr>
<tr>
<td>H360Fd</td>
<td>Getur haft skaðleg áhrif á frjósemi. Grunað um að hafa skaðleg áhrif á börn í móðurkviði.</td>
</tr>
<tr>
<td>H360Df</td>
<td>Getur haft skaðleg áhrif á börn í móðurkviði. Grunað um að hafa skaðleg áhrif á frjósemi.</td>
</tr>
<tr>
<td>EUH 001</td>
<td>Sprengifimt sem þurrefni.</td>
</tr>
<tr>
<td>EUH 006</td>
<td>Sprengifimt með og án andrúmslofts.</td>
</tr>
<tr>
<td>EUH 014</td>
<td>Hvarfast kröftuglega við vatn</td>
</tr>
<tr>
<td>EUH 018</td>
<td>Getur myndað eldfimar eða sprengifimar blöndur af ef納gufu og andrúmslofti við notkun.</td>
</tr>
<tr>
<td>EUH 019</td>
<td>Getur myndað sprengifim efnasambönd (peroxid).</td>
</tr>
<tr>
<td>EUH 044</td>
<td>Sprengifimt við hitun í lokuðu rými.</td>
</tr>
<tr>
<td>EUH 029</td>
<td>Myndar eitraða lofttegund í snertingu við vatn.</td>
</tr>
<tr>
<td>EUH 031</td>
<td>Myndar eitraða lofttegund í snertingu við sýru.</td>
</tr>
<tr>
<td>EUH 032</td>
<td>Myndar mjög eitraða lofttegund í snertingu við sýru.</td>
</tr>
<tr>
<td>EUH 066</td>
<td>Endurtekin snerting getur valdið þurri eða sprunginni húð.</td>
</tr>
</tbody>
</table>
The following shall be added to Part 2 of Annex IV of Regulation (EC) No 1272/2008:

<table>
<thead>
<tr>
<th>No.</th>
<th>Icelandic</th>
</tr>
</thead>
<tbody>
<tr>
<td>P101</td>
<td>Ef leita þarf læknis skal hafa flét eða merkimiða tiltekt.</td>
</tr>
<tr>
<td>P102</td>
<td>Geymist þar sem börn ná ekki til.</td>
</tr>
<tr>
<td>P103</td>
<td>Lesið merkimiðann fyrir notkun.</td>
</tr>
<tr>
<td>P201</td>
<td>Aflið sérstakra leiðbeininga fyrir notkun.</td>
</tr>
<tr>
<td>P202</td>
<td>Nauðsynlegt er að lesa og skilja allar viðvaranir áður en efnið er notað.</td>
</tr>
<tr>
<td>P210</td>
<td>Haldið frá hitagiðjöfum, neistagjöfum, opnum eldi og heitem flötum. — Reykingar bannaðar.</td>
</tr>
<tr>
<td>P211</td>
<td>Má ekki úða á opinn eða annan ikveikjuvald.</td>
</tr>
<tr>
<td>P220</td>
<td>Má ekki nota eða geyma í námunda við fatnað/.../brennanleg efni.</td>
</tr>
<tr>
<td>P221</td>
<td>Gætið þess að blanda efninu ekki saman við brennanleg efni/...</td>
</tr>
<tr>
<td>P222</td>
<td>Má ekki komast í snertingu við andrúmsloft.</td>
</tr>
<tr>
<td>P223</td>
<td>Má alls ekki komast í snertingu við vatn vegna hættu á kröftugu hvarfi og leifureldi.</td>
</tr>
<tr>
<td>P230</td>
<td>Haldið röku með....</td>
</tr>
<tr>
<td>P231</td>
<td>Meðhönldið undir Öhvarfgjarnri lofttegund.</td>
</tr>
<tr>
<td>No.</td>
<td>Icelandic</td>
</tr>
<tr>
<td>-----</td>
<td>-----------</td>
</tr>
<tr>
<td>P232</td>
<td>Verjið gegn raka.</td>
</tr>
<tr>
<td>P233</td>
<td>Ílát skal vera vel lukt.</td>
</tr>
<tr>
<td>P234</td>
<td>Má aðeins geyma í upprunalegu ílátí.</td>
</tr>
<tr>
<td>P235</td>
<td>Geymist á köldum stað.</td>
</tr>
<tr>
<td>P240</td>
<td>Jarðtengið/spennujafnið ílát og viðtökubúnað.</td>
</tr>
<tr>
<td>P241</td>
<td>Notið sprengiheld rafföng/loftarðbúnað/lysingu/...</td>
</tr>
<tr>
<td>P242</td>
<td>Notið ekki verkfæri sem mynda neista.</td>
</tr>
<tr>
<td>P243</td>
<td>Gerið varúðarráðstafanir gegn stöðvarafmagni</td>
</tr>
<tr>
<td>P244</td>
<td>Gætið þess að ekki sé feiti og olía á þrýstingslokum.</td>
</tr>
<tr>
<td>P250</td>
<td>Má ekki verða fyrir hnjaski/böggir/...núningi</td>
</tr>
<tr>
<td>P251</td>
<td>Prýstihyki: Ekki má gata eða brenda hylki jafnvel þótt þau séu tóm.</td>
</tr>
<tr>
<td>P260</td>
<td>Andið ekki að ykkur ryki/reyk/lofttegund/úða/gufu/ýringi.</td>
</tr>
<tr>
<td>P261</td>
<td>Gætið þess að anda ekki inn ryki/reyk/lofttegund/úða/gufu/ýringi.</td>
</tr>
<tr>
<td>P262</td>
<td>Má ekki koma í augu eða á húð eða fót.</td>
</tr>
<tr>
<td>P263</td>
<td>Forðist alla snertingu við efninið meðan á meðgöngu og brjósttagjöf stendur.</td>
</tr>
<tr>
<td>P264</td>
<td>Þvoið...vandlega eftir meðhöndlun.</td>
</tr>
<tr>
<td>P270</td>
<td>Neytið ekki matar, drykkjar eða tóbaks við notkun þessarar vöru.</td>
</tr>
<tr>
<td>P271</td>
<td>Notið eingöngu utandyra eða í vel loftfræstu rými.</td>
</tr>
<tr>
<td>P272</td>
<td>Ekki skal farið með vinnufót af vinnustað hafi þau óbreytast af efninu.</td>
</tr>
<tr>
<td>P273</td>
<td>Forðist losun út í umhverfið.</td>
</tr>
<tr>
<td>P278</td>
<td>Notið hliðfårhanska/hliðfårfatnað/augnhlífar/andlitshlífar.</td>
</tr>
<tr>
<td>P281</td>
<td>Notið tilskildar persónuhlífar.</td>
</tr>
<tr>
<td>P282</td>
<td>Klæðist kulaeinangrandi hönskum/andlitshlífor/augnhlíforum.</td>
</tr>
<tr>
<td>P283</td>
<td>Klæðist brunafólnum/eldfólnum/eldtefjandi fatnaði.</td>
</tr>
<tr>
<td>P284</td>
<td>Notið öndunarhlífar.</td>
</tr>
<tr>
<td>P285</td>
<td>Notið öndunarhlífar ef loftfræsting er öfullnægjandi.</td>
</tr>
<tr>
<td>P231 + P232</td>
<td>Meðhöndlildið undir óhvarfsgjarnri lofttegund. Verjið gegn raka.</td>
</tr>
<tr>
<td>P301</td>
<td>EFTIR INNTÖKU:</td>
</tr>
<tr>
<td>P302</td>
<td>BERIST EFNÍÐ Á HÚÐ:</td>
</tr>
<tr>
<td>P303</td>
<td>BERIST EFNÍÐ Á HÚÐ (eða í hár):</td>
</tr>
<tr>
<td>P304</td>
<td>EFTIR INNÖNDUN:</td>
</tr>
<tr>
<td>No.</td>
<td>Icelandic</td>
</tr>
<tr>
<td>-----</td>
<td>-----------</td>
</tr>
<tr>
<td>P305</td>
<td>BERIST EFNÍD Í AUGU:</td>
</tr>
<tr>
<td>P306</td>
<td>EF EFNÍD FER Á FÓT:</td>
</tr>
<tr>
<td>P307</td>
<td>EF um váhrif er að ræða:</td>
</tr>
<tr>
<td>P308</td>
<td>EF um váhrif eða hugsanleg váhrif er að ræða:</td>
</tr>
<tr>
<td>P309</td>
<td>EF um váhrif er að ræða eða ef lasleika verður vart:</td>
</tr>
<tr>
<td>P310</td>
<td>Hringið umsvifalaust í EITRUNARMÍÐSTÖÐ eða lækni.</td>
</tr>
<tr>
<td>P311</td>
<td>Hringið í EITRUNARMÍÐSTÖÐ eða lækni.</td>
</tr>
<tr>
<td>P312</td>
<td>Hringið í EITRUNARMÍÐSTÖÐ eða lækni ef lasleika verður vart.</td>
</tr>
<tr>
<td>P313</td>
<td>Leitið læknis.</td>
</tr>
<tr>
<td>P314</td>
<td>Leitið læknis ef lasleika verður vart.</td>
</tr>
<tr>
<td>P315</td>
<td>Leitið umsvifalaust læknis.</td>
</tr>
<tr>
<td>P320</td>
<td>Brynt er að fá sérstaka meðferð (sjá .... á þessum merkimiða).</td>
</tr>
<tr>
<td>P321</td>
<td>Sérstök meðferð (sjá .... á þessum merkimiða).</td>
</tr>
<tr>
<td>P322</td>
<td>Sérstakar ræðstafanir (sjá .... á þessum merkimiða).</td>
</tr>
<tr>
<td>P330</td>
<td>Skolið muninn.</td>
</tr>
<tr>
<td>P331</td>
<td>EKKI framkalla uppkóst.</td>
</tr>
<tr>
<td>P332</td>
<td>Ef efnið ertir húð:</td>
</tr>
<tr>
<td>P333</td>
<td>Ef efnið ertir húð eða útbrot koma fram:</td>
</tr>
<tr>
<td>P334</td>
<td>Sökkvið í kalt vatn/vefjið með blautu sáraðindi.</td>
</tr>
<tr>
<td>P335</td>
<td>Dustið lausar agnir af húðinni.</td>
</tr>
<tr>
<td>P337</td>
<td>Ef augnering er viðvarandi:</td>
</tr>
<tr>
<td>P338</td>
<td>Fjarlægðið snertilinsur ef það er auðvelt. Skolið áfram.</td>
</tr>
<tr>
<td>P340</td>
<td>Flytiði viðkomandi í ferskt loft og látið hann hvílast í stellingu sem léttir öndun.</td>
</tr>
<tr>
<td>P341</td>
<td>Ef viðkomandi à erfitt með öndun skal flytja hann í ferskt loft og látu hann hvílast í stellingu sem léttir öndun.</td>
</tr>
<tr>
<td>P342</td>
<td>Ef vart verður einkenna frá öndunarvegi:</td>
</tr>
<tr>
<td>P350</td>
<td>Þvoið varlega með mikilli sápu og vatni.</td>
</tr>
<tr>
<td>P351</td>
<td>Þvoið varlega með mikilli sápu og vatni.</td>
</tr>
<tr>
<td>P352</td>
<td>Þvoið með mikilli sápu og vatni.</td>
</tr>
<tr>
<td>P353</td>
<td>Skolið húðina með vatni/Farið í sturtu.</td>
</tr>
<tr>
<td>P360</td>
<td>Fót og húð, sem öhreinkast af efninu, skal skoła strax með miklu vatni áður en farið er úr fótunum.</td>
</tr>
<tr>
<td>P361</td>
<td>Farið strax úr fötum sem öhreinkast af efninu.</td>
</tr>
<tr>
<td>No.</td>
<td>Icelandic</td>
</tr>
<tr>
<td>-----</td>
<td>-----------</td>
</tr>
<tr>
<td>P362</td>
<td>Farið úr fötum, sem öhreinkast af efninu, og þvoið fyrir næstu notkun.</td>
</tr>
<tr>
<td>P363</td>
<td>Þvoið fót, sem öhreinkast af efninu, fyrir næstu notkun.</td>
</tr>
<tr>
<td>P370</td>
<td>Ef eldur kemur upp:</td>
</tr>
<tr>
<td>P371</td>
<td>Þegar um mikinn eld og mikil efnismagn er að ræða:</td>
</tr>
<tr>
<td>P372</td>
<td>Sprengihætta ef eldur kemur upp.</td>
</tr>
<tr>
<td>P373</td>
<td>EKKI reyna að slökkva eld ef hann kemst að sprengifimum efnun.</td>
</tr>
<tr>
<td>P374</td>
<td>Beitið eðlileguvarðarráðstöfunum við slökkkvistörf og verið í hæfilegri fjarlægð frá eldinum.</td>
</tr>
<tr>
<td>P375</td>
<td>Verið í fjarlægð frá eldinum við slökkkvistörf vegna sprengihætta.</td>
</tr>
<tr>
<td>P376</td>
<td>Stöðvið leka ef það er öhætt.</td>
</tr>
<tr>
<td>P377</td>
<td>Eldur í lekandi gasi: Reynið ekki að slökkva eldinn nema hægt sé að stöðva lekann á öruggan máta.</td>
</tr>
<tr>
<td>P378</td>
<td>Notið ... til að slökkva eldinn.</td>
</tr>
<tr>
<td>P380</td>
<td>Rýmið svæðið.</td>
</tr>
<tr>
<td>P381</td>
<td>Fjarlægðið alla ikveikjuvalda ef það er öhætt.</td>
</tr>
<tr>
<td>P390</td>
<td>Sogið upp allt sem hellist niður til að afstýra eignatjóni.</td>
</tr>
<tr>
<td>P391</td>
<td>Safnið upp því sem hellist niður.</td>
</tr>
<tr>
<td>P301 + P310</td>
<td>EFTIR INNTÖKU: Hringið umsvifalaust í EITRUNARMIDSTÖÐ eða lækni.</td>
</tr>
<tr>
<td>P301 + P312</td>
<td>EFTIR INNTÖKU: Hringið í EITRUNARMIDSTÖÐ eða lækni ef lasleika verður vart.</td>
</tr>
<tr>
<td>P301 + P30 + P331</td>
<td>EFTIR INNTÖKU: Skolið munninn. EKKI framkalla uppköst.</td>
</tr>
<tr>
<td>P302 + P334</td>
<td>BERIST EFNÍÐ Á HÚÐ: Sökkið í kalt vatn/vefjið með blautu sárabindi.</td>
</tr>
<tr>
<td>P302 + P350</td>
<td>BERIST EFNÍÐ Á HÚÐ: Þvoið varlega með mikilli sápu og vatni.</td>
</tr>
<tr>
<td>P302 + P352</td>
<td>BERIST EFNÍÐ Á HÚÐ: Þvoið með mikilli sápu og vatni</td>
</tr>
<tr>
<td>P304 + P340</td>
<td>EFTIR INNÖNDUN: Flytjöð viðkomandi í ferskt loft og látið hann hvlast í stellingu sem léttir öndun.</td>
</tr>
<tr>
<td>No.</td>
<td>Icelandic</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>P304 + P341</td>
<td>EFTIR INNÖNDUN: Ef viðkomandi á erfitt med öndun skal flytja hann í ferskt loft og láta hann hvílast í stellingu sem léttir öndun.</td>
</tr>
<tr>
<td>P306 + P360</td>
<td>EF EFINÐ FER Á FÓT: Föt og húð, sem öhareinkast af efninu, skal skola strax med miklu vatni áður en farið er úr fótunum.</td>
</tr>
<tr>
<td>P307 + P311</td>
<td>EFum vãhrif er að ræða: Hringið í EITRUNARMÍDSTÓÐ eða lækni.</td>
</tr>
<tr>
<td>P308 + P313</td>
<td>EF um vãhrif eða hugsanleg vãhrif er að ræða: Leitið læknis.</td>
</tr>
<tr>
<td>P309 + P311</td>
<td>EF um vãhrif er að ræða eða ef lasleika verður vart: Hringið í EITRUNARMÍDSTÓÐ eða lækni.</td>
</tr>
<tr>
<td>P332 + P313</td>
<td>Ef efnði eðrit húð: Leitið læknis.</td>
</tr>
<tr>
<td>P333 + P313</td>
<td>Ef efnði eðrit húð eða útbrot kom fram: Leitið læknis.</td>
</tr>
<tr>
<td>P335 + P334</td>
<td>Dustið lausar agnir af húðinni. Sókkvið í kalt vatni/vetfjöð með blautu sárabindi.</td>
</tr>
<tr>
<td>P337 + P313</td>
<td>Ef augnerting er viðvarandi: Leitið læknis.</td>
</tr>
<tr>
<td>P342 + P311</td>
<td>Ef vart verður einkenna frá öndunarvegi: Hringið í EITRUNARMÍDSTÓÐ eða lækni.</td>
</tr>
<tr>
<td>P370 + P376</td>
<td>Ef eldur kemur upp: Stöðvið leka ef það er óhætt.</td>
</tr>
<tr>
<td>P370 + P378</td>
<td>Ef eldur kemur upp: Notið ... til að slökkva eldinn.</td>
</tr>
<tr>
<td>P370 + P380</td>
<td>Ef eldur kemur upp: Rýmið svæðið.</td>
</tr>
</tbody>
</table>

P401 Geymist ...

P402 Geymist á þurrum stað.

P403 Geymist á vel loftfræstum stað.

P404 Geymist í lokuðu fláti.
### APPENDIX 6(2382)

**HAZARD AND PRECAUTIONARY STATEMENTS IN NORWEGIAN**

The following shall be added to Annex III to Regulation (EC) No 1272/2008:

<table>
<thead>
<tr>
<th>No.</th>
<th>Norwegian</th>
</tr>
</thead>
<tbody>
<tr>
<td>H200</td>
<td>Ustabile eksplosive varer.</td>
</tr>
<tr>
<td>H201</td>
<td>Eksplosjonsfarlig; fare for masseeksplosjon.</td>
</tr>
<tr>
<td>H202</td>
<td>Eksplosjonsfarlig; stor fare for utkast av fragmenter.</td>
</tr>
<tr>
<td>H203</td>
<td>Eksplosjonsfarlig; fare for brann, trykks bolts eller utkast av fragmenter.</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>No.</th>
<th>Norwegian</th>
</tr>
</thead>
<tbody>
<tr>
<td>H204</td>
<td>Fare for brann eller utkast av fragmenter.</td>
</tr>
<tr>
<td>H205</td>
<td>Fare for masseeksplosjon ved brann.</td>
</tr>
<tr>
<td>H220</td>
<td>Ekstremit brannfarlig gass.</td>
</tr>
<tr>
<td>H221</td>
<td>Brannfarlig gass.</td>
</tr>
<tr>
<td>H222</td>
<td>Ekstremit brannfarlig aerosol.</td>
</tr>
<tr>
<td>H223</td>
<td>Brannfarlig aerosol.</td>
</tr>
<tr>
<td>H224</td>
<td>Ekstremit brannfarlig væske og damp.</td>
</tr>
<tr>
<td>H225</td>
<td>Meget brannfarlig væske og damp.</td>
</tr>
<tr>
<td>H226</td>
<td>Brannfarlig væske og damp.</td>
</tr>
<tr>
<td>H228</td>
<td>Brannfarlig fast stoff.</td>
</tr>
<tr>
<td>H240</td>
<td>Eksplosjonfarlig ved oppvarming.</td>
</tr>
<tr>
<td>H241</td>
<td>Brann- eller eksplosjonfarlig ved oppvarming.</td>
</tr>
<tr>
<td>H242</td>
<td>Brannfarlig ved oppvarming.</td>
</tr>
<tr>
<td>H250</td>
<td>Selvantenner ved kontakt med luft.</td>
</tr>
<tr>
<td>H251</td>
<td>Selvopphetende; kan selvantenne.</td>
</tr>
<tr>
<td>H252</td>
<td>Selvopphetende i store mengder; kan selvantenne.</td>
</tr>
<tr>
<td>H260</td>
<td>Ved kontakt med vann utvikles brannfarlige gasser som kan selvantenne.</td>
</tr>
<tr>
<td>H261</td>
<td>Ved kontakt med vann utvikles brannfarlige gasser.</td>
</tr>
<tr>
<td>H270</td>
<td>Kan forårsake eller forsterke brann; oksiderende.</td>
</tr>
<tr>
<td>H271</td>
<td>Kan forårsake brann eller eksplosjon; sterkt oksiderende.</td>
</tr>
<tr>
<td>H272</td>
<td>Kan forsterke brann; oksiderende.</td>
</tr>
<tr>
<td>H280</td>
<td>Inneholder gass under trykk; kan eksploedere ved oppvarming.</td>
</tr>
<tr>
<td>H281</td>
<td>Inneholder nedkjølt gass; kan forårsake alvorlige forfrysninger.</td>
</tr>
<tr>
<td>H290</td>
<td>Kan være etsende for metaller.</td>
</tr>
<tr>
<td>H300</td>
<td>Dødelig ved svelging.</td>
</tr>
<tr>
<td>H301</td>
<td>Giftig ved svelging.</td>
</tr>
<tr>
<td>H302</td>
<td>Farlig ved svelging.</td>
</tr>
<tr>
<td>H304</td>
<td>Kan være dødelig ved svelging om det kommer ned i luftveiene.</td>
</tr>
<tr>
<td>H310</td>
<td>Dødelig ved hudkontakt.</td>
</tr>
<tr>
<td>H311</td>
<td>Giftig ved hudkontakt.</td>
</tr>
<tr>
<td>H312</td>
<td>Farlig ved hudkontakt.</td>
</tr>
<tr>
<td>H314</td>
<td>Gir alvorlige etseskader på hud og øyne.</td>
</tr>
<tr>
<td>H315</td>
<td>Irriterer huden.</td>
</tr>
<tr>
<td>H317</td>
<td>Kan utløse en allergisk hudreaksjon.</td>
</tr>
<tr>
<td>H318</td>
<td>Gir alvorlig øyeskade.</td>
</tr>
<tr>
<td>H319</td>
<td>Gir alvorlig øyeirritasjon.</td>
</tr>
<tr>
<td>H330</td>
<td>Dødelig ved innånding.</td>
</tr>
<tr>
<td>H331</td>
<td>Giftig ved innånding.</td>
</tr>
<tr>
<td>H332</td>
<td>Farlig ved innånding.</td>
</tr>
<tr>
<td>H334</td>
<td>Kan gi allergi eller astmasymptomer eller pustevansker ved innånding.</td>
</tr>
<tr>
<td>H335</td>
<td>Kan forårsake irritasjon av luftveiene.</td>
</tr>
<tr>
<td>H336</td>
<td>Kan forårsake døsighet eller svimmelhet.</td>
</tr>
<tr>
<td>No.</td>
<td>Norwegian</td>
</tr>
<tr>
<td>-------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>H340</td>
<td>Kan gi genetiske skader &lt;Angi opptaksvei dersom det med sikkerhet er fastlått at ingen andre opptaksveier er årsak til faren&gt;.</td>
</tr>
<tr>
<td>H341</td>
<td>Mistenkes å kunne gi genetiske skader &lt;Angi opptaksvei dersom det med sikkerhet er fastlått at ingen andre opptaksveier er årsak til faren&gt;.</td>
</tr>
<tr>
<td>H350</td>
<td>Kan forårsake kreft &lt;Angi opptaksvei dersom det med sikkerhet er fastlått at ingen andre opptaksveier er årsak til faren&gt;.</td>
</tr>
<tr>
<td>H351</td>
<td>Mistenkes for å kunne forårsake kreft &lt;Angi opptaksvei dersom det med sikkerhet er fastlått at ingen andre opptaksveier er årsak til faren&gt;.</td>
</tr>
<tr>
<td>H360</td>
<td>Kan skade forplantningsevnen eller gi fosterskader &lt;Angi særlige virkninger dersom disse er kjent.&gt; &lt;Angi opptaksvei dersom det med sikkerhet er fastlått at ingen andre opptaksveier er årsak til faren&gt;.</td>
</tr>
<tr>
<td>H361</td>
<td>Mistenkes for å kunne skade forplantningsevnen eller gi fosterskader &lt;Angi særlige virkninger dersom disse er kjent.&gt; &lt;Angi opptaksvei dersom det med sikkerhet er fastlått at ingen andre opptaksveier er årsak til faren&gt;.</td>
</tr>
<tr>
<td>H362</td>
<td>Kan skade barn som ammes.</td>
</tr>
<tr>
<td>H370</td>
<td>Forårsaker organskader &lt;eller angi alle organer som påvirkes dersom disse er kjent.&gt; &lt;Angi opptaksvei dersom det med sikkerhet er fastlått at ingen andre opptaksveier er årsak til faren&gt;.</td>
</tr>
<tr>
<td>H371</td>
<td>Kan forårsake organskader &lt;eller angi alle organer som påvirkes dersom disse er kjent.&gt; &lt;Angi opptaksvei dersom det med sikkerhet er fastlått at ingen andre opptaksveier er årsak til faren&gt;.</td>
</tr>
<tr>
<td>H372</td>
<td>Forårsaker organskader &lt;eller angi alle organer som påvirkes dersom disse er kjent.&gt; ved langvarig eller gjenanteksponering &lt;Angi opptaksvei dersom det med sikkerhet er at ingen andre opptaksveier er årsak til faren&gt;.</td>
</tr>
<tr>
<td>H373</td>
<td>Kan forårsake organskader &lt;eller angi alle organer som påvirkes dersom disse er kjent.&gt; ved langvarig eller gjenanteksponering &lt;Angi opptaksvei dersom det med sikkerhet er at ingen andre opptaksveier er årsak til faren&gt;.</td>
</tr>
<tr>
<td>H400</td>
<td>Meget giftig for liv i vann.</td>
</tr>
<tr>
<td>H410</td>
<td>Meget giftig, med langtidsvirkning, for liv i vann.</td>
</tr>
<tr>
<td>H411</td>
<td>Giftig, med langtidsvirkning, for liv i vann.</td>
</tr>
<tr>
<td>H412</td>
<td>Skadelig, med langtidsvirkning, for liv i vann.</td>
</tr>
<tr>
<td>H413</td>
<td>Kan forårsake skadelige langtidsvirkninger for liv i vann.</td>
</tr>
<tr>
<td>H350i</td>
<td>Kan forårsake kreft ved innånding.</td>
</tr>
<tr>
<td>H360F</td>
<td>Kan skade forplantningsevnen.</td>
</tr>
<tr>
<td>H360D</td>
<td>Kan gi fosterskader.</td>
</tr>
<tr>
<td>H361f</td>
<td>Mistenkes for å kunne skade forplantningsevnen.</td>
</tr>
<tr>
<td>H361d</td>
<td>Mistenkes for å kunne gi fosterskader.</td>
</tr>
<tr>
<td>H360FD</td>
<td>Kan skade forplantningsevnen. Kan gi fosterskader.</td>
</tr>
<tr>
<td>H361fd</td>
<td>Mistenkes for å kunne skade forplantningsevnen. Mistenkes for å kunne gi fosterskader.</td>
</tr>
<tr>
<td>H360Fd</td>
<td>Kan skade forplantningsevnen. Mistenkes for å kunne gi fosterskader.</td>
</tr>
<tr>
<td>No.</td>
<td>Norwegian</td>
</tr>
<tr>
<td>-----</td>
<td>-----------</td>
</tr>
<tr>
<td>H360Df</td>
<td>Kan gi fosterskader. Mistenkes for å kunne skade forplantningsevnen.</td>
</tr>
<tr>
<td>EUH 001</td>
<td>Eksplosjonsfarlig i tørr tilstand.</td>
</tr>
<tr>
<td>EUH 006</td>
<td>Eksplosjonsfarlig ved og uten kontakt med luft.</td>
</tr>
<tr>
<td>EUH 014</td>
<td>Reagerer voldsomt med vann.</td>
</tr>
<tr>
<td>EUH 018</td>
<td>Ved bruk kan brennbart damp/eksplosive damp-luft-blandinger dannes.</td>
</tr>
<tr>
<td>EUH 019</td>
<td>Kan danne eksplosive peroksider.</td>
</tr>
<tr>
<td>EUH 044</td>
<td>Eksplosjonsfarlig ved oppvarming i lukket rom.</td>
</tr>
<tr>
<td>EUH 029</td>
<td>Ved kontakt med vann utvikles giftig gass.</td>
</tr>
<tr>
<td>EUH 031</td>
<td>Ved kontakt med syrer utvikles giftig gass.</td>
</tr>
<tr>
<td>EUH 032</td>
<td>Ved kontakt med syrer utvikles meget giftig gass.</td>
</tr>
<tr>
<td>EUH 066</td>
<td>Gjentatt eksponering kan gi tørr eller sprukket hud.</td>
</tr>
<tr>
<td>EUH 070</td>
<td>Giftig ved øyekontakt.</td>
</tr>
<tr>
<td>EUH 071</td>
<td>Etsende for luftveiene.</td>
</tr>
<tr>
<td>EUH 059</td>
<td>Farlig for ozonlaget.</td>
</tr>
<tr>
<td>EUH 203</td>
<td>Inneholder krom (VI). Kan gi en allergisk reaksjon.</td>
</tr>
<tr>
<td>EUH 204</td>
<td>Inneholder isocyanater. Kan gi en allergisk reaksjon.</td>
</tr>
<tr>
<td>EUH 205</td>
<td>Inneholder epoksyforbindelser. Kan gi en allergisk reaksjon.</td>
</tr>
<tr>
<td>EUH 206</td>
<td>Advarsel! Må ikke brukes sammen med andre produkter. Kan frigjøre farlige gasser (klor).</td>
</tr>
<tr>
<td>EUH 208</td>
<td>Inneholder &lt;navn på sensibiliserende stoff&gt;. Kan gi en allergisk reaksjon.</td>
</tr>
<tr>
<td>EUH 210</td>
<td>Sikkerhetsdatablad er tilgjengelig på anmodning.</td>
</tr>
<tr>
<td>EUH 401</td>
<td>Bruksanvisningen må følges, slik at man unngår risiko for menneskers helse og miljøet.</td>
</tr>
</tbody>
</table>

The following shall be added to Part 2 of Annex IV to Regulation (EC) No 1272/2008:

<table>
<thead>
<tr>
<th>No.</th>
<th>Norwegian</th>
</tr>
</thead>
<tbody>
<tr>
<td>P101</td>
<td>Dersom det er nødvendig med legehjelp, ha produktets beholder eller etikett for hånden.</td>
</tr>
<tr>
<td>P102</td>
<td>Oppbevares utilgjengelig for barn.</td>
</tr>
<tr>
<td>P103</td>
<td>Les etiketten før bruk.</td>
</tr>
<tr>
<td>P201</td>
<td>Innhent særskilt instruks før bruk.</td>
</tr>
<tr>
<td>P202</td>
<td>Skal ikke håndteres før alle advarsler er lest og oppfattet.</td>
</tr>
<tr>
<td>No.</td>
<td>Norwegian</td>
</tr>
<tr>
<td>------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>P210</td>
<td>Holdes vekk fra varme/gnister/åpen flamme/varme overflater. — Røyking forbudt.</td>
</tr>
<tr>
<td>P211</td>
<td>Ikke spray mot åpen flamme eller annen tennkilde.</td>
</tr>
<tr>
<td>P220</td>
<td>Må ikke brukes/oppevares i nærheten av tøy /…/ brennbare materialer.</td>
</tr>
<tr>
<td>P221</td>
<td>Må ikke blandes med brennbare stoffer.</td>
</tr>
<tr>
<td>P222</td>
<td>Unngå kontakt med luft.</td>
</tr>
<tr>
<td>P223</td>
<td>Unngå all kontakt med vann, på grunn av fare for voldsom reaksjon og eksplosjonsaktig brann.</td>
</tr>
<tr>
<td>P230</td>
<td>Holdes fuktet med …</td>
</tr>
<tr>
<td>P231</td>
<td>Håndteres under inertgass.</td>
</tr>
<tr>
<td>P232</td>
<td>Beskyttes mot fuktighet.</td>
</tr>
<tr>
<td>P233</td>
<td>Hold beholderen tett lukket.</td>
</tr>
<tr>
<td>P234</td>
<td>Oppbevares bare i originalbeholder.</td>
</tr>
<tr>
<td>P235</td>
<td>Oppbevares kjølig.</td>
</tr>
<tr>
<td>P240</td>
<td>Beholder og mottaksutstyr jordes/potensialutlignes.</td>
</tr>
<tr>
<td>P241</td>
<td>Bruk elektrisk materiell /ventilasjonsmateriell/belysningsmateriell som er eksplosjonssikkert.</td>
</tr>
<tr>
<td>P242</td>
<td>Bruk bare verktoy som ikke avgir gnister.</td>
</tr>
<tr>
<td>P243</td>
<td>Treff tiltak mot statisk elektrisitet.</td>
</tr>
<tr>
<td>P244</td>
<td>Reduksjonsventiler skal holdes fri for fett og olje.</td>
</tr>
<tr>
<td>P250</td>
<td>Må ikke utsettes for sliping/støt/…/friksjon.</td>
</tr>
<tr>
<td>P251</td>
<td>Beholder under trykk: Må ikke punkteres eller brennes, selv ikke etter bruk.</td>
</tr>
<tr>
<td>P260</td>
<td>Ikke innånd støv/røyk/gass/tåke/damp/aerosoler.</td>
</tr>
<tr>
<td>P261</td>
<td>Unngå innånd av støv/røyk/gass/tåke/damp/aerosoler.</td>
</tr>
<tr>
<td>P262</td>
<td>Må ikke komme i kontakt med øyne, huden eller klær.</td>
</tr>
<tr>
<td>P263</td>
<td>Unngå kontakt under graviditet/amming.</td>
</tr>
<tr>
<td>P264</td>
<td>Vask … grundig etter bruk.</td>
</tr>
<tr>
<td>P270</td>
<td>Ikke spis, drikk eller røyk ved bruk av produktet.</td>
</tr>
<tr>
<td>P271</td>
<td>Brukes bare utendørs eller i et godt ventilert område.</td>
</tr>
<tr>
<td>P272</td>
<td>Tilsatte arbeidsklær må ikke fjernes fra arbeidsplassen.</td>
</tr>
<tr>
<td>P273</td>
<td>Unngå utslipp til miljøet.</td>
</tr>
<tr>
<td>P280</td>
<td>Benytt vernehansker /verneklier/vernebriller/ansiktsskjerm.</td>
</tr>
<tr>
<td>P281</td>
<td>Bruk påkrevd personlig verneutstyr.</td>
</tr>
<tr>
<td>P282</td>
<td>Bruk kuldeisolerende hansker /visir/øyeværn.</td>
</tr>
<tr>
<td>P283</td>
<td>Benytt brannbestandige/flammehemmende klær.</td>
</tr>
<tr>
<td>P284</td>
<td>Bruk åndedrettsvern.</td>
</tr>
<tr>
<td>P285</td>
<td>Ved utilstrekkelig ventilasjon skal åndedrettsvern benyttes.</td>
</tr>
<tr>
<td>P301</td>
<td>VED SVELGING:</td>
</tr>
<tr>
<td>P302</td>
<td>VED HUDKONTAKT:</td>
</tr>
<tr>
<td>P303</td>
<td>VED HUDKONTAKT (eller håret):</td>
</tr>
<tr>
<td>P304</td>
<td>VED INNÅNDING:</td>
</tr>
<tr>
<td>P305</td>
<td>VED KONTAKT MED ØYNENE</td>
</tr>
<tr>
<td>P306</td>
<td>VED KONTAKT MED KLÆR:</td>
</tr>
<tr>
<td>P307</td>
<td>Ved eksponering:</td>
</tr>
<tr>
<td>P308</td>
<td>Ved eksponering eller mistanke om eksponering:</td>
</tr>
<tr>
<td>P309</td>
<td>Ved eksponering eller ubehag:</td>
</tr>
<tr>
<td>P310</td>
<td>Kontakt umiddelbart et GIFTINFORMASJONSSENTER eller lege.</td>
</tr>
<tr>
<td>P311</td>
<td>Kontakt et GIFTINFORMASJONSSENTER eller lege.</td>
</tr>
<tr>
<td>P312</td>
<td>Kontakt et GIFTINFORMASJONSSENTER eller lege ved ubehag.</td>
</tr>
<tr>
<td>P313</td>
<td>Søk legehjelp.</td>
</tr>
<tr>
<td>P314</td>
<td>Søk legehjelp ved ubehag.</td>
</tr>
<tr>
<td>P315</td>
<td>Søk legehjelp umiddelbart.</td>
</tr>
<tr>
<td>P320</td>
<td>Særlig behandling kreves umiddelbart (se … på etiketten).</td>
</tr>
<tr>
<td>P321</td>
<td>Særlig behandling (se … på etiketten).</td>
</tr>
<tr>
<td>P322</td>
<td>Særlige tiltak (se … på etiketten).</td>
</tr>
<tr>
<td>P330</td>
<td>Skyll munnen.</td>
</tr>
<tr>
<td>P331</td>
<td>IKKE framkall brekning.</td>
</tr>
<tr>
<td>P332</td>
<td>Ved hudirritasjon:</td>
</tr>
<tr>
<td>P333</td>
<td>Ved hudirritasjon eller utseitt:</td>
</tr>
<tr>
<td>P334</td>
<td>Skyll i kaldt vann / anvend våt kompress.</td>
</tr>
<tr>
<td>P335</td>
<td>Børst bort løse partikler fra huden.</td>
</tr>
<tr>
<td>P336</td>
<td>Varm opp frostskadede legemsdeler med lukket vann. Ikke gni på det skadete området.</td>
</tr>
<tr>
<td>P337</td>
<td>Ved vedvarende øyeirritasjon:</td>
</tr>
<tr>
<td>No.</td>
<td>Norwegian</td>
</tr>
<tr>
<td>-----</td>
<td>-----------</td>
</tr>
<tr>
<td>P338</td>
<td>Fjern eventuelle kontaktlinser dersom dette enkelt lar seg gjøre. Fortsett skyllingen.</td>
</tr>
<tr>
<td>P340</td>
<td>Flytt personen til frisk luft og sørg for at vedkommende hviler i en stilling som letter åndedrettet.</td>
</tr>
<tr>
<td>P341</td>
<td>Ved pustevansker, flytt personen til frisk luft og sørg for at vedkommende hviler i en stilling som letter åndedrettet.</td>
</tr>
<tr>
<td>P342</td>
<td>Ved symptomer i luftveiene:</td>
</tr>
<tr>
<td>P350</td>
<td>Vask forsiktig med mye såpe og vann.</td>
</tr>
<tr>
<td>P351</td>
<td>Skyll forsiktig med vann i flere minutter.</td>
</tr>
<tr>
<td>P352</td>
<td>Vask med mye såpe og vann.</td>
</tr>
<tr>
<td>P353</td>
<td>Skyll/dusj huden med vann.</td>
</tr>
<tr>
<td>P360</td>
<td>Skyll umiddelbart tilsølte kler og hud med mye vann før klerne fjernes.</td>
</tr>
<tr>
<td>P361</td>
<td>Tilsølte kler må fjernes straks.</td>
</tr>
<tr>
<td>P362</td>
<td>Tilsølte kler må fjernes og vaskes før de brukes på nytt.</td>
</tr>
<tr>
<td>P363</td>
<td>Tilsølte kler må vaskes før de brukes på nytt.</td>
</tr>
<tr>
<td>P370</td>
<td>Ved brann:</td>
</tr>
<tr>
<td>P371</td>
<td>Ved større brann og store mengder:</td>
</tr>
<tr>
<td>P372</td>
<td>Eksplosjonsfare ved brann.</td>
</tr>
<tr>
<td>P373</td>
<td>IKKE bekjemp brannen når den når eksplosive varer.</td>
</tr>
<tr>
<td>P374</td>
<td>Bekjemp brannen med normal forsiktighet på behørig avstand.</td>
</tr>
<tr>
<td>P375</td>
<td>Bekjemp brannen på avstand på grunn av eksplosjonsfare.</td>
</tr>
<tr>
<td>P376</td>
<td>Stopp lekkasje dersom dette kan gjøres på en sikker måte.</td>
</tr>
<tr>
<td>P377</td>
<td>Brann ved gasslekkasje: Ikke slukk med mindre lekkasjen kan stanses på en sikker måte.</td>
</tr>
<tr>
<td>P378</td>
<td>Slukk med:....</td>
</tr>
<tr>
<td>P380</td>
<td>Evakuier området.</td>
</tr>
<tr>
<td>P381</td>
<td>Fjern alle tennkilder dersom dette kan gjøres på en sikker måte.</td>
</tr>
<tr>
<td>P390</td>
<td>Absorber spill for å hindre materiell skade.</td>
</tr>
<tr>
<td>P391</td>
<td>Samle opp spill.</td>
</tr>
<tr>
<td>P301 + P310</td>
<td>VED SVELGING: Kontakt umiddelbart et GIFTINFORMASJONSSENTER eller lege.</td>
</tr>
<tr>
<td>P301 + P312</td>
<td>VED SVELGING: Kontakt et GIFTINFORMASJONSSENTER eller lege ved ubehag.</td>
</tr>
<tr>
<td>No.</td>
<td>Norwegian</td>
</tr>
<tr>
<td>----------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>P301 + P330 + P331</td>
<td>VED SVELGING: Skyll munnen. IKKE framkall brekning.</td>
</tr>
<tr>
<td>P302 + P334</td>
<td>VED HUDKONTAKT: Skyll i kaldt vann / anvend våt kompress.</td>
</tr>
<tr>
<td>P302 + P350</td>
<td>VED HUDKONTAKT: Vask forsiktig med mye såpe og vann.</td>
</tr>
<tr>
<td>P302 + P352</td>
<td>VED HUDKONTAKT: Vask med mye såpe og vann.</td>
</tr>
<tr>
<td>P304 + P340</td>
<td>VED INNÅNDING: Flytt personen til frisk luft og sørg for at vedkommende hviler i en stilling som letter åndedrettet.</td>
</tr>
<tr>
<td>P306 + P360</td>
<td>VED KONTAKT MED KLÆR: Skyll umiddelbart tilsølte klær og hud med mye vann før klærne fjernes.</td>
</tr>
<tr>
<td>P308 + P313</td>
<td>Ved eksponering eller mistanke om eksponering: Søk legehjelp.</td>
</tr>
<tr>
<td>P309 + P311</td>
<td>Ved eksponering eller ubehag: Kontakt et GIFTINFORMASJONSSENTER eller lege.</td>
</tr>
<tr>
<td>P332 + P313</td>
<td>Ved hudirritasjon: Søk legehjelp.</td>
</tr>
<tr>
<td>P335 + P334</td>
<td>Børst bort løse partikler fra huden. Skyll i kaldt vann / anvend våt kompress.</td>
</tr>
<tr>
<td>P337 + P313</td>
<td>Ved vedvarende øyeirritasjon: Søk legehjelp.</td>
</tr>
<tr>
<td>P342 + P311</td>
<td>Ved symptomer i luftveiene: Kontakt et GIFTINFORMASJONSSENTER eller lege.</td>
</tr>
<tr>
<td>P370 + P376</td>
<td>Ved brann: Stopp lekkasje dersom dette kan gjøres på en sikker måte.</td>
</tr>
<tr>
<td>No.</td>
<td>Norwegian</td>
</tr>
<tr>
<td>--------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>P370 +</td>
<td>Ved brann: Slukk med ...</td>
</tr>
<tr>
<td>P378</td>
<td></td>
</tr>
<tr>
<td>P370 +</td>
<td>Ved brann: Evakuere området.</td>
</tr>
<tr>
<td>P380</td>
<td></td>
</tr>
<tr>
<td>P380 +</td>
<td></td>
</tr>
<tr>
<td>P375</td>
<td></td>
</tr>
<tr>
<td>P380 +</td>
<td></td>
</tr>
<tr>
<td>P375</td>
<td></td>
</tr>
<tr>
<td>P401</td>
<td>Oppbevares …</td>
</tr>
<tr>
<td>P402</td>
<td>Oppbevares tørt.</td>
</tr>
<tr>
<td>P403</td>
<td>Oppbevares på et godt ventilert sted.</td>
</tr>
<tr>
<td>P404</td>
<td>Oppbevares i lukket beholder.</td>
</tr>
<tr>
<td>P405</td>
<td>Oppbevares innelåst.</td>
</tr>
<tr>
<td>P406</td>
<td>Oppbevares i korrosjonsbestandig/… beholder med korrosjonsbestandig indre belegg.</td>
</tr>
<tr>
<td>P407</td>
<td>Se til at det er luft mellom stabler/paller.</td>
</tr>
<tr>
<td>P410</td>
<td>Beskyttes mot sollys.</td>
</tr>
<tr>
<td>P411</td>
<td>Oppbevares ved en temperatur som ikke er høyere enn ...°C /... °F.</td>
</tr>
<tr>
<td>P412</td>
<td>Må ikke utsettes for temperaturer høyere enn 50 °C /122 °F.</td>
</tr>
<tr>
<td>P413</td>
<td>Bultmengder på over ...kg/...lbs oppbevares ved en temperatur som ikke er høyere enn ...°C /... °F.</td>
</tr>
<tr>
<td>P420</td>
<td>Må oppbevares adskilt fra andre materialer.</td>
</tr>
<tr>
<td>P422</td>
<td>Oppbevar innholdet under …</td>
</tr>
<tr>
<td>P402 +</td>
<td>Oppbevares tørt. Oppbevares i lukket beholder.</td>
</tr>
<tr>
<td>P404</td>
<td></td>
</tr>
<tr>
<td>P403 +</td>
<td>Oppbevares på et godt ventilert sted. Hold beholderen tett lukket.</td>
</tr>
<tr>
<td>P233</td>
<td></td>
</tr>
<tr>
<td>P403 +</td>
<td>Oppbevares på et godt ventilert sted. Oppbevares kjølig.</td>
</tr>
<tr>
<td>P235</td>
<td></td>
</tr>
<tr>
<td>P410 +</td>
<td>Beskyttes mot sollys. Oppbevares på et godt ventilert sted.</td>
</tr>
<tr>
<td>P403</td>
<td></td>
</tr>
<tr>
<td>P410 +</td>
<td>Beskyttes mot sollys. Må ikke utsettes for temperaturer høyere enn 50 °C /122 °F.</td>
</tr>
<tr>
<td>P412</td>
<td></td>
</tr>
<tr>
<td>P411 +</td>
<td>Oppbevares ved en temperatur som ikke er høyere enn ...°C /... °F.</td>
</tr>
<tr>
<td>P235</td>
<td>Oppbevares kjølig.</td>
</tr>
<tr>
<td>P501</td>
<td>Innhold/beholder leveres til …</td>
</tr>
</tbody>
</table>